Barriers to medication adherence in patients with uncontrolled diabetes in a primary healthcare setting in Qatar: a mixed method triangulation study by Jaam, Myriam Jihad
 QATAR UNIVERSITY 
   COLLEGE OF PHARMACY 
BARRIERS TO MEDICATION ADHERENCE IN PATIENTS WITH 
UNCONTROLLED DIABETES IN A PRIMARY HEALTHCARE SETTING IN 
QATAR: A MIXED METHOD TRIANGULATION STUDY 
BY 
 
MYRIAM JIHAD JAAM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A Thesis Submitted to the  
College of Pharmacy, 
in Partial Fulfillment 
of the Requirements 
for the Degree of  
Masters of Science 
in Pharmacy 
 
 June  2017 
 
© 2017. Myriam Jihad Jaam. All Rights Reserved. 
 ii 
 
COMMITTEE PAGE 
 
The members of the Committee approve the Thesis of Myriam Jaam defended 
on 31/05/2017. 
 
 
 
Dr. Ahmed Awaisu, Ph.D. 
 Thesis Supervisor 
 
 
  
Dr. Mohamed Izham Mohamed Ibrahim, Ph.D. 
Thesis Co-Supervisor 
 
 
 
Dr. Ahmed Nadir Mohamed Kheir, Ph.D. 
Thesis Co-Supervisor 
 
 
 
Dr. Feras Alali, Ph.D. 
Committee Member 
 
 
 
 
Dr. Mohammad Issam Diab, Ph.D. 
Committee Member 
 
 
 
Dr. Muhammed Abdul Hadi, Ph.D. 
Committee Member 
 
 
 
 
 
 
 
 
 
 
 
 
Approved: 
 
 
 
 
 
Dr. Mohammad Issam Diab, Dean, College of Pharmacy
  
   
iii 
 
 
ABSTRACT 
 
JAAM, MYRIAM, J., Masters: June : 2017, Clinical Pharmacy and Practice 
Title: Barriers to Medication Adherence in Patients with Uncontrolled Diabetes in a 
Primary Healthcare Setting in Qatar: A Mixed Method Triangulation Study  
Supervisor of Thesis: Ahmed Awaisu 
 
Background: In Qatar, 86% of patients with diabetes are uncontrolled. Given that 
nonadherence to oral drug therapy and psychological insulin resistance are a common 
phenomenon, one could postulate that patients may not be taking their medications as 
prescribed. Therefore, the primary aim of this study was to explore the barriers to 
medication adherence among patients with uncontrolled diabetes in a primary healthcare 
setting from the perspectives of the patients and their healthcare providers. 
Methodology: This study was divided into two phases: patients’ perspective using 
a mixed-method approach, and healthcare providers’ perspective on the issue using 
qualitative approach. Patients with uncontrolled diabetes responded to a questionnaire 
followed by one-to-one in-depth interviews. On the other hand, healthcare providers 
directly involved in the care of patients with diabetes participated in semi-structured one-
to-one interviews. Descriptive and inferential analyses were used for quantitative data, 
while thematic analysis was used for qualitative data. Finally, data from the two phases 
were triangulated in interpretation. 
 
  
   
iv 
 
Results: Overall, 74% of the sample was nonadherent to diabetes medications. The 
quantitative results indicated that sociodemographic characteristics did not significantly 
influence medication adherence, except living with family. The majority of pre-determined 
barriers to medication adherence were reported by nonadherent patients and the most 
commonly reported barrier was forgetfulness. In addition, significantly higher levels of 
nonadherence were found among patients who were younger than 65 years and those who 
were illiterate. Qualitative data revealed five different themes from both patients’ and 
healthcare providers’ perspectives: (1) patient-related aspects, such as patient’s 
characteristics, perceptions, attitude and knowledge; (2) patient-provider interaction, 
which involved communication and interaction time; (3) appointment system and follow 
up, which was highly varied among patients despite their similar needs; (4) influence of 
other individuals including family support and social stigma and; (5) traveling and the use 
of traditional medicine by the patient in home country in an effort to cure the disease.  
Conclusion: Despite the different perspectives related to medication 
nonadherence, similar themes emerged from patients and their respective healthcare 
providers. The identified barriers warrant concerted efforts and series of interventions 
which should be initiated in a step-wise approach in order to improve medication adherence 
and overall healthcare outcomes.   
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CHAPTER 1: INTRODUCTION 
  
1.1. Introduction  
Diabetes mellitus (DM) is considered a burdensome disease globally. The global 
burden of illness attributed to DM is high and it is projected to continue to rise. In 2015, 
there were about 415 million people diagnosed with DM worldwide, a number that is 
expected to rise to 642 million by 2040 (1-3). The International Diabetes Federation (IDF) 
indicated that 1 out of every 11 people is diagnosed with diabetes with a new case identified 
every 10 seconds (3). Not only does diabetes affect patients with the disease, but it also 
adds to the healthcare expenditure and increase burden to the society. In 2015, it was 
estimated that diabetes accounted for 12% of the total healthcare expenditure globally (3). 
In addition, around $673 billion was spent on diabetes in 2015 alone, a number that is 
expected to increase to $802 billion by 2040 (1, 3).  
Currently, the Middle East and North Africa (MENA) region  ranks the second 
highest in the prevalence of diabetes after North America and Caribbean region (10.7% vs. 
11.5%, respectively) (3). Countries forming the Gulf Cooperation Council (GCC) – 
comprising of Bahrain, Kuwait, Oman, Qatar, Kingdom of Saudi Arabia (KSA), and the 
United Arab Emirates (UAE) – are amongst those with the highest diabetes prevalence 
within the MENA region (1, 4, 5). For instance, Kuwait and KSA both have a comparative 
prevalence of 20%, followed by Bahrain (19.6%) and UAE (19.3%) (3).   
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Qatar, a country with a reported population of slightly more than two million 
people, has a comparative diabetes prevalence of 20%, a current national prevalence rate 
of 13.5%, and is expected to maintain its high prevalence rank up to the year 2035 (3, 4, 
6). The number of diabetes-related deaths in the country was reported as 553 in 2015, 
making it the fifth leading cause of death in Qatar (1, 7, 8). 
DM is associated with many complications and severe consequences if left 
untreated or uncontrolled; thus, it is burdensome for patients as well as their caregivers to 
manage. Through the decades, numerous studies and reports have been published about the 
consequences of uncontrolled diabetes ranging from micro- and macro-vascular 
complications to possible hospitalizations and premature mortality (2, 8-11). Apart from 
cardiovascular diseases, a patient with diabetes has a 25-fold higher risk of amputations 
than a person without diabetes (10). It is also estimated that about one-third of patients with 
diabetes will have diabetes-related eye damage if left uncontrolled (10). 
Despite the recent advances and improvements in the therapeutics and management 
of diabetes, hospitalizations and premature mortality commonly occur due to the disease. 
In 2015 alone, 5 million diabetes-related deaths occurred globally (3). Several studies 
related to DM were conducted in Qatar; reporting the prevalence of diabetes complications 
including nephropathy, retinopathy, and neuropathy to range from 9.7-12.4%, 12.5-18.4%, 
and 9.5-12.6%, respectively. These complications are highly linked to poor adherence (11, 
12). 
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Due to the high burden of the disease, Qatar has placed diabetes as a top priority in 
its national healthcare agenda, in an effort to control its prevalence and reduce the direct 
and indirect costs associated with its management which constitute a serious drain on the 
healthcare budget (13). The current documented average cost per person with diabetes in 
Qatar is USD $2,868 which is the highest among the neighboring GCC countries (3).  
Within the National Health Strategy 2011 – 2016, one of the projects (Project 1.7) is to 
create a diabetes management program (13). For such intervention programs to be efficient 
and population-specific in Qatar, it is crucial to utilize current studies investigating the 
problems associated with uncontrolled diabetes, particularly medication nonadherence.   
Medication adherence is an intricate, multi-dimensional issue which highly 
contributes to treatment success. It plays a vital role particularly in chronic diseases where 
medications are a necessity to maintain disease control and prevent complications and 
mortality. The World Health Organization (WHO) defines adherence as “the extent to 
which a person’s behavior – taking medications, following a diet and/or executing lifestyle 
changes – corresponds, with agreed recommendations from healthcare providers” (14). The 
WHO also emphasizes that having a better intervention to manage medication 
nonadherence may have a far better outcome on the patients’ health than developing new 
medicine (14).  
Nonadherence to medications in patients with diabetes presents a major barrier to 
treatment success (15-17). The reported rate of adherence to oral antidiabetic medications 
ranged from 36-93% (16, 17). In Qatar, researchers reported that about 17-22% of patients 
with diabetes stopped taking their medications when feeling better and without notifying 
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their physicians (12). Despite this, the factors influencing such decisions have not yet been 
investigated in Qatar.  
Studies have investigated the factors associated with intentional nonadherence in 
patients with diabetes worldwide (14, 18-21). For instance, a qualitative study found that 
lifestyle adjustments such as the ability to integrate medications and instructions into work-
life were the main challenges to compliance with treatment (14). Another study found loss 
of motivation, medications side effects, and lack of knowledge about glycemic level targets 
as factors that played a major role in medication nonadherence (20). Additionally, the 
patient-provider relationship was found to influence medication adherence; a good rapport 
was associated with good adherence (22, 23). 
Furthermore, most studies in the literature reported reasons for medication 
nonadherence from the patient’s perspective, but few studies have looked at the healthcare 
provider’s perspective (21, 24, 25). It is important to note that healthcare providers’ 
perspectives and views are important in the delivery of healthcare to the patients. Thus, 
understanding what they believe and perceive as barriers to medication adherence, can 
contribute to better patient care and improve adherence to drug therapy. This is particularly 
important for Qatar since not only the patients are multicultural, but also the healthcare 
providers are of diverse background and come from different countries and different 
cultures. All of these may influence the healthcare providers’ perceptions and attitudes 
towards medication nonadherence in patients with diabetes.  
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1.2. Study Rationale   
 
Although medical services and medications are largely covered by the public health 
insurance for all residents in Qatar, the management and control of diabetes remain to be 
issues of serious concern. An unpublished study conducted among patients with diabetes 
in a primary health center in Qatar found that the majority of the patients had uncontrolled 
diabetes regardless of the regimen they were taking. The mean HbA1c among the cohort 
studied was 8%, and surprisingly patients who were taking oral monotherapy had better 
control of diabetes than those who were taking multiple medications including insulin. This 
strongly suggests that prescribing multiple medications may not necessarily translate into 
better therapeutic outcomes and that there could be several factors underpinning this lack 
of adequate diabetes control beyond treatment optimization. Given that nonadherence to 
oral drug therapy and psychological insulin resistance are a common phenomenon among 
patients with diabetes, one could postulate that patients with diabetes may not be taking 
their medications as prescribed (22, 25-27). Therefore, clinicians may be attempting to 
optimize drug therapy towards improving clinical outcomes without adequate 
considerations to medication nonadherence.  
Factors influencing medication adherence in diabetes and possible solutions to 
overcome the barriers to nonadherence have not been previously investigated in a multi-
cultural population such as in Qatar and rarely did the previous investigations involve the 
perspectives of healthcare providers regarding this topic. Given that nonadherence is a 
complex issue, it becomes apparent to understand the influencing factors from the different 
perspectives (in this case, patients’ and healthcare providers’ perspectives). This is 
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especially important in vulnerable patients with uncontrolled diabetes.  
In addition, many interventions were conducted across the globe to improve 
medication adherence in patients with diabetes (28-31). Most of these interventions have 
two main limitations within their methodologies; they did consider individualized patient 
characteristics regarding specific barriers to adherence, and they mainly targeted type 2 
diabetes (28-31). This not only limits the population and generalizability of the results, but 
can also reflect upon the magnitude of the effect observed which in many instances is either 
modest in size or is observed for a short duration of time. Consequently, it is very crucial 
to understand what barriers and what contributing factors exist in a multicultural population 
such as the one in Qatar in order to achieve better patient-centered and population-specific 
adherence improvement strategies. This would result in designing population-specific 
interventions that will be of more value and potentially yield better health outcomes.  
 
1.3. Study Objectives 
1.3.1.   General objective 
The overall aim of the present study is to identify and explore barriers to medication 
adherence among patients with uncontrolled diabetes in primary healthcare settings from 
the perspectives of the patients and their healthcare providers. 
To achieve this general objective, the project is split into two phases: Phase I is 
directed towards the patients, while Phase II focuses on healthcare providers to achieve the 
below specific objectives.  
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1.3.2.   Specific objectives for Phase I 
i. To determine the level of medication adherence among patients with 
uncontrolled diabetes using a self-reported measure.  
ii. To identify the characteristics, risk factors associated with, and barriers to 
medication adherence from the patients’ perspective.  
iii. To explore possible strategies for improving medication adherence in patients 
with uncontrolled diabetes in Qatar from the patients’ perspective.  
iv. To compare the characteristics, identified barriers and solutions, between 
patients with good medication adherence and patients with poor medication 
adherence.  
 
1.3.3.   Specific objectives for Phase II 
i. To determine the barriers to medication adherence in patients with 
uncontrolled diabetes from healthcare providers’ perspective. 
ii. To explore possible strategies for improving medication adherence in patients 
with uncontrolled diabetes in Qatar from a healthcare providers’ perspective. 
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1.4. Study Significance 
(a) There is a lack of data about barriers to medication adherence among patients with 
diabetes in Qatar necessitating the need for this study. This study will provide 
healthcare providers with information regarding the factors associated with medication 
non-adherence and thus ultimately improve patient care and outcome.  
(b) Patient counseling in current practice does not reflect upon the different cultures and 
diversities of patients in the country. This study will thus reveal whether cultural 
differences act as an influencing factor on medication adherence. Thus, this study will 
identify the needed information to make counseling more patient specific. 
(c) Non-adherence to diabetes medications results in complications that necessitate the 
patient’s increased use of the healthcare resources which is funded by the government. 
This study will potentially help reduce the economic burden of diabetes through 
providing a patient-specific counseling, and interventions therefore, decreasing 
morbidity and diabetes-related complications. 
(d) This project targets a national priority in Qatar as it is in alignment with Qatar National 
Vision 2030 and National Health Strategy 2011-2016, where providing a patient-
centered care in diabetes is very important (32, 33).  
(e) This research will also involve healthcare providers from different disciplines 
(medicine, pharmacy, nursing, and nutrition). Therefore, it will promote and foster 
multidisciplinary research collaboration and capacity building. 
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CHAPTER 2: LITERATURE REVIEW 
This chapter will provide an overview of the literary work relating to medication 
adherence in general and later tailored to medication adherence in diabetes. First, the term 
‘medication adherence’ is defined and brought into perspective. This is followed by 
discussions on the methods  for measuring medication adherence. Second, existing 
conceptual framework models that covered the barriers to medication adherence will be 
described through a systematic review of systematic reviews. The Chapter ends with a 
proposed holistic conceptual framework model derived from all of the evidence described 
and which will be used as a reference model throughout this study.  
 
2.1. Definition of Adherence 
The term adherence stems from the concept of ‘drug utilization’. This concept 
covers multiple aspects and is connected to many terms relating to the medication-taking 
behavior (Figure 1). Initially most reporting literature used the term ‘adherence’ only as a 
synonym to ‘compliance’ (34). The origin of the term compliance comes from the old 
French word compli which means to accomplish or to fulfill, and from the Latin word 
complere which means to fill up and satisfy (35).  However, the term ‘compliance’ has 
become less used in the past couple of years since it indicates that the patient is passively 
following instructions from the healthcare provider without a prior agreement or 
discussions (36, 37). The terms ‘persistence’ and ‘concordance’ were also used as synonys 
for ‘adherence’ or ‘compliance’ (34).  
 
  
   
10 
 
Cramer used both terms, ‘compliance’ and ‘adherence’ in 2008, as synonyms to 
each other and defined them as “the extent to which a patient acts in accordance with the 
prescribed interval and dose of a dosing regimen.” This definition is similar to the earlier 
definition by Osterberg in 2005, who defined adherence as “the extent to which patients 
take their medications as prescribed by their healthcare providers”(36). These definitions 
were then modified and termed ‘adherence’. The new definition became “the extent to 
which the patient’s behavior matches agreed on recommendations from the prescriber” 
(37). This definition indicates that there is a prior discussion and an agreement between the 
healthcare provider and the patient, a factor which was not initially indicated in the 
previous definitions.  
Medication ‘persistence’ on the other hand, is defined as “the duration of time from 
initiation to discontinuation of therapy.” This term was in some instances considered as a 
bigger umbrella for adherence (38). With this definition comes the concept of “permissible 
gap”: a gap in the time allowed between refills based on the pharmacological properties of 
the drug (34, 38). 
Drug 
Utilization 
Adherence Persistence 
Compliance Concordance 
Figure 1: Terms commonly used with drug utilization 
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Another less commonly used term is “concordance” which is a wider concept 
incorporating adherence in addition to the communication and support provided by the 
healthcare provider to the patient in an effort to help them take their medications 
appropriately (37). This term not only incorporates the patient, and their relationship with 
the healthcare provider, but also looks at the outcome of the treatment (37). Despite this 
broader definition, the National Coordinating Center for NHS Service Delivery and 
Organization (NCCSDO) recommends the use of the term ‘adherence’ instead of all the 
other terms to describe the patient’s medication-taking behavior (37).  
Medication nonadherence can be split into two subcategories: primary 
nonadherence and secondary nonadherence. Primary nonadherence refers to the patient not 
filling the initial prescription after the physician provided it. Conversely, secondary 
nonadherence relates to the failure of either following the instructions or refilling the 
medications or both. Another categorization is unintentional nonadherence and intentional 
nonadherence (39). The unintentional nonadherence is the random inappropriate 
medication taking or the random cessation of taking the drug. This could be due to factors 
such as forgetfulness. On the other hand, intentional nonadherence is the purposeful 
decision in stopping or changing a medication regimen by the patient (39).  
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2.2. Measurement of Medication Adherence  
Several methods are used to measure drug adherence, but all could be broadly 
classified into direct and indirect methods by Osterberg and Blaschke (36, 40). The direct 
methods involve objectively observing therapy using procedures such as biological 
biomarkers or having a directly supervised dosing. These direct methods may not always 
be practical and may not reflect upon patients’ behavior. Therefore, they are not routinely 
conducted in real-world practice (40). On the other hand, the indirect methods take into 
consideration patient factors and are much easier to conduct than the direct methods. 
Adherence is reported by the patient through questionnaires and can also be indicated by 
the rate of prescription refills (40). Nonetheless, the indirect methods have their limitations 
such as patient recall and social desirability biases, but they give information about 
modifiable behavior which can ultimately be targeted and corrected, thus improving 
adherence.  
There is no gold standard method for evaluating medication adherence (41). Each 
method has its own limitations. Choosing the best method will depend on its applicability 
in the healthcare setting. Fairman and Motheral summarized the methods used to measure 
medication adherence along with their advantages and disadvantages (41). These methods 
are summarized and briefly described in Table 1.  
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Table 1: Methods used to measure medication adherence 
Method  How it is measured Advantages/Disadvantages 
Biological 
biomarkers 
measurement 
Usually blood tests, 
but could also 
involve other bodily 
fluids 
Advantages: Reliable and accurate 
Disadvantages: Requires availability of 
the patient in the health setting such as 
inpatients, labor-intensive, costly, may 
not work with drugs of short half-lives, 
affected by patient’s metabolism 
Direct observation 
of therapy 
A dedicated person 
observes the patient 
taking the 
medication at each 
dose 
Advantages: Reliable and accurate 
Disadvantages: Very much labor-
intensive  
Pill count Counting medication 
pills after a specified 
duration 
Advantages: Easy to conduct 
Disadvantages: Cannot determine if 
drug was taken on schedule or not 
Electronic 
monitoring system 
An electronic chip is 
attached to the 
medication bottle 
which can record 
how many times the 
medication box was 
opened and at what 
time 
Advantages: Easy to conduct, more 
accurate than pill counts 
Disadvantages: Very costly 
Patient self-
reported measure  
Questionnaires or 
patient diaries 
Advantages: Easy to conduct, provides 
patient perspective 
Disadvantages: Subject to bias  
Prescription claims  Checking pharmacy 
records 
Advantages: Inexpensive and 
accessible data 
Disadvantages: Depends on reliability, 
comprehensiveness, and accuracy of 
existing records, can only be used for 
chronic medications  
Note: Contents of this table were derived from Fairman and Motheral (2000) 
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2.3. Existing Conceptual Framework Models on Medication Adherence 
Barriers to medication adherence have largely been studied and documented in the 
literature (18, 19, 42-47). Thus, multiple conceptual models have been developed to 
illustrate the complex relationship between the different factors relating to medication 
nonadherence (42, 48-50). One proposed model by Gellad et al. is demonstrated in Figure 
2 (42). This model illustrates the different factors that are thought to influence medication 
adherence. Also, it highlights the network of interactions between the factors that influence 
the medication-taking behavior of patients with chronic health conditions. The factors 
illustrated in Figure 2. are briefly described below:  
 
 
Figure 2: Conceptual framework model for medication adherence 
Source: Gellad (2009)  
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Patient factors: This is a domain influenced by many components: 1) illness 
representation, which reflects the patient’s knowledge about the illness and beliefs about 
the medications ; 2) the cognitive function, which is represented by the patient’s ability to 
comprehend and recall information related to the illness and medications; 3) patients 
demographics, such as marital status; 4) coexisting illnesses whether physical or 
psychological and; 5) medication characteristics which represent the regimen complexity 
as well as side effects. 
Health system factors: This includes formulary-related issues, fragmentation of 
care as well as access to care. It is also influenced by cost-sharing which may, in turn, affect 
patient’s adherence. 
Provider factors: This includes patient-provider relationship and interaction.  
This model also reflects upon the different interactions which can exist between the 
various components and factors. Although this model is simple, yet it is not disease-
specific, and at the same time it is not detailed for each category of factors. For instance, 
what specific demographics are mostly influencing medication adherence? What patient-
provider aspects are most important? Also, what do external cues represent? 
Another conceptual model exists for understanding medication adherence in older 
adults (Figure 3). This model was developed as a guiding map for an ongoing project - at 
the time - on heart failure patients who were above 50 years of age. The model focuses on 
the associations between environmental-related factors, patient-related factors, and 
medication adherence. The concepts were mainly developed based on behavioral 
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healthcare utilization model (48). The components of the model are briefly described 
below:  
 
Environment: This includes patient’s community, social support, stress, and 
environmental conditions which may influence the patient’s ability to obtain medications. 
Healthcare system: This includes the regulations, resources, and finances which 
would allow the medications to be available, accessible and affordable.  
Medication use system: This stands for interventions which would work on 
improving medication adherence.  
Patient characteristics: This reflects the features that the intervention should be 
tailored to, and are divided into three different categories: 1) Predisposing characteristics: 
Figure 3: Conceptual framework model for medication adherence in older adults 
Source: Murray (2014) 
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features that are predicting medication adherence but may not change by the intervention; 
2) Enabling resources: these are supporting resources that can improve medication 
adherence; 3) Need: This reflects on the patient's perceived need for adhering to 
medications.  
 Although this model includes the intervention to improve adherence and reflects on 
focusing them on patient’s characteristics, its major drawback is that it does not identify 
possible interactions between the different barriers and does not identify all the potential 
barriers and influencing factors that can contribute to medication nonadherence. Moreover, 
the model was created for developing an intervention specific to patients with heart failure 
and as such may not be useful in other diseases. Therefore, to understand the complexity 
and the influencing factors to medication adherence in diabetes, a new conceptual model 
is warranted. In order to gain a broader insight of the factors associated with medication 
adherence to guide the development of a conceptual framework model that is specific for 
diabetes, a review of systematic reviews was conducted.  
 
2.4. Evaluation of Existing Evidence on Medication Adherence in Diabetes 
Several systematic reviews have been conducted about medication adherence in 
diabetes. Nonetheless, they mainly focused on type 2 diabetes or multiple chronic disease 
conditions, neglecting type 1 diabetes (21, 45, 47, 51, 52). Another major limitation of the 
existing systematic reviews is the lack of risk of bias assessment of included studies, 
making them highly prone to misguided judgments (18, 25, 45, 51, 53). Furthermore, the 
methodological qualities of the published systematic reviews have not been previously 
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evaluated. These reviews report a remarkably diverse complex network of barriers to 
medication adherence, making it challenging to develop holistic, evidence-based 
interventions.  
The availability of multiple systematic reviews on the topic necessitates evidence 
appraisal to answer the question: What are the barriers to medication adherence in patients 
with diabetes and what is the quality of the evidence reporting those? Hence, a review of 
systematic reviews will bring together and appraise the existing evidence (54). This work 
will benefit healthcare providers in identifying the most reliable evidence to apply in 
practice and at the same time provide insight for researchers about the limitations of the 
existing studies to avoid in similar research in the future.  
A comprehensive systematic literature search was conducted to identify existing 
systematic reviews addressing influencing factors and barriers to medication adherence in 
patients with diabetes. The search was performed on the following databases: PubMed, 
Cochrane Library, Campbell Library, Database of Abstracts of Reviews of Effects 
(DARE), Academic Search Complete, EMBASE, Evidence-Based Practice Center 
Program (EPC), SCOPUS, Health System Evidence, ProQuest, ScienceDirect, Global 
Health Database, Joanna Briggs Institute Database of Systematic Reviews and 
Implementation Reports, and Google Scholar. The process also included manual searches 
of the bibliographies of the articles identified electronically as well as gray literature 
including abstracts of thesis and documents published by academic institutions as well as 
conference proceedings.  
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The search terms used were divided into four categories. Category A was 
adherence-related (adher*, compliance, comply*, nonadher*, noncompliance, refuse, 
refusal); category B was condition-related (diabetes, type 1 diabetes, type 2 diabetes, 
diabetes mellitus); category C was barrier-related (barrier, factor, facilitator, predictor, 
challenge, determinant); while category D was related to study design (review, systematic 
review, meta-analysis, scoping review, systematized, mixed method review, mixed studies 
review, integrative, narrative).  Terms were combined differently from categories A, B, C, 
and D using Boolean operators (AND/OR) in such a way that all relevant reviews would 
be retrieved. Medical subject heading (MeSH) terms and limits were used in corresponding 
databases as appropriate. 
Included articles were systematic reviews published in English language addressing 
barriers to medication adherence in patients with diabetes. Studies focusing on substance 
abusers, patients with mental disorders, tuberculosis, HIV, and gestational diabetes were 
excluded since each of these population groups has its circumstances that affect medication 
adherence. However, systematic reviews that looked at a combination of diseases were 
included if they analyzed barriers to medication adherence in diabetes separately. 
Moreover, narrative reviews not following systematic literature search, reviews reporting 
rates of medication adherence only, reviews looking at the impact of interventions as well 
as comparative reviews were also excluded since they are beyond the scope of this review.  
AMSTAR (A Measuring Tool to Assess Systematic Reviews), a quality assessment 
tool for systematic reviews, was used for evaluating the methodological quality of the 
included reviews (55). Items 9 and 10 were not considered in the evaluation since they 
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were not applicable to the types of systematic reviews included. These items are directed 
to the assessment of meta-analysis and relate to the evaluation of heterogeneity and 
publication bias, respectively. All the elements of the AMSTAR tool were weighted 
equally with a quantitative score of 1 for each item. Final grading of the methodological 
quality was based on the following arbitrary criteria: 0 – 3, 4 – 6 and 7 – 9 corresponding 
to “low quality”, “moderate quality” and “high quality”, respectively. 
Data were extracted using a tool developed and pretested for this review. The 
elements extracted included: title, authors, year of publication, primary objective(s) of the 
review, inclusion and exclusion criteria, article sources including databases, search 
strategy, bias and quality assessment methodology for included studies, number of included 
articles, study design of included articles, key findings, conclusion, limitations, sources of 
funding, and quality level. In cases where a review included multiple disease conditions, 
only diabetes-related information was extracted.  
The main outcome measures were factors associated with and barriers to 
medication adherence. Based on the extracted data, textual summaries and summary tables 
were developed. From these, emerging categories relating to factors influencing 
medication adherence were identified. Thematic content analysis was used to further 
categorize some of the emerged categories into subcategories. Specific factors and barriers 
were assigned to each of the categories and sub-categories. No software was utilized for 
the data synthesis and analysis.    
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Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 
guidelines were used in reporting the findings. Through searching and after removal of 
duplicates, 11,684 different references were found of which 26 reviews were potentially 
relevant based on screening of titles and abstracts. After full-text evaluation of the 26 
reviews, nine were excluded. Two of the potentially relevant reviews were presented as 
conference abstracts, and their full-text were not available; therefore, they were excluded 
from the study (56, 57). Other studies were excluded for one or more reasons including not 
systematic reviews or did not use systematic search strategy (58, 59), not related to 
medication adherence in diabetes (60, 61), or presented rates of adherence only without 
investigating barriers (18, 25, 62) (Figure 4). Finally, 17 systematic review articles were 
eligible for inclusion in the review. 
 
  
   
22 
 
 
All of the included systematic reviews were published in English from 1990 – 2016 
covering primary studies published from 1967 – 2016. All the reviews included the details 
of the primary studies, most of which were conducted in the United States (U.S.) and 
United Kingdom (U.K.), with a wide representation of studies from other countries across 
the globe (Table 2). The total number of original investigations (i.e. primary studies) 
included in the 17 reviews was 542, with an average of 32 studies per review (range 6 – 
98). 
Figure 4: Articles selection flow diagram (Evaluating existing evidence) 
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The AMSTAR score for the included systematic reviews ranged from 1 – 6 (Table 
3). Nine of the 17 articles were rated as ‘moderate quality’, while the rest were of ‘low 
quality’. Overall, the evaluated systematic reviews shared common methodological 
pitfalls. For instance, none of the reviews had reported a conflict of interest related to the 
primary studies they included, and only three reported searching the gray literature.  
Furthermore, the majority of the reviews (11 of 17) did not report assessing the 
methodological quality of the primary studies, but those that assessed quality did it 
appropriately.  
 
Table 2: Characteristics of the included systematic reviews 
Reference/year 
of publication 
Population Number 
of 
studies 
included 
Location of primary 
studies 
Factors influencing medication 
adherence 
 
Capoccia K. et 
al. (2016) (63) 
Adults with 
Type 1 or 
Type 2 
diabetes 
98 Not indicated  Patient-related factors: 
demographics, physiological status, 
health literacy, adapting to changes  
 Medication-related factors  
 Provider-related factors 
 Societal-related factors 
 Health system-related factors 
Tiktin M. et al. 
(2016) (64) 
Adults with 
Type 2 
diabetes  
30 U.S., England, 
Netherlands, Mexico, 
Korea, Denmark, 
Belgium  
 Patient-related factors: 
demographics, physiological status  
 Medication-related factors  
 Disease-related factors 
 Provider-related factors 
Brundisini F. et 
al. (2015) (65) 
Adults with 
Type 2 
diabetes  
86 U.S., England, 
Canada, Netherlands, 
Australia, Norway, 
Sweden, Belgium, 
Croatia, Germany, 
Romania  
 Patient-related factors: physiological 
status, health literacy, emotions, 
perceptions, adapting to changes  
 Medication-related factors  
 Disease-related factors 
 Provider-related factors 
 Societal-related factors 
Krass I. et al. 
(2015) (21) 
Adults with 
Type 2 
diabetes  
 
 
27 U.S., Iran, 
Netherlands, 
Malaysia, France, 
Korean, Sweden, 
Japan, Germany, 
Palestine, Egypt, 
Nigeria 
 Patient-related factors: 
demographics, physiological status 
 Medication-related factors 
 Disease-related factors 
 Healthcare system-related factors 
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Table 2: Cont. Characteristics of included systematic reviews 
Reference/year 
of publication 
Population Number 
of 
studies 
included 
Location of 
primary studies 
Factors influencing medication 
adherence 
 
Sohal T. et al. 
(2015) (47) 
Adults with 
Type 2 
diabetes  
 
 
20 U.S., England, 
Scotland, India, 
Norway 
 Patient-related factors: health 
literacy, perceptions, adapting to 
changes  
 Medication-related factors  
 Societal-related factors 
 
Al Hamid A. et 
al. (2014) (66) 
Adults with 
cardiovascular 
diseases or 
diabetes 
21 (15 
diabetes 
related) 
England, Scotland, 
Canada, Australia, 
Malaysia, Spain, 
South Africa, 
Taiwan, Croatia, 
Cameron, Brazil, 
Ireland 
 Patient-related factors: physiological 
status, health literacy, perceptions, 
adapting to changes 
 Medication-related factors 
 
Davies MJ. et al. 
(2013) (67) 
Adults with 
Type 1 or 
Type 2 
diabetes 
17 England, Scotland, 
Mexico, New 
Zealand, South 
Africa  
 Patient-related factors: 
demographics, health literacy, 
perceptions  
 Medication-related factors  
 Disease-related factors 
 Healthcare system-related factors 
Polinski J. et al. 
(2013) (51) 
Adults with 
Type 2 
diabetes 
10  Africa, Middle East, 
Asia, Eastern 
Europe, Latin 
America, Canada, 
Germany, Japan, 
Spain, Turkey, 
U.K., U.S., Spain 
 Patient-related factors: emotions, 
fear, perceptions.  
 Medication-related factors  
 Disease-related factors 
 Societal-related factors 
 Provider-related factors 
 Healthcare system-related factors 
Sarayani A. et al. 
(2013) (68) 
Adults with 
cardiovascular 
disease or 
diabetes  
14 (6 
diabetes 
related) 
Iran  Patient-related factors: emotions, 
fear, adapting to changes  
 Medication-related factors  
 Societal-related factors 
 Healthcare system-related factors 
Peeters B. et al. 
(2011) (52) 
Adults with 
Type 2 
diabetes  
 
12 U.S., New Zealand, 
South Africa  
 Patient-related factors: 
demographics, physiological status, 
perceptions, adapting to changes 
 Healthcare system-related factors 
Gherman A. et 
al. (2011) (69) 
Adults with  
Type 1 or 
Type  2 or 
gestational 
diabetes 
48 U.S., Australia, 
India, Mexico, New 
Zealand, Turkey, 
Taiwan, Japan, 
China 
 Patient-related factors: perceptions 
 Provider-related factors 
Nam S. et al. 
(2011) (45) 
Adults with 
Type 2 
diabetes 
80 Not indicated  Patient-related factors: 
demographics, physiological status, 
health literacy, emotions, fear, 
perceptions, adapting to changes 
 Medication-related factors  
 Provider-related factors 
 Societal-related factors 
 Healthcare system-related factors 
Fu AZ. et al. 
(2009) (70) 
Adults with 
Type 1 or 
Type 2 
diabetes 
6 U.S., England, 
Netherlands  
 Patient-related factors: fear 
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Table 2: Cont. Characteristics of the included systematic reviews 
Reference/year 
of publication 
Population Number 
of studies 
included 
Location of 
primary studies 
Factors influencing medication 
adherence 
 
Pun S. et al. 
(2009) (71) 
Adults with 
Type 2 
diabetes and 
healthcare 
providers  
16 U.S., England, 
Mexico  
 Patient-related factors: physiological 
status, health literacy, emotions, 
perceptions 
 Medication-related factors  
 Disease-related factors 
 Provider-related factors 
 Societal-related factors 
 Healthcare system-related factors 
Gonzalez JS. et 
al. (2008) (72) 
Adolescents, 
or adults with 
Type 1 or 
Type 2 
diabetes  
 
47 (18 
studies 
related to 
diabetes 
medicatio
ns)  
Japan, U.S., New 
Zealand, Mexico, 
Germany, Canada, 
Croatia, Korea, 
England, 
Netherlands  
 Patient-related factors: physiological 
status 
 
Lee WC. et al. 
(2006) (73) 
Adults with 
Type 2 
diabetes  
27 U.S., Scotland, 
France, Switzerland  
 Patient-related factors: physiological 
status 
 Medication-related factors 
 Healthcare system-related factors 
Nagasawa M. et 
al. (1990)  (74) 
Adolescents, 
or adults with 
Type 1 or 
Type 2 
diabetes  
26 Not indicated  
Not indicated 
 Patient-related factors: 
demographics, health literacy, 
emotions, perceptions  
 Societal-related factors 
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Table 3: Quality assessment of the included systematic reviews as per the AMSTAR criteria 
Reference 
/year of 
publication 
Provides 
an “a 
priori 
design” 
Duplicate 
data 
extraction 
Searched 
2 or more 
databases 
plus 
another 
source 
Gray 
literature 
Includes 
a list of 
included 
and 
excluded 
studies 
Reports 
characteristics 
of each 
included 
study 
Assesses 
and 
documents 
scientific 
quality of 
included 
studies 
Used 
scientific 
quality of the 
studies 
appropriately 
Includes conflict 
of interest 
statement 
Overall 
rating of 
quality 
Capoccia 
K. et al. 
(2016) (63) 
No Yes Yes No No Yes Yes Yes No Moderate 
Tiktin M. et 
al. (2016) 
(64) 
No No No No No Yes No No No Low 
Brundisini 
F. et al. 
(2015) (65) 
Yes Yes Yes No Yes Yes No No No Moderate 
Krass I. et 
al. (2015) 
(21) 
No Yes Yes No No Yes No No No Low 
Sohal T. et 
al. (2015) 
(47) 
No No Yes No No Yes Yes Yes No Moderate 
Al Hamid 
A. et al. 
(2014) (66) 
No No Yes No No Yes Yes Yes No Moderate 
Davies MJ. 
et al. 
(2013) (67) 
No No Yes No Yes Yes Yes Yes No Moderate 
 
Polinski J. 
et al. 
(2013) (51) 
No Yes Yes No Yes Yes No No No Moderate 
Sarayani A. 
et al. 
(2013) (68) 
No Yes Yes Yes No Yes Yes Yes No Moderate 
Peeters B. 
et al. 
(2011) (52) 
No Yes Yes No No Yes No No No Moderate 
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Table 3: Cont. Quality assessment of the included systematic reviews as per AMSTAR criteria 
Reference 
/year of 
publication 
Provides 
an “a 
priori 
design” 
Duplicate 
data 
extraction 
Searched 
2 or more 
databases 
plus 
another 
source 
Gray 
literature 
Includes 
a list of 
included 
and 
excluded 
studies 
Reports 
characteristics 
of each 
included study 
Assesses 
and 
documents 
scientific 
quality of 
included 
studies 
Used scientific 
quality of the 
studies 
appropriately 
Includes 
conflict of 
interest 
statement 
Overall 
rating of 
quality 
Gherman A. 
et al. (2011) 
(69) 
No No No No No Yes Yes Yes No Low 
Nam S. et al. 
(2011) (45) 
No No Yes No No Yes No No No Low 
Fu AZ. et al. 
(2009) (70) 
No No Yes No No Yes No No No Low  
Pun S. et al. 
(2009) (71) 
No No Yes No No Yes No No No Low 
Gonzalez JS. 
et al. (2008)  
(72) 
No Yes Yes Yes No Yes No No No Moderate 
Lee WC. et 
al. (2006) 
(73) 
No No No Yes No Yes No No No Low 
Nagasawa 
M. et al. 
(1990)  (74) 
No No Yes No No Yes No No No Low 
 
 
  
   
28 
 
The reviewed systematic reviews indicate that barriers to medication adherence are 
multi-factorial with remarkably consistent findings across the reviews. Barriers to or 
factors associated with medication adherence derived from the included reviews were 
categorized into the following: patient–, medication–, disease–, care provider–, healthcare 
system–, and societal–related factors. Given the considerable variation in patient–related 
factors and its major subtypes across the reviews, it was further classified using thematic 
content analysis into several sub-categories: demographics, physiological status, health 
literacy, emotions, fear, perceptions, and adaptation to changes (Table 4).  
The most predominantly reported patient–related factors included age, depression, 
and health literacy level. On the other hand, side effects and frequency of dosing were the 
most commonly reported medication–related factors. Disease–related factors such as 
duration of diabetes, disease complexity, and complications were rarely addressed. 
Societal–related factors commonly identified by the reviews were social stigma, cultural 
barriers, and lack of support. Moreover, within the healthcare system-related factors, issues 
surrounding insurance coverage and cost of medicines were the most frequently identified 
barriers to medication adherence in the reviewed studies. 
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Table 4: Factors influencing medication adherence in diabetes 
Factors References  
Patient-related factors 
Demographics (age, gender, ethnicity, financial status and 
level of income, marital status, and level of education) 
(21, 45, 52, 63-65, 67, 74, 75) 
Physiological status (comorbidities, depression, smoking) (21, 45, 52, 63-66, 71, 72) 
Health literacy (lack of understanding about the disease and 
treatment, difficulty reading prescription) 
(45, 47, 63, 65-67, 71, 72, 74) 
Emotions (blame, guilt, shock and helplessness, frustration, 
negative attitude, stress, and anxiety) 
(45, 51, 65, 66, 68, 71, 74) 
Fears (injection, blood phobia, and fear of pain) (45, 51, 65, 68, 70) 
Perceptions of (need of medicine, barriers to following 
medication, benefit from treatment, misconception about 
medicines, and self-efficacy) 
(21, 45, 47, 51, 52, 65-67, 69, 
71, 74) 
Adaptation to change (traveling overseas, alterations in 
daily schedule, change or lack of routine in managing 
treatment, and diet adjustments) 
(47, 63, 65-68) 
Medication-related factors 
Frequency of dose or injection (21, 45, 63, 64, 67, 75)  
Length of therapy (75) 
Number of medications and polypharmacy (21, 52, 64, 66)  
Timing of dosing  (63) 
Changing of treatment (67) 
Fluctuating response to medications (71) 
Side effects (21, 47, 51, 52, 63, 65, 66, 68, 
71)  
Complexity of regimen  (51, 63, 65, 66)  
Drug class/type (21, 45, 52, 64, 75)  
Method of drug administration  (51, 64-66)  
Traditional medicine and phytotherapy  (47, 65, 66)  
Disease-related factors 
Diabetes duration  (21, 64)  
Disease complexity (65, 71) 
Lower HbA1c (51, 67)  
Complications (21) 
Provider-related factors 
Support from healthcare providers (63, 64)  
Lack of patient involvement in decision-making process (63, 65)  
Duration of counseling and lack of time (51, 64, 65)  
Relationship with care provider (45, 69)  
Assumptions by providers about the patients’ knowledge (45, 51, 65) 
Providing ambiguous or incomplete information  (45, 65)  
Provider’s lack of experience (51) 
Language and communication barrier  (21, 45, 65, 71, 74)  
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Table 4: Cont. Factors influencing medication adherence in diabetes 
Factors References  
Societal-related factors 
Support from family  (45, 63)  
Lack of support  (45, 65, 71)  
Cultural barriers (45, 65, 71)  
Social stigma (47, 51, 65, 68)  
Healthcare system-related factors 
Insurance coverage (21, 52, 63, 67, 68, 75)  
Lack of guidelines for optimal treatment (51, 71)  
Cost of medicine (21, 45, 65, 75)  
Co-payment amount  (63, 75) 
Convenience of obtaining medications  (63, 64) 
Continuity of care  (63) 
Other: Forgetfulness (18, 63, 64, 66-68, 71) 
 
Systematic reviews and meta-analysis are considered the highest in the hierarchy 
of evidence-based information. Nevertheless, the value of these evidence-based resources 
depends highly on their scientific quality (76). Therefore, it is essential for the reader to 
critically appraise the methodologic quality using appropriate instruments. The AMSTAR 
tool which we utilized is a reliable and widely used tool for the assessment of systematic 
reviews (55).   
One item of the AMSTAR tool refers to disclosing conflict of interest for the 
systematic review itself as well as for all the individually included primary studies, which 
none of the reviews did. This appears to be similar across similarly conducted systematic 
reviews, were looking at the conflict of interest remains to be underestimated (77).  
It is noteworthy that in this review all the AMSTAR items were given equal weight 
during scoring. However, items relating to the quality assessment of the primary studies as 
well as the comprehensiveness of search applied in the systematic review may be 
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considered the most essential elements for systematic reviews and should, therefore, be 
given greater weights. It is worthwhile to note that a new AMSTAR tool which can be used 
for non-randomized studies is under development taking into consideration the suggestions 
and feedback from users. Therefore, the overall scoring of the included reviews may differ 
accordingly (76).  
It is evident that the included reviews have fallen into the common pitfalls of 
published reviews as recently described by MacLure et al. (76). The lack of detailed 
published protocol in most reviews presents a risk of bias in these reviews. In view of  the 
duplicate data extraction item of the AMSTAR - having more than one researcher doing 
the extraction - it may reflect on lack of team experience and independent involvement in 
the methodological process of the reviews which is another issue presented in more than 
half of the reviews included in this study. One major pitfall is the absence of quality 
assessment of primary studies which can be considered as a major source of bias (76). 
These issues can easily be overcome and avoided with the use of focused and detailed 
protocol based on existing guidelines in addition to learning from the experience of other 
researchers.  
There are some inherent limitations in the methodology employed in this review. 
This review relies on information presented by reviews of poor to moderate methodological 
quality which may undermine the quality of this review. Other limitations include 
duplicates of the primary studies within the reviews were not checked. It may, therefore, 
be that some evidence were counted more than once.  The main purpose of this review was 
to assess the quality of the existing evidence. As expected, the quality of this review 
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depends on the quality of the primary studies within the included reviews. Not all reviews 
have assessed the quality of their included studies. Thus, the summary of influencing 
factors may not be as well-founded.  
Our search indicates that the topic of medication adherence in patients with diabetes 
has been extensively studied and published in the literature. The findings of the review 
suggest that influencing factors and barriers to medication adherence are multifaceted with 
remarkably consistent findings across the existing systematic reviews; yet, the reviews 
were judged to be of low to moderate quality. Further comprehensive and well-designed 
systematic reviews as well as primary studies on this topic shall be conducted taking into 
considerations the pitfalls of the existing ones.  
 
2.5. A Proposed Conceptual Framework Model on Medication Adherence in 
Diabetes 
Multiple conceptual models for medication adherence have been published, yet 
they are not disease-specific (42, 43, 48). To have an effective intervention, an 
understanding of the complex network of barriers and factors influencing medication 
adherence in patients with diabetes is highly needed. An earlier review was conducted 
summarizing all these factors, yet their interactions and complexity have not been fully 
demonstrated by the primary studies and the reviews. Therefore, the aim of this section 
was to develop and create a model summarizing the complex network of influencing factors 
to be used as a reference for this thesis project and potentially for interventions targeting 
medication adherence in patients with diabetes in the future.  
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In brief, fourteen databases and gray literature sources were systematically searched 
through April 2016. Systematic reviews reporting barriers to medication adherence in 
patients with diabetes were selected based on predetermined criteria. Data were extracted 
using a pre-tested data extraction tool. Articles were also appraised for quality using the 
AMSTAR tool. Refer to section 2.4. for details and the synthesis of the review. Seventeen 
systematic reviews were initially identified. However, another unpublished systematic 
review was added as it was conducted later bringing the total to 18 systematic reviews.  
From these reviews, a thematic approach was utilized to sort out the barriers and 
the factors into the matrix of the framework. Each barrier and factor was initially coded, 
then clustered into larger categories. Connections between different factors were 
extensively identified. Any emerging category was verified by checking and rechecking as 
well as comparing the categories to each other. Once all the reviews were analyzed 
separately, the factors were regrouped again to create the overall conceptual framework 
model. The overall methodology used to finalize the model utilized the Delphi technique 
(among the MSc student and three supervisors) until a final model was agreed upon. 
A comprehensive list of themes was initially identified from the included 
systematic reviews: (1) patient-related factors; (2) diabetes-related factors; (3) medication-
related factors; (4) healthcare provider-related factors; (5) healthcare system-related factors 
and; (6) societal-related factors. Figure 5 presents the core of the proposed conceptual 
framework model for medication adherence in diabetes. It summarizes the main categories 
and subcategories. This is followed by several extensions that detail the factors identified 
in the core model (Figures 6-11).  
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Medication adherence 
Medication-related factors 
Healthcare provider-related factors 
Patient-related factors 
Societal-related factors 
Healthcare system-related factors  
Diabetes-related factors 
 Specific demographics 
 Knowledge 
 Comorbidities 
 Psychological feelings 
 Comorbidities 
 Quality of life 
 Beliefs and perceptions 
 Other factors  
 Complexity of regimen 
 Lifestyle-related 
changes 
 Drug class 
 Adverse effects 
 Other factors  
 Support 
 Stigma 
 Vicarious experience 
 Culture 
 Financial 
 Resources 
 Care process 
 Type of diabetes 
 Glycemic control 
 Asymptomatic disease 
 Disease complications 
 Disease duration  
 Perceptions 
 Patient-provider interactions 
 Workload 
 Knowledge 
Figure 5: A core conceptual framework on factors associated with medication adherence in diabetes 
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Patient-related factors: Most studies investigated patient-related factors, 
particularly the association of patients’ demographics and medication adherence. It was 
noted that most interactions were observed within this category as well as between the sub-
categories. This complex network of interactions between patient-related factors is 
illustrated in Figure 6. Notably, demographics, perceptions and beliefs, and knowledge are 
associated with many other factors. For instance, studies indicated that an education level 
below elementary level was associated with patients’ beliefs, while advanced age was 
related to comorbidities as well as the disease complications. All of these factors were in 
turn associated with medication adherence. Lack of knowledge about the disease and its 
medications was associated with poor patient’s motivation, perception, as well as self-
esteem (Figure 6).  
Diabetes-related factors: Within this category, it was noted that the type of 
diabetes is associated with medication adherence, whereby patients with type 2 diabetes 
demonstrated lower adherence than those with type 1. An inverse relationship was noted 
between medication adherence and disease duration, while the levels of HbA1c were also 
associated with medication adherence. More details on diabetes-related factors and 
identified interactions are further illustrated in Figure 7. 
Medication-related factors: This category included regimen-related factors such 
as its complexity, drug class, and adverse effects. In addition, polypharmacy, the number 
of injections, treatment duration and method of administration were associated with other 
factors that influence medication adherence. Figure 8 presents the medication-related 
factors and their interactions with other factors. It was noted that patients taking metformin 
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and short acting insulin had poorer adherence than those taking sulfonylureas and long-
acting insulin, respectively. Lifestyle-related changes include changes in medication dose 
based on diet and cessation of medicines when exercising, all of which affect adherence 
(Figure 8). 
 
 
  
  
   
37 
 
 
Figure 6: Patient-related factors associated with medication adherence 
 Social status 
 Psychological status 
 Physical status 
 Mental status 
 Health status  
 
Medication adherence  Patient-related factors 
Specific 
Demographic
s 
Comorbidities 
 Perceptions Knowledge about disease 
 Perceived severity:  
             Seriousness of disease  
             Perception of wellness  
 Perceived barriers: 
             Life restrictions Insulin  
 Perceived benefits:  
             Effectiveness of medications Use of alternative 
therapy  
             Need for medication  
             Medications worsen disease Insulin 
             Long term medication use is harmful  Use 
alternative therapy  
 Self-efficacy   Frustration, anxiety, Depression 
 Others: 
             Religious beliefs (higher power controls the 
condition) 
             Skeptical beliefs 
             Fatalistic beliefs 
             Punishment Insulin 
             Insulin means you are more sick 
 
Quality of life 
Knowledge 
 Knowledge about medications (how they worked)  
 Motivation, self-esteem, perceptions 
about medication  
 Knowledge about the disease  Fear from condition 
and its complications,  motivation, self esteem 
 Ability to read medication label 
 Training  
 Knowledge about glycemic target and glucose levels  
 Gender: Female  
 Ethnicity: African American, Latinos , Filipinos   
 Marital status: Single  
 Education:  
        Less than elementary level of education  Beliefs   
         Higher levels of education  
 Age:  
         Advanced age  Comorbidities, disease complications   
         Less than 65 years old  Routine in medication taking 
  Socio-economic status: Financial status  Medication 
cost, transportation to healthcare system  
 Employment: Students  
  
 Comorbidities Polypharmacy, stress  
 Depression  
 Smoking 
 Vision problems  Ability to read medication label 
Other factors 
 Alterations in daily schedule due to 
holidays and weekends  
 Routine in medication taking 
 Forgetfulness  
 Running out of medications 
 Housing condition  Stress  
 Traveling oversees  
 Newly treated  
 Fasting 
 Using other methods to control disease 
than medications  
 
Psychological 
Feelings 
 Stress  Smoking  
 Anxiety 
 Injection phobia  
 Blood phobia  
 Pain phobia   
 Fear from condition and complications 
 Frustration with medications 
 Fear of chemical nature Perceived 
benefit: Effectiveness of medication 
 Self-esteem  Depression 
 Motivation     
 
Perceptions 
and Beliefs 
  
+ 
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Figure 7: Diabetes-related factors affecting medication adherence 
Medication adherence  Diabetes-related factors 
Type of Diabetes 
Disease Duration 
Asymptomatic 
Glycemic Control 
 Glycemic control  Motivation  
 Levels of HbA1c 
 Type 2 diabetes vs Type 1 diabetes  
Disease Complications 
 Disease duration  Disease complications 
 
+ 
Figure 8: Medication-related factors associated with medication adherence 
Other 
Medication adherence  Medication-related factors 
Drug class  
Adverse Effects  
Complexity of Regimen 
 Injectable vs oral medication 
 Metformin vs sulfonylurea 
 Short acting vs long acting 
 Frequency (more than twice daily)  
 Timing of the medication  
 Number of injections  Anxiety  
 Number of drugs (polypharmacy)  Forgetfulness 
 Treatment duration Injectable drugs 
 Method of administration (vial vs pen insulin) Injectable drugs 
Life style-related 
Changes 
 Diet 
 Exercising 
 Side effects: Perceived benefit: Effectives of 
medication  
 Hypoglycemia  
 Gastrointestinal side effects 
 Injection pain  Stress  
 Weight gain  
  Cues of action: Previous experience 
with medication  Beliefs 
+ 
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Healthcare provider-related factors: This category included the patient-provider 
related aspects, care providers’ knowledge, their attitude and beliefs, and others. It was 
noted that poor patient-provider communication and education skills were associated with 
poor medication adherence. Also, the lack of shared decision making among the different 
healthcare providers was also identified to have a negative influence on medication 
adherence. The only interaction observed within this category is the lack of awareness of 
the healthcare provider about diabetes-related guidelines which reflects on their poor self-
efficacy and in turn associated with patients’ medication nonadherence (Figure 9). 
 
 
Healthcare system-related factor: This category mainly involved three aspects: 
financial issues, care process, and availability of resources. Financial aspects relate to the 
Figure 9: Healthcare provider-related factors associated with medication adherence 
 Time for providing care 
 number of patients covered per 
provider 
 Awareness about new guidelines  
 Self-efficacy  
 Experience with insulin types available  
 When to start insulin? 
 How much insulin to start with?  
 Determining appropriate glycemic 
targets 
 
Medication adherence  Healthcare provider – related factors 
Knowledge  Patient – provider Interaction 
 Patient – provider communication 
 Provider – patient education skills 
 Including patient in decision making 
 Patient autonomy 
 Patient’s disclosure of issues around non-adherence 
 Clarity of information given by provider 
 Shared decision making among multiple healthcare providers 
 Empathy (blaming patient) 
 Provider’s cultural competence 
 A priori assumptions about the patient’s knowledge 
 
Perceptions 
 Perceived benefit of diabetes medications and their efficacy 
 Perceived seriousness of diabetes  
 Self-efficacy  
Workload 
+ 
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systems use of insurance coverage, insurance type as well as the cost of medications and 
services. Care process includes visit duration, continuity of care, strict guidelines and lack 
of interpreters and translators which are reported to be associated with the poor patient-
provider communication (Figure 10).  
 
 
Societal-related factors: Social stigma, social support, culture and vicarious 
experience were all reported to be associated with medication adherence. Vicarious 
experience was linked to the patients’ fear of diabetes and its complications. In addition, 
culture was associated with perceptions and beliefs, and reflected on language which in 
turns was related to patient-provider communication (Figure 11). 
 
Medication adherence  Healthcare system – related 
factors  
Care Process Financial Issues   
 Visit duration  
 Continuity of care (seamless care)  
 Flexibility of guidelines 
 Follow up and monitoring   
 
 Insurance coverage  
 Insurance type  
 Copayment amount 
 Medication cost  
 Healthcare costs   
Resources 
Convenience  
 Availability of medications 
 Availability of guidelines 
 Availability of interpreters and translators  Patient – provider communication  
 Lack of transportation to seek healthcare system   
 
+ 
Figure 10: Healthcare system-related factors associated with medication 
adherence 
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An enormous amount of research has targeted medication adherence in chronic 
diseases and particularly in diabetes. Nonetheless, a holistic conceptual framework which 
summarizes all the factors associated with adherence behavior among patients with 
diabetes has not been previously developed. To our knowledge, this is the first holistic 
conceptual framework model for medication adherence in patients with diabetes. All of the 
identified factors and barriers have been grouped together to allow for the development of 
more effective interventions towards improving medication adherence.  
Although the framework lists all the identified factors that were associated with 
medication adherence and placed them into different categories, they can also be regrouped 
into modifiable and non-modifiable factors. This depends on the level of the intervention. 
Figure 11: Societal-related factors associated with medication adherence 
Vicarious experience   Fear of 
condition and its complication 
 
Medication adherence  Societal –  related factors 
Support 
Stigma 
 Support  Psychological feelings  
 Support from spouse 
 Support from family  
 Proximity from home  
 
 Stigma associated with 
injections 
 
Vicarious Experience  
+ 
 Culture  Perceptions and beliefs 
 Food and dietary preferences  Quality of life 
 Language  Ability to read medication label, patient – 
provider communication  
 Lifestyle  
 Alternative therapy /natural remedies  
Culture 
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For example, a healthcare provider in a primary care setting may not be able to change the 
system-related factors, but should focus on the healthcare provider-related aspects. On the 
other hand, policymakers and administrators can look at the system-related and societal-
related factors.  
Healthcare providers should use the model as a guide to determine patients who are 
more likely to be non-adherent to their drug therapy, requiring greater attention than others. 
Consequently, patient-tailored interventions could be developed based on identified 
factors. We recognize that one-size-fits-all adherence intervention strategy may not be 
appropriate. Therefore, the model is not meant to develop a single action plan for all 
patients at risk of nonadherence, but should only be used as a guide to allow for more 
patient-specific interventions.    
This model indicates that feeling stressed is associated with lack of control and both 
factors contribute to medication nonadherence. This suggests that a healthcare provider 
should determine the patient’s level of stress before prescribing medications that the patient 
is less likely to take and that may also add to their stress resulting in wasting resources and 
continued deterioration of their health.  
Patients’ nonadherence to insulin, in particular, is linked to injection phobia, blood 
phobia, and pain. These fears can be addressed by allowing the patient to try insulin for the 
first time under the observation of the healthcare provider or be exposed to someone who 
dealt with insulin before. This may likely reduce the patient’s fear and increase the 
likelihood of medication adherence.  
Many of the barriers associated with nonadherence can be addressed with proper 
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counseling and education. These include fear, lack of education, beliefs, perceptions, 
quality of life, managing comorbidities, polypharmacy, and many others. A single session 
of counseling and education the first time the patient receives the medication(s) may not 
be adequate. Multi-faceted educational sessions have shown to be effective (78-80). 
Therefore, determining the patient’s needs and specific barriers would allow for more 
targeted interventions. A healthcare provider can use this framework to identify which of 
these factors apply to the patient – perhaps through creating a checklist – before providing 
counseling and education.  
This framework is not limitation-free. The methodologies used in the primary 
studies to identify the barriers and factors were mainly questionnaire-based surveys and 
qualitative interviews which bring bias related issues into perspective. In particular, social 
desirability and recall bias can undermine the quality of the data. However, these 
methodologies are the best ones to obtain reasons for nonadherence and influencing factors 
from the patients’ perspectives. In addition, systematic reviews were the basis of this 
framework and not the primary studies, each of which carries its limitations. Finally, this 
framework served as the basis for this project and was accordingly used to draft the 
research protocol (questionnaire and interview guide).  
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CHAPTER 3: METHODOLOGY 
3.1. Phase I: Identifying Barriers to Medication Adherence in Diabetes from 
Patients’ Perspective 
3.1.1. Study design:  
This was a mixed method triangulation study design where qualitative and 
quantitative data were collected to increase the validity and comprehensiveness of the 
research results (81, 82). This approach provides an expanded understanding through the 
comparison between qualitative and quantitative data (81, 83). The specific model used 
was the “convergence model” in which the quantitative and the qualitative data were 
collected and analyzed separately, and then merged together during the interpretation of 
results (Figure 12) (81). The quantitative part of the study identified the level of adherence 
in patients with uncontrolled diabetes and determined the common barriers to medication 
adherence. On the other hand, the qualitative aspect allowed for an in-depth understanding 
of the problem, since participants would freely express their opinions. Therefore, the 
researcher had a better opportunity to explore reasons and barriers to medication adherence. 
Put together; these two approaches provide sound information which can then be targeted 
for future interventions.   
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3.1.2. Study setting:  
 
The study was conducted in the primary healthcare setting in Qatar. The Primary 
Health Care Corporation (PHCC) is under governmental support and comprises of 21 
different primary health centers distributed across the country (84). The centers provide a 
broad range of services including outpatient management, immunization, health education, 
and antenatal care. Some clinics are specialized such as cardiology clinics, family medicine 
clinics, dental clinics, dietician clinics, non-communicable disease (NCD) clinics, and 
others (84). Health awareness campaigns also take place for different health conditions that 
are of priority to the country such as asthma, diabetes, hypertension, obesity, and cancer 
(84). Moreover, the centers receive a vast number of patients with different health 
conditions on a daily basis who are managed, treated and followed as outpatients or referred 
to hospitals as necessary. Recently, some centers received the platinum level status from 
Accreditation Canada International (ACI) for achieving high-quality standards (85). The 
study was conducted in the two approved centers: Airport Health Center and West Bay 
Health Center. 
QUAN = Quantitative 
QUAL = Qualitative 
Figure 12: Triangulation design - Convergent model 
Source: Creswell et al. (2006)  
QUAN 
data 
collection 
QUAL  
data 
collection 
QUAN 
data 
analysis 
QUAL  
data 
analysis 
QUAN 
results 
QUAL 
results 
Interpretation 
QUAN + QUAL 
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and 
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3.1.3. Target population:  
The target population is patients with uncontrolled diabetes (type 1 or type 2) living in 
Qatar. Currently, the number of patients with a confirmed diagnosis of diabetes in Qatar is 
239,100 as per the latest IDF report in 2015, representing 13.5% of the population (3). On 
the other hand, the percentage of uncontrolled diabetes was extrapolated from an 
unpublished study conducted in a primary health center in Qatar which revealed that 86% 
of patients with diabetes were uncontrolled.  
 
3.1.4. Inclusion/exclusion criteria:  
Participants were included in the study if they were:  
 18 years old or above 
 diagnosed with diabetes for a minimum of one year  
 attending primary health centers  
 living in Qatar for the past 12 months at the time of recruitment 
 having records of blood glucose levels and HbA1c monitoring within the past 12 
months in the center’s database 
 judged as having  uncontrolled diabetes (glycosylated hemoglobin A1c (HbA1c) 
values above 7%, or a fasting blood glucose above 130 mg/dL (>7.2 mmol/L) (86))  
 able to speak English and/or Arabic language  
 
 Patients who did not satisfy the inclusion criteria above were excluded from the 
study. Moreover, pregnant women, patients with gestational diabetes, psychosis, 
HIV/AIDS, cancer, Alzheimer’s, and patients on dialysis were also excluded from the 
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study due to the circumstances associated with these conditions which may influence 
medication adherence.  Moreover, patients sending their drivers or housemaids to collect 
their medications were also excluded.  
 
3.1.5. Quantitative data 
 
3.1.5.1. Sample size determination  
The sample size calculation was based on cross-sectional studies of qualitative 
variables (87). The following equation was used to determine the sample size needed for 
the study:  
𝑠𝑎𝑚𝑝𝑙𝑒 𝑠𝑖𝑧𝑒 =  
𝑍1−𝑎/2
2 𝑝(1 − 𝑝)
𝑑2
 
𝑍
1−
𝑎
2
= 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑛𝑜𝑟𝑚𝑎𝑙 𝑣𝑎𝑟𝑖𝑎𝑡𝑒 
𝑝 = 𝑒𝑥𝑝𝑒𝑥𝑡𝑒𝑑 𝑝𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 𝑖𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 
𝑑 = 𝑎𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝑒𝑟𝑟𝑜𝑟 
 Z represents the Z statistic for a level of confidence chosen to present the results with a 
95% confidence interval (CI). The Z value for 95% CI equals to 1.96.  
 p is the expected prevalence or proportion of uncontrolled diabetes in Qatar. Based on 
unpublished data from a primary healthcare setting in Qatar, the reported rate of 
uncontrolled diabetes was 86%. The prevalence of diabetes in Qatar was 13.5% (1, 6, 
10). Based on these findings, it was assumed that around 12% of the entire population 
would be patients with uncontrolled diabetes. Therefore, the value of p was 0.12.  
 d represents the absolute error or precision which is usually estimated to be 5% to give 
the width of 95% CI; so the d value equals to 0.05. 
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𝑠𝑎𝑚𝑝𝑙𝑒 𝑠𝑖𝑧𝑒 =  
1.962 0.12(1 − 0.12)
0.052
= 163 
 
The minimum effective sample size determined based on the above assumptions was 163. 
In order to account for missing or unusable data, the sample size was increased by 20% to 
reach a goal of 196 patients. 
 
3.1.5.2. Sampling  
A convenient sample of the adult population was recruited from the primary health 
centers while waiting to collect their medications at the pharmacy. Potential participants 
were identified through the administrative and clinical database at the pharmacy. A 
convenient sample was used because a sampling frame was non-existent at the centers. 
  
3.1.5.3. Recruitment and data collection process  
The recruitment and data collection processes are summarized in Figure13 below:  
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3.1.5.4. Study instrument 
The study instrument comprised of three sections: 1) Baseline demographic and 
clinical characteristics; 2) Adherence to Refills and Medication Scale for Diabetes (ARMS-
D); 3) A questionnaire to determine barriers to medication adherence. The instrument 
started with sociodemographic and clinical data which were obtained from the patient’s 
database and then largely verified with the patient. This section was followed by the 
ARMS-D questionnaire (88, 89), a validated 11-item scale used to measure adherence level 
in patients with diabetes (88). This questionnaire has two subscales: 7 items for medication 
taking and 4 items for refills. The final section was developed to identify barriers to 
medication adherence based on the conceptual framework model for factors influencing 
medication adherence in diabetes. Refer to section 2.5. Twenty-five items representing the 
most commonly reported medication adherence barriers were listed in which the participant 
would indicate for each item whether or not it represents a barrier to them (using a 
Identification of patients 
with uncontrolled 
diabetes through 
prescription and clinical 
database
Verification of 
inclusion/exclusion 
criteria through the 
database and patient
Obtaining patient 
consent
Interview administered 
questionnaire and data 
collection from the database
Seeking patient's 
consents to participate 
in qualitative 
interview 
Conduct of 
qualitative 
interview
Figure 13: Recruitment process for the patients 
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dichotomous scale of Yes/No) (Appendix A). The complete study instrument was 
translated into Arabic and five most commonly spoken languages in Qatar (Tamil, Urdu, 
Malayalam, Hindi and Nepali) through the use of a translation agency   
 
3.1.5.5. Questionnaire validation  
The English and Arabic versions of the full questionnaire were pretested and piloted 
on four potential participants (two with type 1 diabetes, and two with type 2 diabetes) to 
check content validity. Comprehensiveness and clarity of the questionnaire were checked, 
and modifications were applied based on the participants’ feedback.  The published 
psychometric properties of ARMS-D indicate that it has a good internal consistency 
reliability (Cronbach α=0.86)  and a good construct validity of the subscales (average factor 
loading of 0.75 and 0.77 for the 7 items relating to medication taking and for the 4 items 
relating to refills, respectively) (88).    
 
3.1.5.6. Data analysis  
Data were analyzed using IBM Statistical Package for Social Sciences (IBM SPSS® 
Statistics for Windows, Version 22.0; IBM Corp, Armonk, NY, USA). Descriptive and 
inferential statistics were used for the data analyses. Normality was checked through 
Kolmogorov-Smirnov test which indicated that the assumption of normality was violated 
for all continuous variables, except for age. Therefore, demographic and clinical 
characteristics, as well as adherence scores, were presented descriptively as median (IQR) 
for continuous variables (except for age which was presented as mean ± SD) and as 
frequencies and percentages for categorical variables. Mann-Whitney U-test was used 
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whenever comparing two groups while Kruskal-Wallis was used whenever comparing 
more than two groups. Associations between different variables and adherence score were 
tested using Spearman Rho test - if variables are continuous or ordinal) -  or using Chi 
Square test whenever the variables are categorical. For all statistical tests, an alpha level of 
0.05 was used to determine statistical significance.  
 
3.1.6. Qualitative data 
3.1.6.1. Sampling  
A purposive sample of patients who participated in the quantitative phase of the 
study (Refer to section 3.1.4.) was invited to take part in the semi-structured interviews. 
Patients were selected from diverse ethnic and cultural backgrounds and from both genders 
in order to broaden the perspectives on the topic. The process of recruitment and interview 
continued until saturation was achieved. Saturation, as defined by Strauss and Corbin, is 
“a point in which further data collection becomes redundant and fails to further contribute 
to the study’s dimensions and categories development” (90). 
 
3.1.6.2. Sample size  
The number of participants interviewed was based on the concept of saturation. 
Therefore, a total of fourteen patients were interviewed.  
 
3.1.6.3. Interview structure  
The semi-structured in-depth interview focused on barriers to and factors associated 
with medication adherence. The interview guide was derived from the conceptual 
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framework model (Refer to section 2.5). During the interviews, open-ended questions were 
used to allow for participants’ expression of their own views and perceptions. The 
introductory section was about the patient's experience with diabetes followed by 
discussing the barriers and factors that affect their medication adherence. Then the 
interview transitioned into the patient’s identified solutions based on their own identified 
barriers.  The interview was conducted in either English or Arabic based on the 
participant’s preference. New entrants were interviewed until saturation point was reached. 
The interview guide is available in Appendix B. 
 
3.1.6.4. Validation of interview guide  
After developing the interview guide, it was reviewed and validated by researchers 
in the field of diabetes with relevant expertise in qualitative and mixed methodology 
research to ensure the coverage and comprehensiveness of the interview. This was then 
followed by piloting the interview guide on two patients to assess for validity, feasibility 
and burden. Since there were no changes to the interview structure, the piloted interviews 
were included in the analysis.  
 
3.1.6.5. Transcribing 
The interviews were audio-taped to allow for transcribing of responses and 
analysis. Interviews that were conducted in Arabic language were translated into English 
language directly and as they were transcribed. The translation and transcription of each 
session took place on the same day directly after the session by the same researcher to 
ensure the meaning was kept intact. Translation accuracy and quality were validated by 
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another research team member than the one who did the translation. 
 
3.1.6.6. Data analysis 
 A thematic approach to data analysis was used. Transcripts were read by the 
researcher for familiarizations, then coded for common phrases that discussed the same 
idea or meaning. Comparisons of codes were conducted, and phrases of similar idea were 
clustered together in the same category. Irrelevant codes were discarded, and similar 
category codes were placed under respective themes. This process was conducted by two 
researchers in order to ensure consistency and reliability of coding and themes generated. 
Consensus and opinions of all research team members were used to finalize the themes.    
 
3.1.7. Data interpretation  
Qualitative and quantitative data were analyzed separately. However, the findings 
were combined in interpretation and presentation. Barriers to medication adherence in 
diabetes were organized and categorized based on the frequency of reporting; then they 
were discussed individually bringing evidence from both the qualitative and the 
quantitative data collected.  
 
3.2. Phase II: Identifying Barriers to Medication Adherence in Diabetes from 
Healthcare Providers’ Perspective 
3.2.1 Study design  
A qualitative semi-structured interview methodology was used in this phase. This 
methodology was chosen in lieu of focus group discussions due to the logistic difficulties 
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of bringing different healthcare providers for focus groups. Therefore, we opted for 
qualitative one-to-one interviews which would allow for the exploration of the perceptions 
and beliefs of healthcare providers about the factors associated with and barriers to 
medication adherence in patients with diabetes. 
 
3.2.2. Study setting  
Healthcare providers’ interviews were conducted at the same primary health centers 
in Qatar from which the patients were selected during Phase 1 of the study. The interviews 
were carried out in individual participant’s offices or clinical rooms during working hours. 
 
3.2.3. Study population and selection  
 Participants were healthcare providers directly involved in the care of patients with 
diabetes. These included physicians, pharmacists, nurses, dietitians and other health 
professionals involved in diabetes management at the health centers. Participants were 
purposively selected from their respective health centers, and this approach was 
supplemented by using the snowballing technique to identify additional healthcare 
providers interested to participate (91). 
 
3.2.4. Inclusion/exclusion criteria 
Healthcare providers were included in the study if they were: 1) practicing in Qatar 
for at least one year; 2) working at the primary health center and; 3) involved in providing 
care for patients with diabetes. Those who did not fulfill these criteria were not included in 
the study.  
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3.2.5. Interview structure  
 The semi-structured in-depth interviews were conducted in English or Arabic 
language based on participant’s preference. The number of interviews conducted was based 
on the concept of saturation; thus, the study continued until there were no new emerging 
themes and ideas identified. A set of questions were developed for each of the study 
objectives in this phase to help guide the discussion and avoid drifting away from the 
study’s focus. The probing questions were identified from the conceptual model developed 
for this study (Refer to section 2.5).  Each session started with a brief introduction to the 
study, then probing the discussion to the barriers to and factors associated with 
nonadherence in patients with diabetes, then moving into what possible interventions can 
be applied to address the identified factors and barriers. The sessions were audio-taped for 
transcribing purposes. The healthcare provider interview guide can be found in Appendix 
C.  
 
3.2.6. Transcribing  
The audio-taped sessions were transcribed verbatim in a similar manner to Section 
3.1.6.5. 
 
3.2.7. Data analysis and interpretation 
 A thematic approach to data analysis was used. Transcripts were read by 
researchers for familiarizations, then coded for common phrases that discussed the same 
ideas or meaning. Comparison of codes was conducted, and similar idea phrases were 
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clustered together in the same category. Irrelevant codes were discarded, and similar 
category codes were placed under respective themes. Consensus and opinions of all 
research team members were required to finalize the themes. A deeper interpretation of 
Phase I and Phase II was conducted through the comparison of the results obtained from 
the different perspectives (patients’ vs. healthcare providers’) in terms of barriers as well 
as identified strategies for improvements. 
 
3.3. Ethical Considerations  
Ethics approval for the study was granted from the PHCC ethics committee prior 
to the conduct of the study (Research Section, Clinical Affairs, PHCC – Approval Number 
PHCC/IEC/16/04/013). A written informed consent form was developed and provided to 
the participants prior to recruitment in the study and after having informed them about the 
purpose of the research. Information sheet about the objectives of the investigation and 
researcher’s contact information was provided to all participants.  Letter of approval is 
available in Appendix D.  
 
A summary of the methodology used to address the study objectives is presented in Table 
5 below. 
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Table 5: Summary of study objectives and method used 
Objective Method 
Phase I 
To determine the level of medication adherence among patients 
with uncontrolled diabetes using a self-reported tool 
Questionnaire: ARMS-D  
Descriptive statistics 
To identify the characteristics, risk factors associated with, and 
barriers to medication adherence from patients’ perspective.  
 
Questionnaire and 
interviews  
Inferential statistics and 
thematic analysis  
To explore possible strategies for improving medication 
adherence in patients with uncontrolled diabetes in Qatar from 
patients’ perspective.  
 
Interviews  
Thematic analysis 
To compare the characteristics, identified barriers and solutions, 
between patients with good medication adherence and patients 
with poor medication adherence.  
 
Questionnaire and 
interviews  
Inferential statistics and 
thematic analysis 
Phase II 
To determine the barriers to medication adherence in patients 
with uncontrolled diabetes from healthcare providers’ 
perspective. 
 
Interviews 
Thematic analysis 
To explore possible strategies for improving medication 
adherence in patients with uncontrolled diabetes in Qatar from a 
healthcare providers’ perspective 
Interviews  
Thematic analysis 
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CHAPTER 4: RESULTS 
This chapter presents the results pertaining to the overall aim of this project which 
is to identify the barriers to medication adherence in patients with uncontrolled diabetes 
from both patients’ and healthcare providers’ perspectives in a primary care setting. The 
study was split into two phases: Phase I – Patients’ perspective, and Phase II – Healthcare 
providers’ perspective on this topic. The results of quantitative data from Phase I are 
presented followed by qualitative data from both Phase I and Phase II.  
 
4.1. Quantitative Data  
4.1.1. Sociodemographic characteristics  
Over a period of three months (October 1, 2016 to January 1, 2017), a total of 260 
patients with uncontrolled diabetes (55.8% male) participated in the quantitative phase of 
the study through answering the study questionnaire. Other relevant clinical data of the 
patients were obtained from the electronic medical records at the study centers. The mean 
± SD age of the patients was 56.1±10.40 years, and the majority (83.5%) were non-Qatari. 
Moreover, about half (51.5%) of the patients were Arabs, 76.9% reported living with 
family, and over two-thirds (69.2%) were employed at the time of data collection. The 
sociodemographic characteristics did not significantly differ between adherent and 
nonadherent patients, except in terms of living status, where 25.7% of the nonadherent 
group lived without their family as compared to 15.9% of those who were adherent 
(p=0.047). The sociodemographic characteristics of the study patients are provided in 
Table 6. 
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Table 6: Sociodemographic characteristics of Phase I patients 
Variable Total 
(N = 260) 
Adherent 
(n = 69) 
Nonadherent 
(n =191) 
P value* 
n (%) 
Gender    0.325 
Male 145 (55.8) 35 (50.7) 110 (57.6)  
Female 115 (44.2) 34 (49.3) 81 (42.4)  
Age category (years)    0.330 
≥ 65  50 (19.2) 16 (23.2) 34 (17.8)  
< 65  210 (80.8) 53 (76.8) 157 (82.2)  
Nationality    0.197 
Qatari 43 (16.5) 8 (11.6) 35 (18.3)  
Non-Qatari 217 (83.5) 61 (88.4) 156 (81.7)  
Ethnicity    0.742** 
Arab 134 (51.5) 35 (50.7) 99 (51.8)  
Asian 110 (42.3) 28 (40.6) 82 (42.9)  
Persian 14 (5.4) 5 (7.2)  9 (4.7)  
Other 2 (0.8) 1 (1.4) 1 (0.5)  
Religion    0.381 
Islam 208 (80.0) 55 (79.7) 153 (80.1)  
Christianity 24 (9.2) 5 (7.2) 19 (9.9)  
Hinduism 20 (7.7) 8 (11.6) 12 (6.3)  
Buddhism  8 (3.1) 1 (1.4) 7 (3.7)  
Living status     0.047 
With family 200 (76.9) 58 (84.1) 142 (74.3)  
Without family  60 (23.1) 11 (15.9) 49 (25.7)  
Employment status    0.188** 
Employed 180 (69.2) 44 (63.8) 136 (71.2)  
Unemployed 49 (18.8) 13 (18.8) 36 (18.8)  
Retired 30 (11.5) 11 (15.9) 19 (9.9)  
Student 1 (0.4) 1 (1.4) 0 (0)  
* p-value was computed using Chi Square test to compare between adherent and nonadherent groups 
** Fisher exact test was used to calculate the p-value  
*** Missing values  
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Table 6: Cont. Sociodemographic characteristics of Phase I patients  
Variable Total 
(N = 260) 
Adherent 
(n = 69) 
Nonadherent 
(n =191) 
P value* 
n (%) 
Education level    0.616** 
Primary 26 (10.0) 5 (7.2) 21 (11.0)  
Secondary 37 (14.2) 7 (10.1) 30 (15.7)  
High school 60 (23.1) 14 (20.3) 46 (24.1)  
Diploma  10 (3.8) 3 (4.3) 7 (3.7)  
University 103 (39.6) 34 (49.3) 69 (36.1)  
None, but literate  6 (2.3) 1 (1.4) 5 (2.6)  
Illiterate 18 (6.9) 5 (7.2) 13 (6.8)  
Monthly income (QR)***    0.665 
Not receiving any income  29 (15.5) 7 (14.3) 22 (15.9)  
Less than 3,000 59 (31.6)  13 (26.5) 46 (33.3)  
3,000 to less than 7,000  30 (16.0) 8 (16.3) 22 (15.9)  
7,000 to less than 15,000 33 (17.6) 12 (24.5) 21 (15.2)  
More than 15,000 36 (19.3) 9 (18.4) 27 (19.6)  
Monthly medication 
costs (QR)*** 
   0.443** 
0 – 100 171 (75.3) 43 (71.7) 128 (76.6)  
101 – 300 56 (24.7) 17 (28.3) 39 (23.4)  
* p-value was computed using Chi Square test to compare between adherent and nonadherent groups 
** Fisher exact test was used to calculate the p-value 
*** Missing values  
 
4.1.2. Clinical characteristics  
Almost all (98.5%) of the patients were diagnosed with type 2 diabetes and the 
median (IQR) HbA1c of the studied cohort was 7.9% (1.4). In addition, the majority of the 
patients (72.3%) were on oral antidiabetic medications, and 91.5% were taking metformin 
as part of the treatment regimen. Regarding comorbidities, 75.0% had hypertension, and 
69.2% had dyslipidemia. The most frequently reported diabetes complication was 
neuropathy followed by retinopathy (29.6% and 21.9%, respectively).  
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The duration of diabetes was higher in nonadherent as compared to adherent 
patients, this difference however, was not statistically significant [6 (8) vs. 7(11) 
(p=0.373)]. On the other hand, statistically significant differences were observed in HbA1c 
and fasting blood glucose, both of which were significantly higher in the nonadherent 
group compared to the adherent group (p=0.002 and p=0.004 respectively) (Table 7). 
Similarly, a significantly higher level of diabetes complications was observed in the 
nonadherent group as compared to the adherent group (p=0.003). The complications 
potentially driving this difference were hyperosmolar hyperglycemic state, neuropathy, 
nephropathy, and diabetes-related emergency visits (p<0.05 each). In addition, 43.5% of 
nonadherent patients were taking sitagliptin as compared to 29.0% in the adherent group 
(p=0.035). Similarly, the majority of patients taking insulin were nonadherent (84.0%, 
p=0.014) (Table 7).  
 
 
  
   
62 
 
Table 7: Clinical characteristics of Phase I patients 
Variable Total 
(N = 260) 
Adherent 
(n = 69) 
Nonadherent 
(n = 191) 
P value* 
n (%) Median (IQR) n (%) Median (IQR) n (%) Median 
(IQR)  
BMI (kg/m2)  28.9 (8.2)  28.1 (7.4)  28.8 (8.3) 0.931*** 
BMI category****       0.982** 
Underweight <18.5 1 (0.4)  0 (0)  1 (0.6)   
Normal weight 18.5 – 24.9 44 (20.1)  12 (21.1)  32 (19.8)   
Overweight 25 – 29.9 83 (37.9)  22 (38.6)  61 (37.7)   
Obese 30 – 39.9 76 (34.7)  20 (35.1)  56 (34.6)   
Morbidly obese >40 15 (6.8)  3 (5.3)  12 (7.4)   
Type of diabetes       1.00** 
Type 1 4 (1.5)  1 (1.4)  3 (1.6)   
Type 2  256 (98.5)  68 (98.6)  188 (98.4)   
Diabetes duration (years)  7 (10)  6 (8)  7 (11) 0.373*** 
Latest HbA1c (%)  7.9 (1.4)  7.8 (0.9)  8 (1.8) 0.002*** 
Latest fasting blood 
glucose (mmol/L) 
 8.65 (3)  8.3 (2.3)  8.9 (3.6) 0.004*** 
Number of diabetes 
medications 
 2 (1)  2 (1)  2 (2) 0.006*** 
Type of diabetes 
treatment  
      0.155 
Oral 188 (72.3)  56 (81.2)  132 (69.1)   
Injections 7 (2.7)  1 (1.4)  6 (3.1)   
Oral and injections 65 (25.0)  12 (17.4)  53 (27.7)   
* p-value was computed using Chi Square test 
** Fisher exact test was used to calculate the p-value 
*** Mann-Whitney U test was used to calculate the p-value 
**** Missing values  
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Table 7: Cont. Clinical characteristics of Phase I patients  
Variable Total 
(N = 260) 
Adherent 
(n = 69) 
Nonadherent 
(n = 191) 
P value* 
n (%) Median (IQR) n (%) Median (IQR) n (%) Median (IQR)  
Medication regimen       0.099 
Single (oral)  49 (18.9)  18 (26.1)  31 (16.2)   
Single (insulin) 7 (2.7)  1 (1.4)  6 (3.1)   
Double (oral and insulin) 30 (11.5)  5 (7.2)  25 (13.1)   
Double (two oral) 74 (28.5)  27 (39.1)  47 (24.6)   
Triple (oral) 56 (21.5)  11 (15.9)  45 (23.6)   
Triple (two oral and insulin) 27 (10.38)  5 (7.2)  22 (11.5)   
Quadruple (oral)  6 (2.3)  1 (1.4)  5 (2.6)   
Quadruple (3 oral and insulin) 11 (4.2)  1 (1.4)  10 (5.2)   
Diabetes medications$        
Metformin 238 (91.5)  66 (95.7)  172 (90.1)  0.152 
Repaglinide 3 (1.2)  1 (1.4)  2 (1.0)  1.00** 
Sitagliptin 103 (39.6)  20 (29.0)  83 (43.5)  0.035 
Vildagliptin 9 (3.5)  1 (1.4)  8 (4.2)  0.452 
Gliclazide 90 (34.6)  24 (34.8)  66 (34.6)  0.973 
Glimiperide  40 (15.4)  10 (14.5)  30 (15.7)  0.811 
Glibenclamide 1 (0.4)  0 (0)  1 (0.5)  1.00** 
Pioglitazone 21 (8.1)  4 (5.8)  17 (8.9)  0.417 
Liraglutide 2 (0.8)  0 (0)  2 (1.0)  1.00** 
Exenatide 1 (0.4)  1 (1.4)  0 (0)  0.265** 
Insulin  75 (28.8)  12 (17.4)  63 (33.0)  0.014*** 
* p-value was computed using Chi Square test 
** Fisher exact test was used to calculate the p-value 
*** Mann-Whitney U test was used to calculate the p-value 
$ Items are not mutually exclusive 
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Table 7: Cont. Clinical characteristics of Phase I patients  
Variable Total 
(N = 260) 
Adherent 
(n = 69) 
Nonadherent 
(n = 191) 
P value* 
n (%) Median (IQR) n (%) Median (IQR) n (%) Median (IQR)  
Number of pills per day  8 (4)  (8) 4  8 (4) 0.486*** 
Number of injections per 
day 
 0 (1)  0 (0)  0 (1) 0.040*** 
Number of all medications  8 (3)  7 (4)  8 (3) 0.375*** 
Number of comorbidities  2 (2)  2 (2)  2 (2) 0.981*** 
Comorbidities$         
Cardiac disease 33 (12.7)  7 (10.1)  26 (13.6)  0.458 
Hypertension  195 (75.0)  53 (76.8)  142 (74.3)  0.685 
Dyslipidemia 180 (69.2)  47 (68.1)  133 (69.6)  0.815 
Vitamin D deficiency 41 (15.8)  18 (26.1)  23 (12.0)  0.006 
Gastroesophageal reflux 
disorder 
16 (6.2)  4 (5.8)  12 (6.3)  1.00** 
Hypothyroidism 22 (8.5)  4 (5.8)  18 (9.4)  0.353 
Others  64 (24.6)  17 (24.6)  47 (24.6)  0.996 
Number of diabetes 
complications 
 1 (2)  0 (1)  1 (2) 0.003*** 
* p-value was computed using Chi Square  
** Fisher exact test was used to calculate the p-value 
*** Mann-Whitney U test was used to calculate the p-value 
$ Items are not mutually exclusive 
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Table 7: Cont. Clinical characteristics of Phase I patients  
Variable Total 
(N = 260) 
Adherent 
(n = 69) 
Nonadherent 
(n =191) 
P value* 
n (%) Median (IQR) n (%) Median 
(IQR) 
n (%) Median (IQR)  
Diabetes complications$         
Diabetic ketoacidosis 2 (0.8)  1 (1.4)  1 (0.5)  0.461** 
Hyperosmolar hyperglycemic 
state 
14 (5.4)  0 (0)  14 (7.3)  0.024** 
Retinopathy 57 (21.9)  13 (18.8)  44 (23.0)  0.470 
Neuropathy 77 (29.6)  14 (20.3)  63 (33.0)  0.048 
Nephropathy 38 (14.6)  5 (7.2)  33 (17.3)  0.043 
Foot complications 30 (11.5)  7 (10.1)  23 (12.0)  0.672 
Diabetes-related emergency 
visits in past year 
27 (10.4)  2 (2.9)  25 (13.1)  0.017 
Diabetes-related 
hospitalization in past year 
4 (1.5)  0 (0)  4 (2.1)  0.226** 
ARMS-D score  15 (7)  11(0)  17 (5) <0.001*** 
* p-value was computed using Chi Square test 
** Fisher exact test was used to calculate the p-value 
*** Mann-Whitney test was used to calculate the p-value 
$ Items are not mutually exclusive 
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4.1.3. ARMS-D items responses 
Adherence levels were calculated using the ARMS-D questionnaire, whereby a 
score of 11 corresponded to “adherent” and higher values (12 to 44) indicated 
“nonadherence”. Accordingly, a total of 191 patients (73.5% of the sample) were 
nonadherent to antidiabetic medications as measured by the ARMS-D. The median (IQR) 
ARMS-D score among the patients was 15 (7). The most frequently reported item to be 
problematic was forgetting to take antidiabetic medication (46.2%) of which 8.1% reported 
that they forget all the time. This was followed by planning ahead and refilling the medicine 
before they ran out (44.2%), and forgetting to take the medicine when it is more than once 
a day (35.1%). Table 8 presents the responses to the ARMS-D questionnaire. 
 
Table 8: Patients' responses to the items of ARMS-D questionnaire (n=260) 
ARMS-D Items 
None of 
the time 
Some of 
the time 
Most of 
the time 
All of the 
time 
n (%) 
Forget to take diabetes medicine 140 (53.8) 65 (25.0) 34 (13.1) 21 (8.1) 
Decide not to take your diabetes medicine 210 (80.8) 26 (10.0) 15 (5.8) 9 (3.5) 
Forget to get your prescription filled  215 (82.7) 25 (9.6) 15 (5.8) 5 (1.9) 
Run out of diabetes medicine 171 (65.8) 54 (20.8) 20 (7.7) 15 (5.8) 
Skip a dose of diabetes medicine before 
you go to the doctor 
175 (67.3) 23 (8.8) 19 (7.3) 43 (16.5) 
Miss taking your diabetes medicine when 
you feel better  
206 (79.2) 26 (10.0) 19 (7.3) 9 (3.5) 
Miss taking your diabetes medicine when 
you feel sick 
233 (89.6) 15 (5.8) 9 (3.5) 3 (1.2) 
Miss taking your diabetes medicine when 
you are careless 
238 (91.5) 16 (6.2) 4 (1.5) 2 (0.8) 
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Table 8: Cont. Patients’ responses to the items of ARMS-D questionnaire (n=260) 
ARMS-D Items 
None of 
the time 
Some of 
the time 
Most of 
the time 
All of the 
time 
n (%) 
Forget to take you diabetes medicine 
when you are supposed to take it more 
than once a day 
169 (65.0) 55 (21.2) 27 (10.4) 9 (3.5) 
Put off refilling your diabetes medicine 
because they cost too much money  
236 (90.8) 11 (4.2) 7 (2.7) 6 (2.3) 
Plan ahead and refill your medicines 
before they run out 
15 (5.8) 33 (12.7) 67 (25.8) 145 (55.8) 
 
4.1.4. Barriers to medication adherence 
The median (IQR) number of barriers reported by the patients was 3 (4). The most 
frequently reported barriers to medication adherence in the questionnaire were 
forgetfulness (41.5%), followed by inconvenience, and the use of traditional medicine 
(36.5% each), while the only barrier that was not reported by the sample was “taking 
medications is against my culture.” Table 9 and Figure 14 indicate the response rates to the 
barriers to medication adherence. More barriers to medication adherence were reported in 
those who were nonadherent than those who were adherent (median [IQR) 4 (4) vs. 1(1)] 
respectively, p<0.001). Table 9 compares between adherent and nonadherent groups in 
terms of the reported barriers.  
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Table 9: Reported barriers to medication adherence from quantitative data 
Barrier Total 
(N = 260) 
Adherent 
(n = 69) 
Non 
adherent 
(n =191) 
p value* 
n (%) 
Time or schedule problems  58 (22.3) 4 (6.9) 54 (93.1) <0.001 
Inconvenience  95 (36.5) 17 (17.9) 78 (82.1) 0.017 
Side effects of the medicine 66 (25.4) 5 (7.6) 61 (92.4) <0.001 
Forget to take the medicine 108 (41.5) 3 (2.8) 105 (97.2) <0.001 
Health problems  24 (9.2) 2 (8.3) 22 (91.7) 0.034 
Too painful to administer the medicine  16 (6.2) 1 (6.3) 15 (93.8) 0.077** 
Too costly to buy the medicine 41 (15.8) 8 (19.5) 33 (80.5) 0.267 
Special occasions  42 (16.2) 6 (14.3) 36 (85.7) 0.050 
Feeling depressed or other negative 
emotions  
81 (31.2) 8 (9.9) 73 (90.1) <0.001 
Believe that the medication prescribed is 
not helpful 
29 (11.2) 1 (3.4) 28 (96.6) 0.003 
Interferes with you daily activities 19 (7.3) 3 (15.8) 16 (84.2) 0.270 
Having multiple diseases 19 (7.3) 2 (10.5) 17 (89.5) 0.101 
Taking many medications 34 (13.1) 4 (11.8) 30 (88.2) 0.038 
Regimen is too complicated to follow  22 (8.5) 1 (4.5) 21 (95.5) 0.015 
Taking the medicine multiple times a 
day 
65 (25.0) 6 (9.2) 59 (90.8) 0.001 
Use of traditional medicine  95 (36.5) 21 (22.1) 74 (77.9) 0.219 
Long diabetes duration  28 (10.8) 7 (25.0) 21 (75.0) 0.845 
Time or schedule problems  58 (22.3) 4 (6.9) 54 (93.1) <0.001 
Diabetes is too complicated to manage  35 (13.5) 8 (22.9) 27 (77.1) 0.596 
Healthcare provider is not very 
supportive 
16 (6.2) 3 (18.8) 13 (81.3) 0.571** 
I don’t know why I am on diabetes 
medications  
11 (4.2) 1 (9.1) 10 (90.9) 0.297** 
Healthcare provider does not give me 
enough information  
29 (11.2) 4 (13.8) 25 (86.2) 0.099 
* p-value was computed using Chi Square test 
** Fisher exact test was used to calculate the p-value 
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Table 9: Cont. Reported barriers to medication adherence from quantitative data  
Barriers Total 
(N = 260) 
Adherent 
(n = 69) 
Non 
adherent 
(n =191) 
p value* 
n (%) 
Not understanding what the healthcare 
provider is telling me about the 
medicines 
25 (9.6) 6 (24.0) 19 (76.0) 0.762 
Family is not very supportive 23 (8.8) 6 (26.1) 17 (73.9) 0.959 
Taking these medications is against my 
culture 
0 0 0 - 
Having health insurance  12 (4.6) 2 (16.7) 10 (83.3) 0.738** 
* p-value was computed using Chi Square test 
** Fisher exact test was used to calculate the p-value 
 
 
 
 
 
 
4.1.5. Difference of adherence score across different patients’ characteristics  
Figure 14: Top eight reported barriers to medication adherence 
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Tables 10-12 represent the differences of adherence scores across patients’ 
characteristics, while Table 13 indicates the correlations between patients’ characteristics 
and adherence scores. Patients below 65 years of age had significantly higher adherence 
score than those who were 65 years of age or older (p=0.039) (Table 10). This difference 
is further emphasized with the weak negative correlation observed between age and 
adherence score (r = - 0.175, p=0.005). Moreover, patients living with family had lower 
adherence scores as compared to those living without family [median (IQR) 14 (6), 17 (5), 
respectively, p=0.004]. In addition, the highest adherence score was amongst those with 
no formal education when compared with other educational levels [23(0), p=0.042] (Table 
10). On the other hand, the lowest adherence score was observed to be in patients taking 
single oral therapy followed by dual oral therapy as compared to other types of regimens 
(12 (5) and 13.5 (7), p=0.005) (Table 11).  
Differences in adherence score across different barriers to medication adherence 
are presented in Table 12. Overall, patients who indicated any item as a barrier always had 
higher adherence score compared to those who did not indicate the same item as a barrier. 
However, for seven items the difference between the two groups was not statistically 
significant (Table 12). The top five barriers based on mean adherence score are presented 
in Figure 15 which indicates that the highest adherence score was amongst patients who 
believed that the prescribed medication was not useful, followed by those who reported 
that it was painful to administer the medicine (21.31 ± 6.27 and 19.93 ± 6.17, respectively).  
When testing the correlations between different factors and adherence score, 
significant but weak correlations were noted with the number of diabetes complications 
(r=0.195, p=0.002), the number of diabetes drugs (r=0.202, p=0.001), and latest HbA1c 
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level (r=0.353, p<0.001). Furthermore, a moderate positive correlation was noted between 
adherence score and the total number of barriers reported (r=0.503, p<0.001) (Table 13). 
 
Table 10: Differences in adherence score across different sociodemographic 
characteristics 
Variable  Adherence score 
Median (IQR) 
p value* 
Gender  0.059 
Male 16 (7)  
Female 14 (6.5)  
Age category (years)   0.039 
≥ 65  13 (5)  
< 65  15 (7.5)  
Nationality  0.965 
Qatari 14 (5.5)  
Non-Qatari 15 (7)  
Ethnicity  0.595** 
Arab 14 (6)  
Asian 15.5 (7)  
Persian 13 (7.25)  
Other 14.5 (7)  
Religion  0.813** 
Islam 15 (6)  
Christianity 12 (7)  
Hinduism 12 (8.5)  
Buddhism  17 (3.8)  
Living status   0.004** 
With family 14 (6)  
Without family 17 (5)  
* p-value was computed using Mann-Whitney U test  
** Kruskal-Wallis test was used to calculate the p-value  
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Table 10: Cont. Differences in adherence score across different sociodemographic 
characteristics 
Variable  Adherence score 
Median (IQR) 
p value* 
Employment status  0.223** 
Employed 15 (6.3)  
Unemployed 15 (7)  
Retired 12.5 (5.5)  
Student 11 (0)  
Education level  0.042** 
Primary 16 (7)  
Secondary 17 (3.8)  
High school 15 (8)  
Diploma  15 (9.8)  
University 14.5 (7)  
None, but literate  23 (0)  
Illiterate 13.5 (7.5)  
Monthly income (QR)*   0.667** 
Not receiving any income  15 (6.5)  
Less than 3,000 16 (7)  
3,000 to less than 7,000  15 (7)  
7,000 to less than 15,000 13 (6.5)  
More than 15,000 14 (6)  
Monthly medication costs (QR)*  0.626 
0 – 100 15 (8)  
101 – 300 15 (6.75)  
* p-value was computed using Mann-Whitney U test  
** Kruskal-Wallis test was used to calculate the p-value  
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Table 11: Differences in adherence score across different clinical characteristics 
Variable  Adherence score 
Median (IQR) 
p value* 
BMI category (kg/m2)  0.842** 
Underweight <18.5 16 (0)  
Normal weight 18.5 – 24.9 16 (8)  
Overweight 25 – 29.9 15 (8)  
Obese 30 – 39.9 15 (4)  
Morbidly obese >40 15.5 (11.8)  
Type of diabetes treatment   0.095** 
Oral 14.5 (7)  
Injections 15 (4.8)  
Oral and injections 17 (7)  
Medication regiment   0.005** 
Single (oral)  12 (5)  
Single (insulin) 15 (4.8)  
Double (oral and insulin) 17 (5.5)  
Double (two oral) 13.5 (7)  
Triple (oral) 16 (5)  
Triple (two oral and insulin) 16 (7)  
Quadruple (oral)  27 (0)  
Quadruple (3 oral and insulin) 17 (0)  
Diabetes medications    
Patients on Metformin  0.181 
 Yes 15 (7)  
 No 15 (5.5)  
Patients on Repaglinide  0.512 
 Yes 14 (0)  
 No 15 (7)  
Patients on Sitagliptin  0.042 
 Yes   16 (5.8)  
 No 14 (7)  
Patients on Vildagliptin  0.088 
 Yes 18.5 (7)  
 No 15 (7)  
* p-value was computed using Mann-Whitney U test  
** Kruskal-Wallis test was used to calculate the p-value  
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Table 11: Cont. Differences in adherence score across different clinical characteristics 
Variable  Adherence score 
Median (IQR) 
p value* 
Patients on Gliclazide  0.450 
 Yes 16 (7)  
 No 15 (7)  
Patients on Glimiperide   0.640 
 Yes 15 (7.25)  
 No 15 (7)  
Patients on Pioglitazone  0.020 
 Yes 16.5 (9.25)  
 No 15 (7)  
Patients on Liraglutide  0.196 
 Yes 23 (0)  
 No 15 (7)  
Patients on Insulin   0.025 
 Yes 16 (6)  
 No 15 (7)  
Comorbidities    
Cardiac disease  0.533 
 Yes 16 (6)  
 No 15 (7)  
Hypertension   0.734 
 Yes 15 (7)  
 No 15 (7)  
Dyslipidemia   0.481 
 Yes 15 (7.5)  
 No 14 (7)  
Vitamin D deficiency  0.104 
 Yes 14.5 (7.25)  
 No 15 (6)  
Gastroesophageal reflux disorder  0.677 
 Yes 15 (7.25)  
 No 15 (7)  
Hypothyroidism  0.473 
 Yes 16 (5)  
 No 15 (7)  
* p-value was computed using Mann-Whitney U test  
** Kruskal-Wallis test was used to calculate the p-value  
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Table 11: Cont. Differences in adherence score across different clinical characteristics 
Variable  Adherence score 
Median (IQR) 
p value* 
Diabetes complications    
Diabetic ketoacidosis  0.654 
 Yes 14 (0)  
 No 15 (7)  
Hyperosmolar hyperglycemic state  0.004 
 Yes 18 (10)  
 No 15 (7)  
Retinopathy  0.640 
 Yes 15 (8)  
 No 15 (7)  
Neuropathy  0.472 
 Yes 15 (7)  
 No 15 (7)  
Nephropathy  0.040 
 Yes 16 (5.75)  
 No 15 (7)  
Foot complications  0.082 
 Yes 17 (6.25)  
 No 15 (7)  
Diabetes-related emergency visits 
in past year 
 0.002 
 Yes 17 (5)  
 No 15 (7)  
Diabetes-related hospitalization in 
past year 
 0.173 
 Yes 20.5 (17)  
 No 15 (7)  
* p-value was computed using Mann-Whitney U test  
** Kruskal-Wallis test was used to calculate the p-value  
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Table 12: Differences in adherence score across different barriers to medication 
adherence 
Variable  Adherence score 
Median (IQR) 
p value* 
Time or schedule problems   <0.001 
 Yes 17 (9)  
 No 15 (6)  
Inconvenience   <0.001 
 Yes 16 (7.75)  
 No 14 (6)  
Side effects of the medicine  <0.001 
 Yes 11 (6)  
 No 14 (6)  
Forget to take the medicine  <0.001 
 Yes 17 (5)   
 No 13 (5)  
Health problems   0.026 
 Yes 17 (5.5)   
 No 15 (7)  
Too painful to administer the medicine   0.001 
 Yes 18 (7)   
 No 15 (7)  
Too costly to buy the medicine  0.030 
 Yes 17 (4.5)   
 No 14.5 (7)  
Special occasions  0.020 
 Yes 16.5 (5.75)   
 No 15 (7)  
Feeling depressed or other negative emotions   <0.001 
 Yes 17 (5)  
 No 14 (6)  
Believe that the medication prescribed is not helpful  <0.001 
 Yes 19 (10.5)  
 No 14 (6.5)  
Interferes with you daily activities  0.021 
 Yes 18 (13.25)  
 No 15 (7)  
* p-value was calculated using Mann-Whitney U test  
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Table 12: Cont. Differences in adherence score across different barriers to medication 
adherence 
Variable  Adherence score 
Median (IQR) 
p value* 
Having multiple diseases  0.016 
 Yes 17 (10)  
 No 15 (7)  
Taking many medications  0.019 
 Yes 16 (9)  
 No 15 (7)  
Regimen is too complicated to follow   0.005 
 Yes 17 (4)  
 No 15 (7)  
Taking the medicine multiple times a day  <0.001 
 Yes 19 (9)  
 No 14 (6)  
Use of traditional medicine   0.125 
 Yes 16 (7)  
 No 15 (7)  
Long diabetes duration   0.307 
 Yes 15 (12.25)  
 No 15 (7)  
Diabetes is too complicated to manage   0.011 
 Yes 17 (11.5)  
 No 15 (7)  
Healthcare provider is not very supportive  0.727 
 Yes 14.5 (7.5)  
 No 15 (7)  
I don’t know why I am on diabetes medications   0.213 
 Yes 17.5 (7.5)  
 No 15 (7)  
Healthcare provider does not give me enough information   0.009 
 Yes 18 (7.5)  
 No 15 (7)  
Not understanding what the healthcare provider is telling 
me about the medicines 
 0.165 
 Yes 16.5 (7.75)  
 No 15 (7)  
* p-value was calculated using Mann-Whitney U test  
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Table 12: Cont. Differences in adherence score across different barriers to medication 
adherence 
Variable  Adherence score 
Median (IQR) 
p value* 
Family is not very supportive  0.663 
 Yes 15 (6.25)  
 No 15 (7)  
Having health insurance   0.384 
 Yes 16.5 (6)  
 No 15 (7)  
* p-value was calculated using Mann-Whitney U test  
 
 
  
 
 
 
 
Figure 15: Top five barriers based on adherence score 
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Table 13: Correlations of patients' characteristics and adherence score 
Variables Correlation with adherence score 
R p-value* 
Age (years) -0.175 0.005** 
Level of education -0.191 0.002 
Level of income -0.118 0.108 
BMI (kg/m2) -0.030 0.661 
Diabetes duration (years)  0.001 0.984 
Number of comorbidities 0.019 0.764 
Number of diabetes complications 0.195 0.002 
Number of diabetes drugs 0.202 0.001 
Number of all medications 0.005 0.930 
Latest HbA1c (%) 0.353 <0.001 
Latest fasting blood glucose (mmol/L) 0.236 <0.001 
Total number of pills -0.05 0.423 
Total number of injections 0.110 0.078 
Total number of barriers to adherence 0.503 <0.001 
* p value was calculated using Spearman Rank test  
**p value was calculated using Pearson Correlation test  
 
4.1.6. Summary of quantitative data 
Overall, 74% of the studied population (i.e. patients with uncontrolled diabetes) was 
nonadherent to diabetes medications. It was found that the median ARMS-D score was 15 
(7). The quantitative results indicated that sociodemographic characteristics did not 
influence medication adherence, except living with family. However, several clinical 
characteristics were found to influence the medication adherence. Notably, HbA1c, fasting 
blood glucose, and diabetes complications were significantly higher among nonadherent 
patients compared to their counterparts who were adherent to drug therapy. The majority 
of barriers to medication adherence were reported by nonadherent patients and the most 
commonly reported barrier was forgetfulness. Higher levels of nonadherence (i.e. higher 
adherence scores) were reported among patients who were younger than 65 years old and 
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illiterate. Patients who believed that medications are not useful as a barrier had the highest 
adherence score among all the barriers.  
 
4.2. Qualitative Data  
 In-depth interviews were conducted with both patients and healthcare providers to 
gain an insight of the barriers to medication adherence in uncontrolled diabetes. This 
section will cover the themes that emerged from both perspectives.  
 
4.2.1. Patients’ interviews 
Fourteen patients with uncontrolled diabetes of varied gender, age, educational 
level, and nationality consented to be interviewed. Their characteristics are presented in 
Table 14. The average duration of the interviews was 33.86 ± 16.25 minutes with a range 
of 11-63 minutes. The average age of the interviewees was 58.29 ± 8.06 years (range: 46 
to 68 years old), while the average diabetes duration was 11.36 ± 6.22 years (range: 1 to 
20 years). The mean ± SD of HbA1c was 9.91 ± 1.43. All the interviewees were taking 
metformin as part of their diabetes treatment regimen, and five were taking insulin 
concomitantly. Six patients had neuropathy, three had nephropathy, and two had 
retinopathy. Other diabetes complications experienced by the included patients included 
foot complications (infection), increased hospitalization in the past year and amputation 
(of little toe).   
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Table 14: General characteristics of patients who participated in interviews (n=14) 
Patient 
No. 
Nationality Gender Religion Education level DM 
meds 
DM complication 
Pt. 1 Indian Male Hindu University 1 1 
Pt. 2 Sudan Male Muslim University 2 2 
Pt. 3 Indian Female Hindu High school 3 0 
Pt. 4 Sri Lankan Male Buddhism  Primary school 2 1 
Pt. 5 Yemeni Male Muslim University 2 0 
Pt. 6 Sudan Male Muslim Primary school 5 4 
Pt. 7 Egyptian Female Muslim Secondary 
school 
2 2 
Pt. 8 Iranian Male Muslim Primary school 2 0 
Pt. 9 Qatari Male Muslim Illiterate 3 2 
Pt. 10 Sri Lankan Female Buddhism Diploma 2 2 
Pt. 11 Indian Male Hindu University 2 0 
Pt. 12 Egyptian Female Muslim High school 3 2 
Pt. 13 Pakistani Male Muslim High school 3 0 
Pt. 14 Palestinian Male Muslim University 4 0 
Patient No.: Patient interview number; Pt.: Patient; DM meds: Diabetes medications.  
 
4.2.2. Healthcare providers’ interviews 
A total of 16 healthcare providers of diverse characteristics (profession, gender, 
nationality, and experience) were interviewed with an average interview time of 46.50 ± 
15.30 minutes (range: 21 to 129 minutes). The average duration of practice experience of 
the participating healthcare providers was 7.53 ± 5.93 years. The characteristics of the 
healthcare providers who participated in the interviews are summarized in Table 15.  
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Table 15: General characteristics of healthcare providers who 
participated in interviews (n=16) 
HCP No.    Gender Profession  
HCP. 1   Male Pharmacist  
HCP. 2   Female Pharmacist  
HCP. 3   Female Pharmacist  
HCP. 4   Male Pharmacist  
HCP. 5   Male pharmacist   
HCP. 6   Female pharmacist  
HCP. 7   Female Health Educator   
HCP. 8   Female Nurse  
HCP. 9   Female Social worker  
HCP. 10   Female Dietician   
HCP. 11   Female Nurse  
HCP. 12   Male Physician   
HCP. 13   Male Physician   
HCP. 14   Male Physician   
HCP. 15   Female Physician   
HCP. 16   Male Physician   
HCP No.: Healthcare provider interview number  
 
4.2.3. Barriers to medication adherence   
Despite the different perspectives of patients and healthcare providers, similar 
themes in relation to medication adherence emerged from the two groups. Since the themes 
retrieved from the perspectives of patients and healthcare providers were similar in context, 
the results provided a triangulation that enhances the validity of the results and are 
presented together to give an overall understanding of the barriers to medication adherence. 
All quotes from healthcare providers are denoted as HCPI followed by the interview 
number, while patients’ quotes are designated as PI followed by the interview number.  A 
total of 5 themes emerged from healthcare providers’ and patients’ interviews. Table 16 
represents all the identified themes and subthemes that emerged from the interviews.  
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Table 16: Themes and subthemes related to barriers to medication adherence 
Theme: Patient-related aspects (HCPI, PI) 
  Patient’s characteristics (HCPI, PI) 
  Patient’s perceptions, attitude and behavior (HCPI, PI) 
  Patient’s knowledge and source of information (HCPI, PI) 
Theme: Patient-provider interaction (HCPI, PI) 
  Patient-provider communication (HCPI) 
  Patient involvement in the decision-making process (HCPI, PI)  
  Patient-provider interaction time (HCPI)  
  Seeing more than one physician/care provider (HCPI)  
Theme: The appointment system and patient’s follow up (HCPI, PI) 
Theme: The influence of other people on patients with diabetes (HCPI, PI) 
Theme: Traveling and use of traditional medicine (HCPI, PI) 
HCPI: Theme or subtheme was identified from healthcare providers’ interviews  
PI: Theme or subtheme was identified from patients’ interviews 
 
4.2.3.1. Theme: Patient-related aspects  
Due to the diversity of codes and categories identified within this theme, three 
subthemes were generated. This includes patient’s characteristics; patient’s perceptions, 
attitude and behavior; and finally, patient’s knowledge and source of information.  
 Patient’s characteristics  
Patient’s age: Some healthcare providers perceived that older individuals or elderly 
patients tend to have lower adherence than younger adults due to being more forgetful, 
having many medications and are less independent than younger people.  
“The age yea .. the age .. as he gets older, he would forget .. because it's 
also with older age there would be other medications. it's not only diabetic 
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medications; there is antihypertensives, medications for cholesterol. Things 
would be crowded” HCPI 4.  
Conversely, some providers believe that younger patients are more prone to to 
medication nonadherence compared to older patients.   
“On the contrary, I find that older people are more careful and they come 
to their appointments .. and the young ones too most of them but the older 
people they are.. they come, and they are caring.. they come with their 
family or by themselves so that they take care” HCPI 7.  
Patients level of education: The level of education can contribute to the patient's 
ability to comprehend and understand the instructions given by the healthcare provider. It 
was mostly perceived that those who are more educated are more likely to be adherent than 
those who are less or not educated.  
“Of course if the patient is highly educated he would be able to receive the 
information and stick to the information that he received and everything 
will go smoothly and also it will reflect on the case itself like he would be 
mostly stable. But if someone who is not educated or not highly educated, 
you find that there is difficulty at least in the beginning like the first few 
months until things go smoothly and he knows how to control himself like 
how to make things, and he doesn't have problems” HCPI 5.  
When medications are dispensed, the patients are provided with verbal instructions 
as well as written labels on each medication box. There is, however, a general assumption 
that the patient will be able to read these labels and remember the instructions provided. 
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One of the interviewed patients was completely illiterate and therefore, depends on others 
to help him understand how to take his medications correctly.  
“I am uneducated .. illiterate. I cannot read or write. Now it’s been a while 
so I know them all.. If there is a new medication .. it would be written on it, 
so my wife would read it and tell me” PI 9.  
Patient’s socioeconomic status: Most of the participants (both patients and 
healthcare providers) indicated that the cost of medications is not a barrier to medication 
adherence since the amount paid by the non-Qatari nationals is only 20% of the total 
medication(s) cost, while for Qatari nationals it is provided for free. Therefore, for the 
majority of patients, this constitutes a minor proportion of their living expenses.  
“It's absolutely very, very reasonably subsidized .. for the same medicine 
you pay a lot outside. It's absolute.. It’s a rare kind service you don’t get 
anywhere in the world .. This kind of subsidized service, nowhere else. State 
people should feel happy that they are paying one-third or not even one-
fourth of the outside .. even if it’s increased because of economic issue .. 
The government is giving us more options .. People should not be upset .. 
People should be happy to pay” PI 11.  
On the other hand, there were patients with low-income levels or even with no fixed 
income and even the 20% of the total cost was considered expensive based on its proportion 
to the rest of their expenses.  
“Medication is expensive because I am jobless .. I pay like 170 and also my 
wife .. Medicine is more than four to five hundred per month. It's very 
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expensive .. anyhow .. we took before free of charge .. You see all these, still 
Crestor I didn’t take, because it's costly.., so medicine 400 to 500 per month 
for me. There is also Asthma.. myself also seratide .. I have Seratide with 
me .. so monthly I have for me only 150, 160 .. my wife also she took .. my 
son also .. Singular .. like this .. medicine expensive for us .. But we cannot 
purchase outside.. never .. Thank God” PI 13.  
 
“These [poor patients] are also few ..very small in number. You are talking 
about something [barriers], and this is one of the things that we face, but 
this is very small number, because as you can see the medication is not 
expensive and is available, but despite this there are some who can't afford 
so we send them to the social worker. So these are few, like for example in 
a couple of months you find one only. So not big number, the government 
here provides everything thank God. We pray it stays like this. Sometimes 
there are some people who cannot get the medications. He can’t, he is a 
laborer, he can't buy it. Money wise he can't afford the medications, so he 
takes one tablet and stops one tablet [alternating].. like this” HCPI 7.  
Patient’s working conditions: At many instances, the patient’s working conditions 
appeared to affect medication adherence. This was noted from both patients’ and healthcare 
providers’ perspectives.  
“I observed those patients who are busy and working and have stress also 
sometimes they are not compliant with the medicine .. I just observed.. 
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Because they just come here ‘oh I'm tired’ .. ‘I'm busy in my work’.. like this. 
If they are working under pressure .. sometimes .. they are tense .. they 
forgot their medicine” HCPI 8.  
 
“My work involves traveling a lot … this is actually one of the problems .. 
too much moving. Because once I went to Libya and there were problems, 
the medication finished and with the political tension I was out of 
medications for about ten days I did not take any medication .. But I also 
was controlling my diet .. until I get back” PI 2.  
Work conditions do not only affect the patient's ability to take the medications 
correctly, but also influence their ability to go to the healthcare center, hence, late collection 
of medications.  
“Some people it's a problem of coming to the health center you know .. They 
don't get time off to come here. They don't manage to get time off work, 
like you know, because they are working very long hours. Its specific people 
like housemaids, like drivers, security guards.” HCPI 13.  
Religious aspects: Qatar is a multicultural country, bringing people from different 
religions and cultures. Religious rituals and beliefs may differ from one religion to another. 
Fasting, however, is one ritual which is not limited to Muslims only, but is practiced by 
other religions as well. One patient who was Hindu indicated that he fasts for a specific 
duration of time, and during this period he only eats vegetables but does not take his 
medications.  
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“There is one-month fasting but not complete; we can use vegetable, not 
non-vegetable. Light food and I don’t use insulin, no, because the food is 
very light food, so I don’t take it. Only vegetable, so I don’t think this will 
increase my sugar” PI 1.  
It was noted that Hinduism has many affiliations and not all the affiliations have a 
dedicated fasting period as mentioned above, while in Buddhism, the patients indicated 
that they do not have fasting period. On the other hand, Muslim patients are asked to come 
before Ramadan to fix their doses and assess the ability to fast. Yet some patients use their 
own experiences to adjust the medications dosing during this holy period.  
“I change the dose in Ramadan by myself .. It’s two times.. morning and 
evening same..” PI 13.  
 Patient’s perceptions, attitude and behavior 
 Patient’s perceptions and attitude about diabetes and their health: One healthcare 
provider noted that some patients do not care much about their health status or about their 
disease control; and some become careless because of the realization that diabetes is a life-
long chronic disease condition. They realize that they will be taking medications for the 
rest of their lives, so they just give up trying to make it controlled. 
“They are not very happy with the fact that it’s a lifetime disease .. This is 
one of the reasons. Also they feel that it should be for their lifetime.. this 
doesn't make them happy .. So they feel okay I can take it [medications] all 
my life so maybe one day yes one day no” HCPI 2 
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Laziness to re-fill medication was perceived a sign of lack of motivation by some 
healthcare providers and patients alike. One of the participating healthcare practitioners 
noted.  
“and some when their medication is finished already they are like lazy or 
tired to go to collect their medicine like that” HCPI 8. 
 
“Honestly I was very careless in taking the medication on time and they 
[healthcare providers]  just told me now that I have to take it at this time, 
then it must be on the same time, I was taking it anytime, when I remember 
I would take it, so of course, they told me this is wrong and so, things were 
messy in this regard, and I try to fix it” PI 8.  
 
“Thank God .. I am taking my medications, but sometimes someone would 
just get lazy about taking the medicine .. so .. like Januvia it’s been two days 
it’s finished and I was lazy to come here, so today they found my sugar 11” 
PI 11.   
Data generated pointed out that many patients with diabetes may present without 
symptoms. Some of the participants indicated that such patients have a hard time accepting 
the disease, and therefore, they do not take the medications as instructed.   
 “The patient is unconvinced about the disease. There are patients who 
deny they are sick and they are not convinced they need all these 
medications especially in the elderly… I see this” HCPI 3.  
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“This is more common in type 2 diabetes because of type 2 diabetes. Here 
in particular, they are lucky that they are diagnosed early before 
complications. They tell you or for example they go to do a surgery and says 
if you do anything in Hamad they will tell you that you have diabetes ‘I went 
for surgery and ended up with diabetes‘, ‘I don't feel any complications’ 
‘there are no symptoms for diabetes, I don't feel thirsty, or frequently go to 
the toilet’” HCPI 10.  
On the other hand, some patients realize the seriousness of the disease after the 
occurrence of a serious complication or after witnessing the death of someone they care for 
due to complications associated with diabetes. Such trauma creates a motivation for the 
patient to care more about their health to avoid going through the same path as others.  
“I got an abscess in my foot, so they amputated my little toe, so that you 
know, it affected me a lot. Now I care more, especially about my feet. So 
when you see it [the disease] hitting you even if it’s a little toe you start 
being more protective of himself, because sometimes these things make 
you realize that diabetes is very important to control” PI 2.  
 
“If you don’t take care of diabetes, ultimately diabetes will make you suffer, 
because I know in my family there is a history. People are dying because of 
diabetes. I have seen,  I am seeing,  my mother died because of diabetes. 
From diabetes she developed complications and then she died, my own 
father, everyone was diabetes, they did not take care of the things. My own 
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brother who is younger than me by one and a half years,  very serious 
disease,  he is diabetic. His kidneys are damaged, he is on dialysis every day. 
He is younger than me. He did not bother about his food habits. He did not 
bother about his things. During his engagement he knows he is diabetic. So 
what’s happening? It has a direct effect. It kills you slowly. It doesn’t kill you 
fast, it kills you slowly” PI 11.  
Patients’ refusal and fear of medications:  Results from interviews revealed that 
patients fear medications particularly insulin since it is an injection. Some of the 
interviewed patients expressed fear of needles and apprehension to self-inject while others 
were afraid of side effects. Many regarded insulin as a final or late treatment, and can cause 
more harm than benefit  
“Once you start insulin, means you have to continue… you cannot stop it, 
your body will get used to it,  and that’s it, no escape” PI 3.  
 
“Insulin, yeah there is a total fear from it because it's a needle prick every 
time so yes. There are many patients that say I will not take insulin let me 
get tablets and I will manage with the sugar even if its high a little, I will 
manage, but I will not take insulin. insulin is something which is scary and 
the procedure itself people are afraid of the needle prick and everything” 
HCPI 2. 
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“yes that is the biggest barrier: starting patients in insulin. I have like a 
problem with two or three patients, I tried my best to convince them to start 
insulin ok; first it's the needle phobia, they don't like this every day needle; 
second it’s the understanding, like this [insulin] means there is no hope, this 
is bad thing gone very bad; so I think it affects their whole lifestyle. That's 
what I have noted” HCPI 13.  
 
“and fear from hypoglycemia .. they hear that this person was taking insulin 
got hypoglycemia and died, so they completely refuse it because of fear 
from dangerous side effects” HCPI 15.  
Part of this fear is due to what others say about insulin, the stigma associated with 
its use, and also the misconception that insulin is addictive. Consequently, even when the 
patient fulfills the criteria of insulin initiation, they tend to refuse to take it.  
 “I took insulin for a short time and then I stopped it. I didn’t like to take it 
in front of people; it’s just they look at you like you have something very 
bad. I stopped it because people told me I should never start insulin and I 
should stay on tablets only. They told me that it could damage the body. 
Actually, they told me to stop all medications. So I stopped insulin and the 
doctor tried to convince me, but I don’t want to take it” PI 14. 
 
“Yes that is the biggest barrier starting patients on insulin. I have like a 
problem with two or three patients, you know, I tried my best to convince 
them to start insulin ok. First, it's the needle phobia; they don't like this 
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every day needle. Second, is still the understanding, you know, like this 
means there is no hope. This is bad thing, gone very bad and the third thing 
is they think once they got insulin there is no, like, it will affect their jobs, 
and you know things like that. So that's what I have noted” HCPI 13. 
  
Although health care providers try their best to convince patients about the 
importance of insulin in managing their diabetes, patients exhibit resistance to taking 
insulin. Therefore, providers end up adding more oral medications in an effort to reduce 
the high blood sugar and risk of complications as noted by one of the healthcare providers. 
He commented”:  
“People have a fear from insulin, and at many times they really refuse to 
take it, so you see a doctor going for Quadramed [four different diabetes 
medications] which is really weird because it's not recommended by any 
guideline, but it's done because the patient does not want insulin at all. I 
DON'T want to start anyone on insulin because insulin here is killer… People 
can die because of insulin.” HCPI 12.  
Patient’s perceptions about the effectiveness of medications: Many patients stop 
taking their medications because they did not see any improvements in their sugar levels.  
“I used all the tablets there is, but, from my opinion, these tablets are 
useless. So I tried Daonil, Amaryl, Diamicron, and whatever... All of these 
did not control my sugar, except for insulin. Tablets they are very slow. They 
should stop it! It doesn’t have any effectiveness. I tell them; the people who 
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use tablets: you must be on diet control and must have exercise on daily 
basis. They ask me why, I tell them these tablets are slow and insulin is much 
faster, but since you are taking tablets and stuff, you must control your diet 
and do exercise on daily bases” PI 2.  
One patient considered that all chronic medications are ineffective, because 
pharmaceutical companies do not really want to cure these diseases as they are a source of 
profit to them.  
“Look, you see all these medications, they are useless! Companies lie to us.  
I read once they get over 100 billion from diabetes medications. They don’t 
want to help people, because keeping them as they are means yearly profit 
of billions and billions of dollars on yearly basis. If they cure you, they lose 
all this money. So they make useless medications that barely affect your 
sugar, so you take more and more of it.” PI 14.  
On the other hand, there are patients who do not believe that insulin pens are as 
effective as vials. Therefore, they do not take the pens when prescribed for them and ask 
for the vials instead.  
“The second thing is the injection itself, before there was the vial, now there 
is the pen. Some people are complaining about the pen, and they ask for 
the vial. Imagine!  I have three, four patients, they tell me they don't want 
the pen. I don't know, my dear this pen is painless, but these are very few 
like in all my patients just three or four. No, he feels that the pen is not 
controlling his sugar. “He feels”. Okay but the blood tests are the ones that 
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would inform and he can't understand that the vial is the same as the pen. 
There is no difference between Novomix and Mixtard, it's the same” HCPI 
16.  
 
“I had a bit of perception on the pen and on the regular insulin injection the 
bottle. One time I have taken the pen, I felt that my sugar level is not 
controlled with the pen, because I felt that the insulin is not going inside,  
so I have changed. Then I asked the doctor. Psychologically you should be 
happy taking this new medicine. I told him very clearly that I am not happy 
by taking the pen; I would like to switch over to my injection, my syringe.” 
PI 11.  
Patient-initiated changes in medication regimen: In many instances, patients 
intentionally change the prescribed dose of medications. This happens at the discretion of 
the patient based on the blood sugar level or based on their diet.  If they notice their glucose 
readings are high they tend to take more of the medication and vice versa. These changes 
are not limited to insulin, but to the oral medications alike.  
“Sometimes they [the patients] want to take the medication according to 
their convenience, “this one is ok .. ah .. this I don't like”, sometimes the 
patients are like that” HCPI 8.  
 
“Sometimes you get a patient who takes Januvia twice, and there is no 
added benefit from taking this twice, so you see for example he is taking it 
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like this by himself like he felt he is uncontrolled, so he decided to take 
Januvia twice” HCPI 3.  
 
“Sometime, this Amaryl,  it's supposed to be three tablets in the morning, 
but I take 2 tablets. Sometimes when I see that the meal has no rice, like 
this” PI 13. 
Patients on insulin are generally educated about adjusting their dose based on their 
diet. This is very common with type 1 diabetes. However, all the patients who were 
interviewed had type 2 diabetes and most of them were taking insulin glargine, a long 
acting insulin usually taken in the evening. Nonetheless, patients would adjust the dosing 
of the medication based on what they perceive appropriate and without a standard 
procedure or actual calculations.  
“When my blood sugar is high. I would take higher dose, I just do it myself, 
I estimate and I just take it when my sugar is high.  Like yesterday, I didn’t 
eat or anything, and I don’t know why my blood sugar was high. For the 
first time I found it 300, so for 300 the only thing that works is insulin dose. 
When I took it, unfortunately I got hypoglycemia at night. When I get 
hypoglycemia I am not the type that can sleep; I can’t sleep. There are 
people who can get diabetes-related coma. I just feel that I can’t sleep. 
When I feel this I would get up and measure my blood sugar and I find it 
low, so I feel this is what make me unable to sleep” PI 7.  
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Taking medications is a burden on its own, yet sometimes the healthcare provider 
does not take this into consideration when prescribing medications. Some patients would 
be prescribed more than one tablet of the same medication, and the patient would not 
administer them all at once in an effort to reduce the burden.  
“I don’t take them [tablets] all at once. In the morning after breakfast I take 
half of them, the controller [Glucophage] and sometimes the aspirin, and 
at night I take the rest of them. It's too much tablets to take together” PI 
14.  
On the other hand, providers indicated that some patients stop the medications once 
they are stable. This is because of the wrong belief that diabetes is a short-term acute 
disease that is curable.   
“As soon as he [the patient] notices stability.. Look there is a belief in some 
people that yeah .. they tend to convince themselves that if they are better, 
they can stop the medication, so he tends to do this or believes that this is 
something minor and it would go away, and he sees himself stable once, 
twice, and three times that's it; the disease went away, so he starts to get 
worse again. This keeps happening until he is convinced” HCPI 5.  
However, sometimes the patient tends to unintentionally forget to take the 
medication due to house chores for example and would take it at an incorrect timing.  
“Sometimes I would be cooking and so, I forget to take the injection before  
... Like I set the table and we start eating, and I would forget.  I could be 
eating, and in the middle, I would remember, but sometimes I forget, and I 
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feel .. I remember after that, and I find the sugar really high, and sometimes 
I feel that my arm hurts and I remember that I did not take the injection. 
Because when I don’t take it I feel that my arm is numb,  and it would hurt, 
I feel it’s heavy, so I remember that I didn’t take the injection, so I take it 
and thank God it gets fixed. Most of the time I don’t take it, but thank God 
when I forget I would end up taking it after food” PI 7. 
Some patients would combine medication doses when they missed a dose, which 
predisposes them to possible adverse effects.  
“Sometimes I don’t take it [mediation tablet], I forget. Some medications I 
am taking one in the morning and the other medication in the evening, so 
if I forget the morning medication, I will have it combined with the evening” 
PI 10.   
Patients always try to incorporate their medications in their daily routine; however, 
sometimes the routine is changed because of a special occasion which results in them 
forgetting to take the medications. These special occasions usually happen during the 
weekend which by itself is a different routine than weekdays.  
“Weekends it is distorted. Simply distorted because of any other thing. It 
[the routine] is never distorted other than the weekend. Sometimes I go for 
dinner. Sometimes some friends call us. We just go there and at 11:30 or 
12:00 we come back. Ok 12 o'clock you don’t take medicine. You are 
supposed to take medicine at 9 o'clock, so at night you skip it. Next day 
again you start.” PI 11.  
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Experiencing side effects is one common reason expressed by the patients for 
stopping or changing the dose of medications. Most commonly discussed side effects were 
gastrointestinal-related side effects mainly with metformin and hypoglycemia with insulin.   
“I stopped taking insulin long time ago because one time I fell down in my 
office because my sugar was very low, was very low, it's very bad feeling 
when you can’t move” PI 5.   
 
“For me Glucophage causes me disturbance, always disturbance. This is one 
reason why I prefer not to take it. Like sometimes I remember it's time for 
the dose, but I don't want to take it because of the disturbance it causes 
me” PI 8.  
 Patient’s knowledge and source of information   
Many patients gain knowledge about diabetes and its management from family 
members who have the diseases. This prior knowledge seems to help the patient be more 
adherent than those who never had an experience with the disease through someone they 
know. The majority of patients, however, receive the education from the healthcare 
provider. Nevertheless, there were a couple of patients who did not know what diabetes is. 
This could be because they were not initially diagnosed at the primary care center.  
“Yeah the nurse told me, because of its model of care, you know. Why do 
you become diabetic? What is pancreas? How does it work and how does it 
not work? What are you supposed to do etc. and why are you given insulin, 
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and how are you compensating with insulin, so all this I know from here 
[center]” PI 11.  
 
“Researcher: You know when you have the disease someone will explain 
what is the disease, how does it happen, what is the treatment, did anyone 
explain this to you?  
P: Never, never, no. No one explained, because for them it's ten years I have 
diabetes” PI 13.   
As for medications, all interviewed patients know the correct instructions for their 
medications. However, when asked about their knowledge of how medications help in 
diabetes, many could not answer. The patients who do not receive education or information 
about the disease and the medication, usually will seek the information from other sources 
such as the Internet, or from other people.  
“I saw on YouTube what is diabetes, yeah. Anything you want; YouTube is 
there just type that only” PI 3.  
 
“No I refer to the Internet also, and I am getting educated by the Internet 
also, and most of my friends also are having the same medical condition so 
by them also I learned” PI 10.  
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“It’s [education] from the physician yes. But they [patients] have you know 
may be from other people or other friends or those who have experience” 
HCPI 2.  
Many patients indicated that they did not know their HbA1c levels or the goal 
they should achieve. Healthcare providers justify this by saying that they do not tell the 
patient if the levels are within normal range, but would only indicate if it is good or not.  
“Maybe they don't know the levels because the doctor told them and they 
forgot, or they don't know what HbA1c is, or it could be that we have seen 
it normal so why bother the patient and tell him you are 6 point something. 
But if there is something major, like for me I always tell them, their HbA1c 
is good, this is good” HCPI 15.  
Generally, patients gain information and expand their knowledge about the disease 
and medication from the healthcare providers especially through medication reconciliation. 
Medication reconciliation which involves educating the patient about his/her medications 
is highly underutilized. This service is provided by the pharmacist in a dedicated room 
within the pharmacy, but is only used upon physician referral. 
 “May be for the physician if he noticed that the patient is uncontrolled and 
he did not know how to use his medications and the purpose of taking the 
medications.. Maybe he (the physician) can ask for medication 
reconciliation so the pharmacist can sit personally with the patient to 
educate him about it. This happened in the last three years two or three 
times only” HCPI 1. 
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Unfortunately, pharmacists are not allowed to bring the patients from the 
dispensing window to the medication reconciliation room even if they identify that the 
patient is confused about their medications or lacks certain medication- or disease-related 
knowledge. This can only be done upon the physician’s referral.  
“This year no we didn’t do medication reconciliation, last year I did .. This 
year I didn't get the chance.. It was maybe 2 to 3 times last year. Surprised 
right! .. We don't have medication reconciliation regularly .. They are not 
sending too many patients.. Very less. That’s what this is.. Depending on 
the physician themselves .. He has to refer to the pharmacist” HCPI 2. 
 
4.2.3.2. Theme: Patient-provider interaction  
Several aspects are involved in the patient-provider interaction. These include 
communication, patient’s involvement in decision making, time of the interaction and the 
involvement of many physicians in the patient care.  
 Patient- provider communication  
Patient-provider interaction, particularly communication, plays a vital role in the 
care of the patient. Although the main languages spoken are Arabic and English, healthcare 
providers often see patients who are unable to speak either Arabic or English, and some 
find it difficult to communicate.  
“The language barrier is a huge problem .. For example here we have two 
to three Indian sisters with us here, but unfortunately not in all the areas .. 
Sometimes I have my colleague and I working on shifts, she has some days, 
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and I have some other days. Ok, if I  found that it is difficult to deal with the 
patient because of the language .. like if I had a patient and he is Indian I 
tell him to go and take the appointment on date x, the date where she is 
available because she knows Indian and sometimes I request one nurse, and 
from reception there are boys, and they can come and interpret” HCPI 10.  
Sometimes the patient is able to speak the same language as the provider. However, 
the provider would use medical jargons which the patient is not familiar with.  
“Language is one barrier also sometimes they [other providers] use medical 
terms and the patient doesn't understand what is meant. So the patient 
comes and asks me, and I explain to them” HCPI 2.  
The magnitude of this barrier could not be adequately investigated from the 
patient's side as those who can speak either English or Arabic were selected to participate 
in the interviews.  
 Patient’s involvement in the decision-making process  
Another feature of the interaction between the patient and the healthcare provider 
appears to be the involvement of the patient in the decision-making process. Some 
providers indicated that there is no patient autonomy in the decision-making process.  
“Generally, no - the patient does not know what medications were 
prescribed to him … He [the physician] just writes the order, and the patient 
comes to the pharmacy, and we tell him this is the medication prescribed 
for you by the doctor .. We ask did the doctor tell you he will add a new 
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medication "yes" that's all .. did he tell you how to use it "yes" but that's 
all” HCPI 3.  
 
“... some medications they [healthcare providers] change.. I am not aware 
of this plan.. .. But I showed these medications in my country and they told 
me these are the best medicines” PI 10.  
 
 Patient-provider interaction time 
There is a continuous increase in the number of patients attending primary health 
centers, while resources and number of providers remain to be limited. This has a direct 
influence on patient management and the quality of care provided which ultimately affects 
the patient’s adherence to medications. Therefore, interviews pointed out that the time of 
the interaction between the patient and the physician could be another perceived barrier to 
medication adherence.  
“There is not really enough time, actually there is never enough time, but 
you also can’t do it all in one visit. You educate the patient about the 
condition the first time and then ask them to come back a week later to 
carry on from where you left off .. You have a total of 15 minutes with the 
patient of which only 7.5 minutes go to educating the patient about what 
they have, the symptoms, and how to manage with the diet and exercise, 
and their medications, and side effects… Time is inadequate especially if the 
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patient comes late or misses an appointment and we don't know what 
happens” HCPI 12.  
 
“I don't know if he [the patient] is taking his medications because I don't 
ask .. I don't ask if you take the medications or not. I just dispense here, and 
that's it .. There is no time to even deal with him much with the pressure 
here in this center .. And the number of patients lining up, it’s impossible to 
take more time with the patient” HCPI 4.  
 Seeing more than one physician/care provider 
Some participants indicated that seeing more than one care provider for the same 
issue (i.e. diabetes) can create unnecessary confusion and complications in the care 
management plan. When the patient seeks care from different providers, he/she often 
receives different information from each, a situation that can lead to confusion.  
“Some patients they are like doctor shopping, so they go and see all the 
doctors because they are not convinced by one physician .. These are always 
having poor adherence … His physician has changed, so he didn't like to 
continue .. or he came to a different doctor and the doctor gave him 
information different from the first physician .. So these could be some 
reasons for not taking the medications” HCPI 15. 
Sometimes the patient gets an appointment with different physicians, but not 
intentionally as it is not ideally set in the appointment system itself.  
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“I saw so many doctors here .. I once told my friend.. I told him in Hamad, 
it’s like the United Nations .. one day it's Indian, one day it’s Egyptian, one 
day it’s Sudanese, one day it's Jordanian, and each has his own way of doing 
things” PI 2. 
Other times, the patients seek different providers from different health settings and 
even different countries if they have the opportunity to do so, such as having private 
insurance.  
“I’m following up with another physician outside in Doha Clinic .. and I 
follow up with him .. because I have private insurance as well” PI 2.  
Patients who seek different providers in different locations are much more difficult 
to manage, particularly that the patient records are incomplete and split in multiple 
locations. This clearly reflects on the patient's treatment plan and medications. Each 
provider would change the treatment plan according to what they deem appropriate.  
“I change the doctor, then now he changed the medicine .. Before.. actually 
first, I used two [medications] for a month .. then I go to another hospital .. 
and then they do nice medicine, and everything is good .. then after 
suddenly they changed medicine.. then I went to three. four pharmacies .. 
each doctor, is changing the medicine” PI 3.  
 
“There was a patient … one physician told him there is no need to take this 
medication while another tells him no you should take it ..We have many 
like this and on the system you can note the conflict of opinions between 
  
   
107 
 
the doctors.. Of course when you change the physician or when you change 
the opinion between physicians in Hamad and physicians in PHCC this can 
affect medication adherence” HCPI 3.  
When such changes occur, the patient may get confused and end up taking all the 
prescribed medications from the different prescribers which only adds to the complexity of 
the regimens, leading serious adverse effects and nonadherence to therapy.  
“Look I know in general the attitude of the geriatric in general like they have 
a problem in sometimes trusting the medication or trust in the physicians 
themselves for example or conflict of opinion between the doctors and the 
rapid change in medications for them.. The patient becomes confused, he 
doesn't know should I take this or that.. and sometimes he takes all 
together” HCPI 3. 
 
4.2.3.3. Theme: The appointment system and patient’s follow up  
The late appointment is a barrier noted in many interviews from both patients’ and 
providers’ perspectives alike. Participants indicated that over three months appointments 
(mostly six months) are not good as a follow-up timeframe. During this time, it is unknown 
whether complications occurred, or whether the patient faced any problem with the 
medications.  
“Six months for diabetic patients is a lot .. especially if they start on new 
medications, and you ask them to come back in six months .. If there is a 
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start of complication like in kidney .. If there is proteinuria .. he will come 
back with high creatinine the next time” HCPI 10. 
 
“Medication adherence is a major problem for a number of reasons. First, 
in general, follow-up is poor. Six months follow-up will not really help the 
patient. The patient comes every six months and gets medications in three 
batches every two months as refill.. You don't know what is going on within 
this period if they are attending for refills or not.. and you just have no idea 
about what is going on… and when the patient comes after six months it's 
all a waste to the clinic.. It’s a problem and all what the doctors do is repeat 
the medications” HCPI 12.  
Even patients find the appointment schedules problematic for them and perceive 
these as very long especially if they are facing problems with the medications or their 
condition.  
“Now look .. to be honest with you .. here in the center if you want to meet 
the physician for diabetes, it’s as if you are meeting the Prime Minister .. 
They give you appointments you know after 3 months.. four months .. very 
long … and sometimes when they give you after three months and four 
months.. you find yourself without an appointment” PI 2. 
However, some providers indicated that the late appointment schedule is not fixed 
for all patients, yet it was not clear if there is a set of standards or criteria identifying which 
patients would be scheduled for two months appointment for instance compared to those 
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scheduled for six months appointments. There were obvious inconsistencies between 
providers in terms of follow up duration.  
“I think the six months NCD is not fixed .. Like if the patient's compliance is 
good .. the blood test is generally ok .. we give them a six months 
appointment .. but if we feel that their HbA1c is not good .. or they need 
slightly more .. we also give them three or four months appointment as well 
.. But because NCD clinics are quiet overbooked .. we tend to give them six 
months if they are you know .. reasonable .. but if their control is very poor, 
we have the ability to give an early appointment as well … I tend to give 
them 2 to 3 months appointment to see them extra if things are not very 
good .. I try to bring them to the general clinic” HCPI 13. 
4.2.3.4. Theme: The influence of other people on patients with diabetes 
 Social stigma is a factor which highly influences treatment success especially if the 
disease is perceived negatively by individuals close to the patient or the society in general. 
If the patient needs to hide the condition from the surrounding people, he/she surely would 
not be taking the medication as he should.   
“I had one patient with type 1 diabetes, and she got married and pregnant, 
and she did not tell her husband she is diabetic, and she came, and I didn't 
know this information. So we started talking about diet, and she would say 
its gestational diabetes .. because her husband was with her .. So I went to 
the doctor and told him is she type 1 diabetes and he explained the situation 
to me .. So we started to deal with her that this is temporary .. it came 
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during your pregnancy and we gave you insulin for it .. We did this and 
moved on because of patient privacy.. and also because it is something that 
could create a problem for her which could possibly lead to a divorce 
because she did not tell her husband about it before.” HCPI 10. 
Patients also indicated that it is difficult to take injections in the presence of other 
people as injections are associated with addiction.  
“Honestly, I intentionally sometimes not take it in front of people .. I 
remember I was once taking insulin and someone got up .. and from far he 
screamed .. hey heroine! .. I told him does it make sense for someone to 
take it like that! .. So since then I intentionally don’t take it in front of 
people” PI 2. 
Patients are highly influenced by what the surrounding individuals say and talk 
about. Sometimes they share information about the disease and the medications, and they 
advise each other on the best treatment according to their experience.  
“Honestly I asked him [the physician] to prescribe it [sitagliptin] for me .. 
because my siblings in Egypt they are taking it .. and they are doing well on 
it .. So I told him my siblings are taking this .. so he told me okay we stop 
the glucophage and we take this” PI 12.  
 
“Sometimes patients are inviting each other over medications ..like he [the 
patient] has high blood sugar and is taking a specific medication and he 
happened to be a guest at someone or at his friend’s house, so he [the host] 
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gives him a tablet of medication “and this will fix it for you” … sometimes it 
could be completely wrong” HCPI 5.  
The majority of interviewed patients indicated that they receive family support 
through reminding them to take the medication on time or through helping them in diet 
management. However, one patient indicated that family support is lacking which 
influences how she manages her health.  
“That one [family support] really we need .. someone will take care .. 
someone .. something .. Here it’s a routine .. My husband will go off .. he 
will go for ten days .. one week. Then he will come .. I am alone in my house 
only .. children I have to care about I have to pick ..I have to drop, I have to 
go to health center .. This is my life.. so minimal support” PI 3. 
Many patients are being cared for by housemaids and individuals other than their 
close relatives. It is very important to determine who is taking care of the patient and to 
educate them as well about the patient management.  
“There was once a housemaid and there was a Qatari woman on a 
wheelchair and I was asking her [the maid] who gives the medications to 
the patient? .. She said I give her .. So I said ok come on how do you give her 
the insulin .. and it’s all wrong ..all her answers were wrong!! And there was 
another pharmacist .. I told him come and see .. the patient is sitting over 
there on the wheelchair and the maid is giving her, her medications and I 
ask her about each medication and each is given wrong there wasn't one 
medication correct answer.. All were wrong” HCPI 6.  
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4.2.3.5. Theme: Traveling and use of traditional medicine 
More than 60% of the Qatar’s population are non-nationals and majority of them 
would travel back to their home countries for vacations and on special occasions. There 
was a consensus among all the interviewed providers that traveling is a big barrier to 
medication adherence. Patients generally go back to their home countries and change in 
their medications, believing that their levels will automatically be improved once there. 
“He [patient] has an idea that when traveling to his home country, he will 
get better and his health will improve, he will get better. These two things 
are very common, so that's why he would reduce the dose by himself. It may 
have a right aspect to it, because when he goes to his family, he will 
psychologically improve. Also, in his country, he doesn't use cars, and so he 
walks. He also considers that the food there is healthier, etc. So anyone who 
travels and comes back from travel, I automatically consider him 
noncompliant.” HCPI 14.  
 
“When I go to Egypt, I think my sugar can be controlled without insulin, 
because I move; I go around and up and down. So there is always 
movement, but here I can’t move; I just stay at home” PI 7.  
Another provider considered nonadherence during the travel period to be 
acceptable as it is difficult to be controlled all the time.  
  
   
113 
 
“In Christmas, in Eid, Ramadan, these are seasons patients get messed up. 
Holidays; they go travel back to their families, they eat, and I don't insist on 
the patient. To win the patient over, I don't scare him.  I tell him it's okay 
once in a year its fine, because he is human at the end, for sure he will be 
invited and for sure he will go. It’s a vacation!” HCPI 15.  
The general policy at the primary healthcare centers is the provision of medications 
for a maximum of two months for non-Qatari patients and three months for Qatari patients. 
There are no exceptions to this rule, therefore, patients who travel for a longer time (e.g. 
exceeding two months) are not given enough supply. This is considered problematic from 
patient’s perspective, while providers consider this to be acceptable.  
“Sometimes, because they give only two months and sometimes the 
medicine finishes before, so I buy from outside. I don’t know why they do 
this.  I think they don’t believe I travel or maybe they think I take medicine 
for other people, because here it's cheap yes. I don’t know .. Can you tell 
them this is bad” PI 8.  
It is well known that certain items are not allowed on the aircraft, one of which is 
sharp objects such as needles. One patient indicated that it is very difficult to take his dose 
of insulin when traveling because of this factor.  
“I am here in the gulf area for the last 30 years. I have seen each security 
man in the airport, so as a patient you don’t take it [to the airplane] because 
you are afraid why, because they will remove it and throw it away. They will 
not do anything but throw it away. So you don’t take the insulin on that 
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day. Traveling you take 5 to 6 hours to reach home, then what happens is, 
you are traveling from seven you are supposed to take your dose at 8 you 
don’t take it” PI 11.  
Moreover, there are patients who start using traditional and complementary 
medicines or natural products that are common in their home countries and difficult to 
obtain in Qatar. This is not limited to one culture over the other, but was noted in many 
patients from different cultures and ethnicities.  
“I take Sri Lankan medicine, but it’s very time consuming and you have to, 
when you are taking that,  you have to continue it. You should not do lots 
of things, you should not eat some kind of food .. There are lots of 
instructions, and it takes lots of time and the thing is in this country you 
can’t do it because I have to go to Sri Lanka and do it.  it’s not easy. When I 
am in Sri Lanka,  I think of doing it, because it is more effective and fewer 
side effects” PI 4. 
 
“I am living here for the past 14 years here, so I can’t take except these 
medications, but when I go for vacation I use them [traditional medicine]... 
Yes they are useful, because they are more useful and are safe. Our 
grandparents they teach us these are good and they come from nature, so 
they are good” PI 10.  
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Nonetheless, there are patients who use some herbs and spices which are easily 
found in Qatar to help reduce the blood sugar; this includes okra, cinnamon, and many 
others.  
“Yes so many [use herbal and traditional medicine]. The garlic tablets, 
cinnamon ginger, whatever. And these things they take it a lot;  Roselle,  a 
lot. Its everyone; people from the gulf countries, from Qatar, from outside. 
On the contrary, not only Indians for example, they have a lot of beliefs in 
herbs” HCPI 13.  
One provider indicated that people tend to use these products in an effort to 
completely cure themselves of diabetes.  
“To be honest, I have noticed that mostly the people between 30 to 40 
middle aged as we call them; those are the ones mostly they experiment a 
lot, you know they will go to India as they heard about this herbal medicine. 
They say if you take it for six months,  you know. So mostly drivers, house 
workers, low socioeconomic, they tend to try in the initial phase alternative 
medications as well. Its more cultural, because in India there is historical 
tradition of going to the natural path and most of these people you know, 
they are from villages or small cities in which still there is strong culture of 
trying natural remedies first. So this population they will start taking it, but 
they will just disappear and come after few months, with very bad HbA1c 
and everything is all over the place and when you ask them what happened, 
you know, they will say I have been taking this medicine from India because 
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I don't want to take this medicine for whole of my life. So I was just trying 
that to be cured completely” HCP 13.  
 
4.2.4. Strategies and interventions to tackle medication nonadherence  
Interventions to improve medication adherence are widely reported in the literature. 
However, the interventions are usually planned and tested from researchers’ perspective. 
Long-term benefits of interventions and their sustainability can possibly be achieved if the 
stakeholders (patients and healthcare providers) were both involved in identifying the best 
interventions that work for the patients and are applicable in the primary healthcare setting.  
 
4.2.4.1. Theme: Patient-related interventions  
Multiple intervention strategies to tackle the problem of medication nonadherence 
were proposed by both patients and healthcare providers.  
Providing more patient education was the most prominent strategy stressed upon 
by the interviewees. Other suggested interventions include the use of mobile phone 
applications and pillbox for medications.  
 Providing more patient education  
Many of the identified barriers can be overcome with the provision of more 
education. Even patients who have diabetes for a long time were asking for more education 
and more emphasis on the information.  
“Now I have had diabetes for twelve thirteen years, so I know now how to 
control, but there should be education and awareness more than this” PI 2.  
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One provider suggested the use of demonstration of complications as a means of 
convincing the patient about the seriousness of the disease. One interesting suggestion was 
the use of a video which can demonstrate the journey of a nonadherent patient.  
“For me because I am a visual person, so maybe a video clip every time they 
would show to them [the patients] may be some situations we can show to 
them.  So if there is a video clip that would show what would happen if you 
are not compliant to the medicine, could also create an impact. But the 
problem is may be the language ..if the patient is not speaking that 
language may be can’t understand, but if it’s moving,  it could relate. So 
maybe during the visit it will take time also for each patient fifteen minutes” 
HCPI 8.  
Another suggested educational material was the use of brief, easy-to-read patient 
information leaflets (PILs) which can be provided in more than one language. Leaflets 
should describe the disease and its management and avoid complicated terms and 
instructions.  
“I used to have leaflets in Urdu for patient and give them out, but I ran out. 
They included information about the disease, but I never had any in Arabic. 
Arabic leaflets would be really helpful” HCPI 12.  
 
“For example leaflets that have brief information in Arabic, in simple 
English. What is the medication? How it works? Not the medication leaflet, 
this would confuse the patients and give the things that are rare sadly, they 
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write rare things. It should tell them simple things like if you had this, do 
that. If this happens, this is expected. This would help a lot” HCPI 15.   
Patients group discussions and meeting was also another suggestion by a healthcare 
provider. The idea is to bring a number of patients for an educational session and providing 
them with information as a group rather than one at a time. 
“First we need like, especially for the new patients, we need proper diabetes 
education program. May be we have once a week something like we call all 
the newly diagnosed and bring them together. Like if we are diagnosing 2, 
3, 5 patients, they have the opportunity to, you know, meet with the 
diabetes educator, like a formal meeting in which she has lots of time; may 
be half an hour or something .. as a group .. to educate them. That’s one 
thing in which she will explain what is the illness,  how insulin would affect,  
you know,   depending  on what they do” HCPI 13.  
 Mobile phone application and SMS reminders  
The use of technology and mobile phones in addressing medication adherence was 
recommended by one patient. He suggested that mobile reminders and SMS text messages 
would help him remember to take his medications and would solve the problem of 
forgetfulness.  
“The best way, cheapest, through the SMS services. Everyone has got a 
mobile. If an SMS comes to the diabetic patient saying that please time for 
your medicine, time for your insulin. It’s just a reminder; time for insulin. 
You tend, the moment the mobile bleeps, everyone in this world right from 
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the age of 8 to 80 they have the habit to check what is this message. The 
message for a diabetic patient will help. You need to develop an application 
as a reminder. The technology is so much advanced now so the healthcare 
system should develop a system. Its heaven, I am telling you, it’s going to 
help with anything” PI 11.  
On the other hand, one healthcare provider indicated that the mobile phone use for 
reminding the patient to take the medication will be annoying and not practical to 
implement.  
“It [mobile reminders] will be annoying .. no, no, no it’s not practical. First 
it could be that his hearing is a bit impaired, he has to have it [mobile] at all 
times and it will keep ringing. There are patients taking so many 
medications. It will be annoying to the people around him, annoying to him 
and it’s not practical.” HCPI 7.  
 Use of medication pillbox  
Pillbox, a simple medication divider unit can help the patient remember his/her 
doses. Many providers indicate that it can be useful if applied and used for patients 
medications.  
“A pillbox filled by the day and the month, so you just empty the 
medications, so that even if the patient is traveling or even if he is an elderly 
he knows this is the dose for today, for tomorrow and for morning and 
evening. I have seen this pillbox in a private pharmacy and I got it for my 
mother in-law. It will help a lot for the patient, because for me, my mother 
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in-law is old so she takes a lot of medications, so I empty them in the pillbox 
and the box has the days. The pillbox will act like an alarm especially for 
older age is a good idea I would try to implement it here” HCPI 4.  
 
4.2.4.2. Theme: Healthcare system-related interventions 
 The majority of the interventions suggested within this theme were identified by 
the healthcare providers themselves. These included adjusting the appointment system, 
hiring more healthcare providers, increasing the use of medication reconciliation, 
introducing Arabic induction courses, and simplifying medication regimens.  
 More frequent appointments and less refill orders  
The late appointment system is, as previously indicated, a barrier that was 
mentioned in almost all the interviews. One suggested solution is to improve the 
appointment system and allow the patients to see their healthcare provider more frequently. 
At the same time reduce the number of refill orders and allow the patient to do more 
frequent check-ups. Moreover, the appointments should be set in a way to allow the patient 
to see the same healthcare provider and avoid unnecessary barriers mentioned before.  
 “The only thing I am having is the time period of visiting the doctor only 
after six months, so I prefer to visit them more frequently that’s all” P10 
 
“The receptionist should take into account which doctor referred the 
patient to the NCD and to give the patient the booking with the same 
doctor. This will not only save the problem of continuity of care, but will also 
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be very important for the language barrier so the patient that speak English 
can be booked with those who speak English and this will solve the 
communication issue and the language barrier” HCPI 12.  
 Hiring more healthcare providers 
More education is needed; therefore, more time is needed with the patients to 
address their needs. This ultimately requires more staff. Many healthcare providers 
indicated the need for more providers to help reduce the workload and improve the quality 
of care.  
“They should reduce the number of patients seen by the physician per day 
especially for the chronic patients” HCPI 1.  
 
“Increase the number of physicians so that the allocated time for the 
patient is enough for him to talk and get information and ask whatever he 
wants” HCPI 5.  
 
“They should recruit more doctors or more clinics that are available in the 
morning and the evening so that the patient gets his rights to be able to see 
the doctor every month” HCPI 6.   
One care provider indicated the cost saving and the benefits of hiring more staff.  
“You have to increase the staff in the clinic, because the cost of disease and 
the cost of complications is much higher than the cost of salaries for new 
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staff. Recruit new staff, because if the patient received a good education 
and good service; first you reduce the medications, you reduce 
complications, you reduce time of production because when the patient 
comes a lot to the clinic, these are patients excuses from work. So he will 
stop the work for some time. Also for a productive person, unfortunately 
you find the diabetes complications present in younger age, for example in 
40s and 30s. These are the people working and if you are wasting time in 
the clinics and started renal failure for example, three times a week, just 
think about the cost of dialysis is how much, the cost of the medications, 
the cost of things is how much, in addition he is also leaving his work for 
medical excuse. All these are costs, it’s a huge,  huge cost. Diabetes burden 
is very high. There are lots of studies on this. So if you come and increase 
the staff, how much would this cost? You will reduce the complications, 
reduce the medications, that’s a huge benefit.  HCPI 10.  
The role of pharmacists in Qatar is continuously evolving. Clinical pharmacists 
were introduced into the hospitals (secondary and tertiary care levels), but not yet in the 
primary healthcare setting. Many providers indicated that having a clinical pharmacist in 
the NCD clinic would improve patient’s adherence to medications.  
“Each clinic dealing with diabetes should have a pharmacist in this clinic. 
The pharmacist is really important and the benefit for the patient will be 
much higher so that’s a perfect solution, but until now they [administration] 
don’t see it as practical” HCPI 5.  
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Medication reconciliation is an important highly underused service. This service 
requires some attention to make it more efficient and useful for the patients. Providers 
indicated that pharmacist should be identifying patients needing reconciliation in addition 
to physicians’ referrals.  
“It’s pharmacists who can increase the adherence of the patients and do 
reconciliation with the patients. It should not be for all patients, but they 
should get the chance to do the reconciliation and review the patients 
medications with no referrals” HCPI 6.  
 Learn Arabic courses  
Although language did not appear to be a major barrier, some providers struggle 
when encountering patients who do not speak the same language. Some providers can 
speak only English, while the majority can speak both Arabic and English. One English 
speaking provider suggested Arabic courses during the training or induction period.  
“For us doctors when we come, we have to do three months training which 
is basically doing nothing; they should give the non-Arabic speaking doctors 
like myself an Arabic course which would be really useful” HCPI 12.  
 Simplify medication regimens  
Complex medication regimens can be simplified and be made patient-specific. One 
physician suggested the use of combination tablets or long acting medications in order to 
reduce the burden of medications. In addition, another provider suggested the slow 
initiation of medications to not overwhelm the patient.  
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“There is now the combinations. That’s why in order to reduce this issue 
[burden] we try to give combination tablets. Like if the patient is taking 
Januvia and Glucophage, so we give Janumet. The combination therapy 
improves and fixes the issue of compliance or nonadherence. Now there are 
also the medications that are sustained-release; once per day better than 
twice or three times per day. This improves adherence” HCPI 14.  
 
“Gradual initiation, like you don’t see a patient who is scared of insulin and 
we give him basal and three rapid insulin injections! We do it gradually” 
HCPI 16 
Table 17 provides a summary of the solutions proposed by the patients and the 
healthcare providers detailed above.  
 
Table 17: Themes and subthemes related to interventions to tackle medication 
nonadherence from the interviewees perspective 
Theme: Patient-related interventions (HCPI, PI) 
  Providing more patient education (HCPI, PI) 
  Mobile phone application and SMS reminders (HCPI, PI)  
  Use of medication pillbox (HCPI) 
Theme: Healthcare system-related interventions (HCPI, PI) 
  More frequent appointments and less refill orders (HCPI, PI) 
  Hiring more healthcare providers (HCPI) 
  Learning Arabic courses (HCPI) 
  Simplify medication regimens (HCPI) 
HCPI: theme or subtheme was identified from healthcare providers’ interviews  
PI: theme or subtheme was identified from patients’ interviews 
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4.2.5. Other relevant factors that require attention  
Despite the focus of this research on barriers to medication adherence and the 
possible interventions, interesting findings were captured within the interviews in relation 
to the primary healthcare setting in general. Although these issues may not directly affect 
medication adherence, they do indirectly influence it and generally affect the patient care 
outcomes. Therefore, such emerging issues require serious attention and intervention.  
 Lack of role clarification  
The findings indicated that there is a lack of understanding of other professions’ 
roles and scope of practice which is further illustrated in the minimal referrals done to other 
professions. This means that a patient may not get all the necessary education about his 
disease and its management including medication use.  
“There is one nurse in the NCD clinic, but I don't know what they are telling 
the patients, if they are checking what the patient is taking and if they 
enquire about the disease management. I'm not sure if there is a 
standardized practice that goes to all patients because sometimes the 
nurse would document useful things like the labs and the missing vaccines 
and ophthalmologist visits but it’s more of a tick box () exercise like do 
you take your meds? Check (). Did you take your vaccine? Check (), Did 
you do, etc., etc. they are more of a reminder for the physician and the 
patient, but I don't know what education they give. But there is a need for 
role awareness” HCPI 12.  
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“What makes me upset, I found many doctors they are not recognizing 
what a dietician is and what is the role of health educator .. What is the role 
of diabetic educators .. and there is overlap between our jobs and as you 
know .. diet management is being done by everybody.. except a dietician!” 
HCPI 10.  
 Although there is a specified dietician for the NCD clinic who has clinical expertise 
in managing diabetes, some providers were not aware of her role and her expertise. 
Therefore, patients were not referred to her on a regular basis.   
“There is a nutritionist, but she is not specific .. If specific then the patient 
would go to her a lot .. But she [nutritionist] is mostly with children and 
antenatal and things like that obese and all but not specific for diabetes” 
HCPI 7. 
 
 “I have diabetes since 15 years. I have been referred to nutritionist ..yes.. 
but once or twice I have seen her only.. since a long time” PI 11. 
Many providers do not know each other’s roles and scope of practice. Accordingly, 
many providers suggested conducting sessions or workshops on role clarification which 
would identify each person’s role. Another solution was to apply the roles in case 
discussions and regular meetings. This will address many issues at once; first, role 
clarification and communication among providers and second, improve patient care 
through providing a plan developed through teamwork.  
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 “I’m thinking we should have lectures for all the paramedics .. for all the 
team to tell them this is the role of this and this is the role of this .. and the 
difference between us and educator” HCPI 10.  
 
“We should have group discussions.  There should be group meetings. The 
group discussion when the patients’ cases are set and each is talking about 
his experience especially in newly diagnosed,  You could see two patients 
with the same history of diabetes, same age of diabetes, but different 
complications, one controlled and the other one with problems and 
complications. So you start really to see” HCPI 10. 
  
“and we should have some sort of multidisciplinary cases at which all the 
physicians who are doing this NCD clinic would show the difficulties, they 
should discuss at least once or twice a month along with dietician and 
others they should sit together. They should discuss all those cases … and 
make like a uniform approach, and that would help us understand each 
other as well, clarify the role of each other” HCPI 13  
There is a clear hierarchy in the organizational structure which reflects upon 
the duties done by each profession. Almost all healthcare providers including 
physicians themselves indicated that the physician is the key player in patient care.  
“Look sorry, the control all happens from the physician, and if he starts to 
follow correctly, you will see that things are going the right way” HCPI 5. 
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When asking which profession should be involved in educating the patient about 
their medication and the disease, one interviewee indicated that patient management should 
be solely by the physician.  
“It should be the doctors full stop. They are the ones who know the patients 
and the diagnosis and they are the ones following up with the patient and 
communicating with them their diagnosis, give them choices of therapy, 
increase their awareness of the disease and follow up” HCPI 12.  
 Duration of care process 
The process of care which the patient has to go through within the primary 
healthcare setting is sometimes perceived as a long one from both the provider and patients’ 
perspectives alike.  
“So the process here if he [patient] came to the center, he needs to take an 
appointment first over the phone, or he has to come to the reception to take 
an appointment, then he will come to take the vital signs and then wait to 
see the physician. Then, he will take an order for the laboratory to take a 
blood sample, then he will have to wait for the results and then come back 
to the physician to make an order for the pharmacy. Then, he will come to 
the pharmacy and then wait for his turn and wait for maybe 30 minutes to 
one hour to collect his medications .. it's a very long process so if I were the 
patient I would not even bother to come” HCPI 1. 
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Due to the time required to go through the entire process of care; some patients 
would skip seeing the care providers and go directly to collect the medications. Therefore, 
may not receive the necessary education of treatment plan.  
“There are patients who come here and say that I don't want any blood 
tests. I just want you to write me the medications” HCPI 7. 
Some patients would seek care from the private sector such as hospitals and clinic 
due to the long waiting time. This mainly happens in patients who have private insurance. 
This can indirectly influence medication adherence.   
“Health center coming waiting like that .. I go private hospital ..I feel private 
hospitals you go and finish very fast ..” PI 3. 
 The use of treatment guidelines in managing diabetes 
Guidelines for managing diabetes are accessible for healthcare providers through 
the intranet of the center. In addition, continuing education sessions and documents as well 
as guidelines updates are sent via email followed by multiple choice questions. Despite the 
availability of these resources, not all healthcare providers are following the same 
guidelines in managing diabetes. Although this factor may not directly result in patient’s 
nonadherence; it reflects on the differences in treatment regimens observed from one 
patient to the other.  
“The guideline is available on the system .. But most of the physicians don't 
check it .. They don't see it .. When to give statin, when to give aspirin .. 
There are differences in perspectives” HCPI 16.  
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“You have a varying degree of practice and experience. Some doctors are 
not competent in diagnosing diabetes and not informed about guidelines, 
and some don't even follow guidelines in managing their patients. You can 
become deskilled quickly if you are not following the right approaches. The 
thing is that patient comes asymptomatic, and they ask for a full checkup, 
and the doctors diagnose them with diabetes based on one test only, when 
guidelines recommend two tests for asymptomatic patients and one test if 
the patient presents with symptoms.. You don't know from which guidelines 
they are doing this. When doctors diagnose based on one test, they ruined 
it for the patient because you need a second test to confirm and if the 
patient is already on medication that's it, the HbA1c levels will be useless. 
Adherence to guidelines is a problem” HCPI 12.  
Some providers rely on their experience which was originally based on guidelines. 
However, they perceive that the current guidelines are not specific to the population in 
Qatar and that is why they do not rely on it but use their personal judgement.     
“These guidelines were made for Caucasian people and not people who eat 
rice three times a day and bread and whatever…all these are killers for 
diabetes… You see strange things here like patients having HbA1c of 16. 
And when they start managing their diet it drops significantly in just a few 
months.. The guidelines don’t have such values at all.. the guidelines tell 
you that medications would lower the levels by fractions! Not from 16 to 8” 
HCPI 12. 
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“Let me tell you, scientifically there are no guidelines in diabetes .. In the 
management of diabetes .. because of the good .. the very good guideline 
in diabetes .. tailor your guideline on your patient so no fixed guideline in 
diabetes” HCPI 14.  
 Documentation of patient information 
There is a clear variation in the quality of documenting information between one 
provider and the other. The system itself does not indicate mandatory fields for the provider 
to fill and is open for the reporter’s convenience. This problem highly affects the patient 
management from one provider to the other. In addition to poor documentation, some 
providers believe that whatever is being documented is not actually read by others, but 
rather done for the purpose of just documenting and following the policy.   
“Documentation is also an issue .. For me, I don't document everything, but 
I document what is relevant in the clinic.. The plan needs to be there, so we 
know what was done and what the doctor wants to do.. This is really a 
shame because I have seen patients whom I'm sure they have cancer and 
you know I order labs and all, but on their next visit they are only prescribed 
things like iron because apparently, the patient has anemia. Doctors don't 
check what others have written to know what is really the plan and at the 
same time I cannot step on anybody's toes and ask them to document and 
read” HCPI 12.  
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 “I think documentation side is very poor here, to be honest .. People don't 
document the full story .. which needs a lot of improvement especially in 
changing the medications .. with the chronic disease why they change from 
one medication to another one .. was it a patient problem? .. Like you know 
the patient did not like it? having side effect? or it was physician choice to 
try this one? .. and most of the time the notes are blank ..” HCPI 13. 
 Feedback system within the healthcare center 
The healthcare providers are the ones directly involved in managing the 
patients care and the ones applying the policies and regulations stipulated by the 
management of the primary healthcare setting. These providers come from various 
countries and have diverse experiences which can add value to the practice in the 
primary care. It is of paramount importance to understand their views on how to 
improve the system further, and also to identify the problems they face in their 
practice in order to improve. Despite this, a good feedback system which would 
allow the providers to speak freely and comfortably is lacking in this setting.   
“Another thing is that no one here is allowed to give any input into the 
system which is a shame, because we are the ones seeing the patients and 
we come from different backgrounds and different educational systems so 
at an organizational level things need to be fixed… There are these 
occasional meetings that they do here which I stopped attending because 
it’s in Arabic and I can’t speak the language, and at the same time things 
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turn out really intense, and people are not comfortable with each other” 
HCPI 12. 
 
4.2.6. Summary of qualitative findings  
Figure 16 summarizes the different factors that can contribute to medication 
nonadherence.  
 
 
  
 
  
Patient Society 
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Figure 16: Barriers to medication adherence identified in uncontrolled diabetes in 
primary healthcare centers in Qatar – patients’ and providers’ perspectives 
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CHAPTER 5: DISCUSSION AND CONCLUSION  
5.1. Introduction  
Medication adherence is an important determinant of treatment success for any 
disease condition. The literature has unequivocally documented poor adherence to 
medications in chronic diseases including diabetes (36, 92). Diabetes and its complications 
are highly burdensome (1, 3). Therefore, it is very important to keep the blood glucose 
under control. Previous unpublished studies conducted in Qatar have found high 
prevalence of uncontrolled diabetes in the primary care setting. The general assumption 
and reason for uncontrolled diabetes has always been that patients may not be taking their 
medications as prescribed. To improve medication-taking behavior, it is important to 
understand why nonadherence occurs. It is therefore imperative to investigate medication 
adherence and its associated barriers among patients with uncontrolled diabetes. 
Nevertheless, barriers to medication adherence identified in one country or region may not 
necessarily be the same as those in another country or region due to environmental, socio-
economic, and cultural differences across countries. This project was therefore conducted 
to gain a better understanding of the barriers to medication adherence in patients with 
uncontrolled diabetes from the context of Qatar. To date, this is the first mixed-method 
study conducted in Qatar and within the MENA region, to investigate barriers to 
medication adherence in uncontrolled diabetes from both patients’ and healthcare 
providers’ perspectives. The project was accordingly designed to address the following 
primary question: What are the barriers to medication adherence in patients with 
uncontrolled diabetes attending primary healthcare centers in Qatar?   
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5.2. Adherence Level  
Diabetes management involves three main components: medications, diet, and 
physical activity (66, 93). Nonadherence to these components can lead to high or 
uncontrolled blood glucose levels. This study focused only on one aspect which was 
medication nonadherence. Medication nonadherence represents a failure in transferring the 
benefits of the medications to the individual’s health improvement (37). The findings of 
this study revealed that around 74% of patients with uncontrolled diabetes were 
nonadherent to drug therapy. On the other hand, an unpublished study conducted in Qatar 
indicated that 86% of patients with diabetes are uncontrolled, therefore, it can be postulated 
that 64% of all patients with diabetes are nonadherent. The remaining 26% of patients with 
uncontrolled diabetes who reported adherence to drug therapy can have other factors such 
as dietary indiscretion or lack of treatment optimization contributing to their uncontrolled 
blood glucose levels (66, 93). The very high percentage of nonadherence found in this 
study further emphasizes the magnitude of the problem, especially that significantly more 
diabetes complications were observed in the nonadherent group as compared to the 
adherent group. It has already been demonstrated in the literature that medication 
nonadherence leads to uncontrolled diabetes and contributes to diabetes-related 
complications (2, 8-12). The nonadherence rate found in this study is much higher than that 
reported from neighboring countries such as Saudi Arabia and the United Arab Emirates 
which indicated nonadherence rates of 43% and 40%, respectively (94, 95). The lower 
adherence rate in these countries can be explained by the inclusion of all patients with 
diabetes regardless of disease control (i.e. both controlled and uncontrolled patients).  
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5.3. Barriers to Medication Adherence  
Several important barriers to medication adherence were identified from the 
qualitative and quantitative analyses in this study. Studies investigating medication 
adherence generally identified many patient-related aspects and linked some 
sociodemographic characteristics to nonadherence (15, 18, 19, 42-47, 92). Similarly, 
certain sociodemographic characteristics were identified to play a role in medication 
nonadherence among this cohort of patients with uncontrolled diabetes. Age as a variable 
did not differ between adherent and nonadherent patients. However, a significantly higher 
level of nonadherence (higher adherence score) was noted among patients who were less 
than 65 years old. This finding was interestingly different from what was found in the 
qualitative interviews whereby healthcare providers indicated that older patients as 
compared to the younger ones are less adherent to drug therapy due to forgetfulness and 
polypharmacy. The qualitative findings are consistent with Rolnick et al. who conducted a 
study examining patients’ characteristics and their influence on medication adherence and 
found the odds of being nonadherent increasing with older age (96). Nonetheless, one 
provider indicated that younger patients are more likely to experiment in terms of using 
traditional medicine. Moreover, the younger individuals represent the working force; 
therefore, the influence of working conditions may be the factor influencing their 
adherence rather than the age itself. Hence, this is a case of interaction between the age and 
busy working condition. It is worthwhile to note that the majority of studies conducted 
within the MENA region did not find any significant influence of age as a variable on 
medication adherence (97-104).  
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The majority of the reported literature investigated employment status and linked 
it to medication adherence (52, 63, 66, 68, 95, 98, 100, 102, 105-107). Although in the 
present study, employment status did not statistically differ between the adherent and the 
nonadherent patients quantitatively, qualitative interviews indicated that working 
conditions, rather than status, can highly contribute to the appropriate use of medications. 
Working conditions such as traveling and prolonged working hours, in particular, were 
mentioned to be problematic. This finding emphasizes the importance of enquiring about 
the working conditions of patients with diabetes and identifies how it can contribute to 
medication adherence rather than just associating employment status alone to medication 
adherence.  
When talking about work or occupation, income and expenses come into 
perspective. It is well known that patients who cannot afford the medications will less likely 
be adherent (15, 63, 92, 95, 108). Although the majority of participants indicated that 
medications are quite affordable, particularly that health insurance is provided to almost 
all residents in Qatar, there were few patients who still found medications to be expensive 
due to their small income. Those patients noted that the cost of medications represents a 
high proportion of their living expenses. The cost of medications and health services was 
noted as a barrier to medication adherence in studies conducted in Egypt and the United 
Arab Emirates, both of which indicated a negative influence of cost on medication 
adherence (95, 108). Nonetheless, the availability of social support within the primary 
healthcare setting in Qatar that primarily targets those who cannot afford the medications 
can help in reducing the burden of this barrier. 
Many of the adherent patients were living with family as compared to nonadherent 
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patients suggesting that family support can positively contribute to patient’s adherence to 
therapy. Several studies indicated that family support can positively contribute to 
medication adherence in diabetes, one of which is a study published by the American 
Diabetes Association (109). This study indicated that patient’s perception of family 
members performing diabetes-related supportive behavior was associated with better 
medication adherence (109). This corroborates with the qualitative interviews in which 
many patients indicated that family members would remind them of their dose, give them 
the medication doses themselves, and take care of their diet management. Nonetheless, an 
interesting notion in patients with diabetes, particularly those on insulin, was that they were 
willing to conceal their disease from their loved ones for fear of being stigmatized. Hiding 
such information means the patient is not taking the medication in front of the family 
members, therefore, not taking the medications as prescribed. In fact, no previous study 
has reported that patients with diabetes would withhold their diabetes diagnosis from their 
spouses as found in the present study. This further emphasizes the importance of family 
support and the need for family involvement in the management and care of the patient 
with diabetes.  
The fear of being rejected or stigmatized - by family members or the public - stems 
from the society’s misconceptions about and stereotyping of diabetes. Patients indicated 
that they do not like to take medications in public because they are worried about being 
discriminated, a behavior that is common among patients taking insulin (46, 110). 
Therefore, patients resort to taking their medications while hiding away from other people 
or, in some instances, not taking them at all. This behavior is also reflected in quantitative 
data where “inconvenience” as a barrier was reported higher in the nonadherent group. 
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The study findings showed that the majority of the patients were not on insulin 
despite their uncontrolled diabetes. Healthcare providers progressively added medications 
to patients with uncontrolled diabetes. Both triple and quadruple therapies were commonly 
provided to the patients, while they still remained uncontrolled. This can be explained by 
the high rate of psychological insulin resistance (i.e. reluctance of patients to accept insulin) 
observed in many patients and attested by healthcare providers in this study (111). Brod et 
al. and Snoek both indicated that social stigma and the misconceptions about insulin can 
highly affect patients’ acceptance of the medication as well (112, 113). Qualitative data 
revealed that insulin is quite problematic for the patients to accept due to the social stigma 
and fear associated with side effects and self-injection. Similar findings have been reported 
by other studies (47, 66, 111, 113, 114). This reemphasizes the need for educating the 
society and not only the patients about insulin. Recently, the US Food and Drug 
Administration (FDA) approved insulin inhalation which is not yet available in the primary 
healthcare centers in Qatar (115). It is however unclear whether this new route of 
administration will mitigate the fear of insulin injection and psychological insulin 
resistance in general. Further studies are needed to investigate the impact of this new 
insulin product on adherence and the psychological resistance. 
The society, culture, and beliefs direct patients towards the use of traditional and 
complementary medicine or natural remedies (15, 47).  Surprisingly, this factor was not 
restricted to certain cultures or ethnicities as expected, but was found to be a common 
phenomenon in patients from different countries including Qatari nationals. Participants in 
this study tried numerous products such as cinnamon, dried okra, herbs from Thailand, 
natural products from Sudan, Sri Lanka and others. A study conducted in Saudi Arabia 
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indicated that 24.6% of diabetic patients use herbal products as well (116). While in the 
quantitative phase of this study, 36.5% indicated that they use traditional medicines in 
managing diabetes. These high percentages indicate the need for real assessment of 
patients’ beliefs and behaviors in relation to the use of traditional medicine. Patients seek 
these products in belief of their ancestors and in the hope of being completely cured of 
diabetes (47). At the same time, some patients believe that these traditional remedies are 
more effective and have fewer side effects than modern or orthodox medicines (15, 47). 
Nonetheless, the literature indicated that the effectiveness of Ayurveda herbs in diabetes 
control is inconclusive and most of them are ineffective (117, 118).  
It was intriguing to find that patients with diabetes can invite their counterparts with 
the same disease to share their medications with the belief that theirs is more effective in 
managing diabetes. To our knowledge, this finding is unique since no previous studies have 
reported similar findings about medications sharing in diabetic patients. It is well known 
that diabetes is a chronic condition which requires lifelong management and medications 
to maintain glucose levels within an acceptable range. Qualitative data reflected an 
interesting perception with regards to the effectiveness of medications whereby patients 
believe that the pharmaceutical industry is not making efforts to cure diabetes, but rather 
makes the medications a necessity to sustain life, and a source for making profit by the 
manufacturers. Such beliefs and perceptions are highly emphasized by the media which 
always reflects on the pharmaceutical profit gained from chronic disease medications such 
as those used for diabetes (119, 120). This notion is somewhat reflected in the quantitative 
data where the item “believe that the medication prescribed is not helpful” was the most 
frequently reported barrier by those with the highest nonadherence level and appears to be 
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consistent with findings from Palestine and United Arab Emirates (103, 121-123).  
Although studies reflected on the improvement in adherence, patient satisfaction 
and convenience with the use of insulin pen (124, 125), some patients perceive that this 
“new” insulin delivery device is ineffective as compared to the traditional insulin vials. 
Such patients request the prescription of vials instead of pens, which is surprising 
especially given the ease of administration and convenience of the pens as compared to the 
vials (124, 125). However, healthcare providers indicated that these patients are very few 
in number as compared to those using insulin pen.  
Another interesting finding was that a significant proportion of patients taking 
sitagliptin were nonadherent. This finding is not consistent with a previous study which 
reports that patients are more adherent to sitagliptin than they are to sulfonylureas (126). 
Qualitative data, however, reflected what is found in the literature and showed that patients 
usually discontinue metformin due to gastrointestinal side effects and stop insulin due to 
hypoglycemia (12, 99, 101, 108, 123). Therefore, the significant difference observed in 
quantitative data for sitagliptin deserves further investigations to identify the reasons 
behind it.  
Unlike other studies (95, 102, 104, 107, 121, 122, 127), the number of pills per day 
or polypharmacy did not significantly influence medication adherence in the present study. 
However, it was interesting to note that patients would try to reduce the burden of 
medications through splitting their medication doses throughout the day. Some 
medications like glimepiride are available in a strength of 2mg in the primary health 
centers; therefore, when the doctor prescribes 6mg or 8mg, the patient will be asked to take 
three or four tablets at once. The increased pill burden causes the patient to take half the 
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dose in the morning and the rest in the evening. Consequently, the desired therapeutic 
concentration of the drug is not achieved, and the patient would remain uncontrolled.  
Although changing the dose of medications based on diet is sometimes considered 
appropriate in diabetes, it is usually recommended in patients with type 1 diabetes who are 
on rapid acting insulin and not usually in patients with type 2 diabetes who are on oral 
medications with or without long-acting insulin (128). At the same time, the patients 
changed their medication doses according to what they deem appropriate and in some 
instances reported experiencing adverse drug events such as hypoglycemia. This could be 
due to lack of education and counseling in regards to dose adjustments. Also, patients do 
not commonly inform their healthcare providers about these changes which can highly 
influence treatment success. One reason for concealing information is the patient-provider 
relationship and trust (15, 129). At the same time patients are passively receiving 
information rather than being part of the decision making process (129). Moreover, the 
limited patient-provider interaction time can also contribute to lack of disclosing 
information as time is not enough to examine the patient, provide information and listen to 
their illness story (15).  
When the patient does not have adequate information about the disease and its 
management, they will likely not be as adherent as they should be, particularly if they do 
not know the risks and benefits of being on the medications (46, 95, 97, 130). Quantitative 
data showed that 11% of the patients were not provided with adequate information by the 
healthcare providers. This concurs with the qualitative data whereby many patients were 
not aware of what diabetes is and how their medications could help them maintain glucose 
levels within normal range. One major factor contributing to patients’ lack of information 
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is the limited use of medication reconciliation. Several studies have demonstrated the 
positive influence of pharmacist in improving medication adherence (78-80, 131). Yet, the 
medication reconciliation service which is done by the pharmacists in the healthcare 
centers is highly underutilized.  
The American Diabetes Association periodically publishes standards of medical 
care in diabetes which recommend performing HbA1c testing twice a year for patients with 
controlled levels of HbA1c, while patients who are uncontrolled must be monitored more 
frequency (every 3 months) (132).  One major barrier identified in this study was the poor 
follow-up in the primary healthcare centers. Many of the patients interviewed were visiting 
the centers for refilling their medications, while their records clearly indicated uncontrolled 
blood glucose. The usual practice in this setting is that patients are scheduled for follow-
up appointment every four to six months, and if they experience any issue with their 
medications in between the appointments, it may not be addressed until their next follow-
up appointment. Odegard et al. indicated that inadequate follow-up could highly contribute 
to medication nonadherence (18). It is highly risky to delay follow-up visits especially 
knowing that persistence to medications drops dramatically within the first six months of 
therapy (36). At the same time, these patients are at high risk of experiencing complications 
since they are uncontrolled. Healthcare providers indicated that the prolonged follow-up 
schedule is also a problem and a potential barrier to medication adherence. This barrier 
highly contributes to medication nonadherence, especially that patients would seek care 
elsewhere during the waiting period as reported by some of the participating patients in 
this study. Seeing different physicians for diabetes in different settings could mean that the 
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patient’s medical record is split, and so is the care plan, which again, can contribute to 
patient’s confusion and nonadherence to therapy.  
Factors such as interprofessional collaboration between the healthcare providers, 
appropriate use of guidelines, proper documentation of care, and workload could indirectly 
influence patients’ management and ultimately medication adherence (15, 133, 134). 
Therefore, it is imperative to address these factors and consider them when developing 
intervention strategies. Figure 17 summarizes how different organizational factors and 
patient’s lack of information can contribute to medication nonadherence.  
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Figure 17: Organizational factors and their influence on medication adherence 
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5.4. Matching the Barriers to Medication Adherence with the Conceptual 
Framework Model  
 Section 2.5. of this thesis covered the development of the conceptual framework 
model for medication adherence in diabetes. The barriers to medication adherence 
identified within this project were matched with the conceptual framework model as 
presented in Figure 18.  
Barriers that are highlighted in red within the model above are ones which were not 
initially identified from the literature review. In terms of patient-related factors, working 
conditions rather than working status appeared to influence medication adherence, while 
for medication-related factors, taking sitagliptin as compared to other diabetes medications 
such as metformin was more common in nonadherent patients. This factor was not 
justifiable within the scope of this project and requires further studies to confirm and 
understand why nonadherence was significantly higher among those on sitagliptin. 
Investigating healthcare provider-related factors revealed that provider-provider 
interaction can also indirectly influence medication adherence. This is in terms of 
interprofessional collaboration and role clarification, as well as the provision of care to the 
same patient by more than one physician.  
 On the other hand, system-related factors indicated that documentation, guidelines 
use and availability, as well as process duration all influence medication adherence 
indirectly. In general, having a feedback system is also important for continuous 
improvement and addressing any barriers to medication adherence and patient care 
outcomes.  
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Figure 18: Matching the barriers to medication adherence with the conceptual model 
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5.5. Recommendations to Improve Medication Adherence  
The identification of the barriers to medication adherence alone is insufficient in 
addressing the problem. On the other hand, there is no solution or strategy to overcome all 
the barriers medication adherence at once. Although numerous strategies and interventions 
aiming at improving medication adherence have been published, the best interventions are 
yet to be determined (31, 131). It was interesting to identify some potential solutions from 
the participant’s perspective through this research. Many of the participant-identified 
interventions in this study have previously been reported in the literature (31, 78, 79, 131, 
135-139). This section covers the suggested interventions by the participants in addition to 
the researchers’ perspective and ends with a summary of all barriers and possible 
interventions.  
As previously highlighted, pharmacists play an important role in addressing 
medication adherence (78-80, 131).  Many patients were not referred to the pharmacist for 
medication reconciliation despite the clear need for it. Therefore, guidelines and criteria on 
patient referral for medication reconciliation should be developed. In addition, the scope 
of practice and the role of pharmacist should expand to allow them to perform medication 
reconciliation without the need for physician’s referral. A reconciliation session should be 
structured and focused on patient’s perceptions and fears that were identified in this study 
as well as the patient-initiated changes such as adjusting the medications according to their 
diet. One interesting suggestion was the use of videos for educating patients (e.g. to show 
the negative consequences of diabetes such as complications). Such videos can include 
information about what is diabetes, what are the medications and how they help patients 
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achieve positive outcomes, and what would happen if diabetes is uncontrolled. Such 
imagery will reinforce the patient’s information (140). Surprisingly, no recent studies have 
investigated the use of interactive videos in educating patients with diabetes and its 
influence on patient’s understanding of the disease and treatment plan; indicating the need 
for such studies.  
Healthcare providers need to be aware of the needs to tailor health information to 
the level of patient’s understanding and health literacy level, given the varying levels of 
education or literacy, and languages among patients (15, 141). Diabetes is a complex 
chronic disease condition that requires a high level of patient involvement including 
reading, understanding, and acting on complex health information and medication 
regimens as well as consenting to invasive investigations and monitoring of outcomes 
(142). In the studied sample, about 7% was completely illiterate and much higher 
proportion may have limited or poor health literacy. These individuals may not be able to 
read medication labels and other health information. Therefore, visual instructions and 
other strategies to enhance communication such as pictograms and teach-back method 
should be used for those individuals (143). Pictograms have demonstrated a positive 
influence on medication adherence (143, 144). Nonetheless, pictograms must be tested in 
the targeted population (i.e. user testing) prior to their application in practice, to ensure 
they are correctly comprehended by the patients (145).  
The two main languages spoken in Qatar are Arabic and English. Nevertheless, 
many expatriate healthcare providers can only speak English. One provider suggested 
introducing Arabic courses during the orientation period of new hires which will 
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significantly help them when managing patients who speak Arabic. Moreover, a significant 
portion of the immigrant workforce in Qatar is from India, Nepal, Bangladesh, Sri Lanka 
and others (146). Many of these workers may neither speak English nor Arabic which 
significantly impacts patient-provider interactions and communication. Therefore, the use 
of voice-to-voice translation software, which is now readily available, can considerably 
reduce the problem of language barrier (147).  
The appointment system in the primary healthcare setting needs significant 
attention as well. The follow-up visits need to be convenient and efficient in order to 
improve medication adherence and ultimately healthcare outcomes (36). Criteria needs to 
be set for which patients should be scheduled later and which should be scheduled earlier. 
At the same time, patient should be advised about the means of reaching the healthcare 
provider if the need to do so arises. One good intervention is creating interactive online 
platforms for the patients where they can receive answers to their inquiries in a timely 
manner and at the same time from a reliable source. In fact, previous studies have shown 
that online platforms and electronic health tools have a promising outcome in terms of 
improving medication adherence, patients’ knowledge and satisfaction (148-150).  
Therefore, such a platform can be designed and used in Qatar for patients with diabetes. 
This can be in the form of informal care technology using cloud-based systems. 
Similar to what is well-documented in the literature (63, 66-68, 71), the most 
commonly reported barrier to medication adherence was forgetfulness. Interventions 
targeting this barrier are numerous such as mobile phone application reminders, SMS text 
messages, and incorporating the medication into daily routine (135, 136). Many mobile 
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applications are available for free and can easily be set up by the patients to remind them 
of their medication doses (151).  
As indicated by some providers, there is a clear need to upscale the health 
workforce in primary care setting in Qatar by recruiting more healthcare providers. 
Currently, the primary healthcare centers are increasing in number in response to increasing 
population and increasing demand for healthcare services (84). Nonetheless, increasing the 
number of providers within each center is highly needed and will significantly help in 
reducing the burden and costs associated with diabetes management.  
The use of clinical practice guidelines is another problem highlighted by the 
healthcare providers, where they pointed that the diabetes guidelines available and used in 
their setting are not specific to the population of Qatar. Therefore, creating evidence-based 
population-specific guidelines is warranted. These guidelines should include a section 
about the process of care for patients who refuse taking insulin, thereby creating a standard 
of care amongst all the providers across primary care centers. This will also minimize the 
problem of huge treatment discrepancies when the patient seeks care from different 
healthcare providers.  
Another factor that indirectly influences adherence is poor documentation of care.  
For example, the documentation system requires improvement by making certain fields 
mandatory to fill (such as the provider’s plan for the patient and the patient’s adherence 
level). Some practitioners tend to repeat general patient information such as age, gender, 
and past medical history, most of which are already available in the system. Therefore, 
documentation should focus on what is really needed rather than being repetitive. Some 
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new fields need to be introduced in the electronic health record system such as the patient’s 
socioeconomic status which could guide the selection of medications for a particular 
patient. Similarly, the patient’s religious, spiritual, or cultural obligations such as dietary 
restrictions or fasting obligations should also be documented in the system. This will 
remind the provider to adjust a patient’s treatment plan and make it more individualized 
and patient-centered. Table 18 summarizes the identified and suggested interventions that 
can address the identified barriers.  
 
Table 18: Suggested interventions to tackle the identified barriers to medication 
adherence among patients with diabetes in primary care setting in Qatar 
Barrier Intervention  
Illiterate patients  Validated pictograms  
 Teach-back method 
Poor socioeconomic status of 
patients  
 Documenting patient’s socioeconomic status 
 Selecting cheaper alternative medications  
Religious rituals of patients    Documentation in the patient profile 
 Adjusting treatment plan accordingly 
Patient forgetfulness  Using pillbox  
 Reconciliation point: incorporating the medication 
into daily routine 
 Mobile phone applications  
Social stigma  Educating the general public to demystify stigma 
and misconceptions 
 Platform for the public to access information about 
diabetes and its management 
Use of traditional medicine by the 
patient  
 Reconciliation point: educating the patient about 
the importance of the medications and the risks of 
traditional medicines 
Patient’s beliefs and perceptions   Medication reconciliation and therapy management 
Patient’s confusion about 
medications  
 Using medication chart  
 Using pillbox 
Lack of roles clarifications 
among providers  
 Developing clear policies about the roles and duties 
of each profession  
 Role clarification through case discussions 
Lack of referrals to other 
providers 
 Role clarification through case discussions  
 Audit system  
 Setting criteria for patients referrals  
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Limited medication 
reconciliations 
 Setting criteria for patient referrals 
 Allowing pharmacists to do reconciliation without 
physician’s referral  
 Introducing clinical pharmacist in the NCD clinic 
Long process duration   Use of the waiting time for more education  
 Hiring more healthcare providers  
Late appointments  Setting criteria for late vs. early appointments  
 Hiring more healthcare providers 
Lack of population-specific 
clinical practice guidelines  
 Developing evidence-based population-specific 
guidelines  
Nonadherence to clinical practice 
guidelines  
 Conducting audits to check compliance with 
guidelines  
Poor documentation of care  Performing audits to check the quality of 
documentation  
 Setting mandatory fields in the system for the 
providers to fill  
High workload and large number 
of patients 
 Expanding workforce through employing more 
healthcare providers  
Poor feedback system  Allowing an efficient feedback system for 
continuous improvement  
Language   Introducing Arabic course during orientation 
periods of new recruits  
 Using translation software  
 Hiring interpreters  
Caretaker  Involving caretaker during patient counseling and 
education  
Careless/lack of motivation   Reconciliation point: emphasizing the importance 
of medications  
 Use of videos to show-case the complications of 
disease if left uncontrolled  
Patient refusal of medications   Medication reconciliation 
 Correcting misconceptions through public 
campaigns 
 Developing guidelines for managing patients who 
refuse injections or have injection phobia   
Patient self-adjust their dosing  Medication reconciliation  
Number of pills  Using fixed-dose combination medications 
 Using long-acting medications  
Side effects  Medication reconciliation  
Patient’s lack of information    Medication reconciliation  
 Online platform/website  
 Brochures  
Traveling to other/home countries  Medication reconciliation  
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5.6. Strengths and Limitations of the Study   
To our knowledge, this is the first study which addresses medication adherence in 
uncontrolled diabetes using a mixed-method approach. The findings of this study highlight 
the complexity of medication adherence and the influencing factors that contribute to 
nonadherence. One of the main strengths of this study is the robustness of the methodology 
used which allowed addressing the study objectives comprehensively.  
The two methods (quantitative and qualitative) were complementary to each other 
which reflected on the breadth of the barriers identified. The quantitative data allowed for 
understanding the characteristics of patients with uncontrolled diabetes and the comparison 
between adherent and non-adherent groups, while the qualitative data provided an in-depth 
understanding of the patients’ and healthcare providers’ experiences.  
To our knowledge, this is also the first study in the MENA region to involve 
healthcare providers’ perspective on the subject of medication adherence. The interviews 
with the healthcare professionals who provide care to patients with diabetes further 
reaffirm and stress the fact that adherence is a multi-faceted problem.  
Another important strength of the study is the identification of possible 
interventions and solutions from the participants’ and not only from the researchers’ 
perspectives which would reflect on the applicability of the interventions in real-world 
practice in Qatar.  
The focus of the study on “patients with uncontrolled diabetes” is another strength 
of the study, since these are the patients at higher risk of developing complications and 
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therefore requiring more attention. Moreover, Qatar is currently investing in improving the 
care management in the primary healthcare sector. In fact, the Qatar Primary Healthcare 
Strategy was recently published emphasizing the importance of transforming care in this 
setting (152). Therefore, this project is in concert with the Primary Health Strategy goals 
and plays a significant role in supporting it.  
The development of a holistic conceptual framework model adds so much value to 
the current knowledge about medication adherence in diabetes, as it summarizes all the 
evidence on the topic. This is a useful tool that can be used as the ground bases for diabetes 
medication adherence-related studies.  
Despite these strengths, there are some important limitations that need to be 
acknowledged. First, the sample size was calculated based on the assumption that all 
patients with uncontrolled diabetes were non-adherent to their medications. However, the 
effect of such assumption on the study was minimized since there was 60% increase in 
recruitment over the required sample size. Nonetheless, there is still a limited 
generalizability of the quantitative results with this sample size and limited stings requiring 
the need for a larger scale study taking into consideration multiple primary healthcare 
centers and their population.   
Second, the adherence measurement tool used in the study (ARMS-D) was 
translated into five most commonly spoken languages in the country, yet the psychometrics 
of the translated instrument were not determine due to time constraints. However, 
throughout the study, only the Arabic and English versions were used as the sample who 
consented to participate in the study could speak either or both languages.  
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Third, the method used to assess adherence level in patients was the self-reported 
questionnaire (ARMS-D), which subject the responses to social desirability bias. However, 
published literature has reported appreciable validity and reliability of this questionnaire 
as an adherence measurement tool (88). Unfortunately, other objective methods of 
assessing medication adherence such as proportion of days covered (PDC) and medication 
possession ratio (MPR) were not applied as the healthcare system does not clearly and 
reliably reflect the medication refill times.  
Fourth, the quantitative results of the study can only be generalized to patients with 
diabetes who are uncontrolled and attending the specifically mentioned primary healthcare 
and not necessarily to those attending other settings such as secondary or tertiary level 
hospitals. Two healthcare centers may not be reflective of the entire population which has 
many expat laborers and people of low socioeconomic status.  
Moreover, the study was conducted in Qatar; an oil-rich country, with reasonably 
advanced and far-reaching health services that does not represent most of the health 
environments world-wide. For example, medicines are available and affordable to most 
patients, and healthcare providers are accessible compared to what we find in many other 
countries worldwide. On the other hand, qualitative data are not usually generalizable, but 
provide a wealth of information that help in better conceptualizing the area studied and 
provides an insight into all the possible barriers to medication adherence.  
The validity of the transcripts could not be checked with the participants for 
multiple reasons including time constraint, and at the same time, the contact information 
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of the participants were not sought. However, the coding process was conducted by two 
researchers to ensure reliability of the generated themes.  
Finally, selection bias might have occurred as it was possible that those who turned 
up to refill their medications and follow-up appointments and agreed to participate in the 
current study are those who are more likely to be adherent to their medications. 
Additionally, patients who could neither speak English nor Arabic were excluded from 
participating in the qualitative interviews even if they fulfilled the other inclusion criteria. 
Patients who did not attend to their appointments and those who could not speak either 
languages might have important barriers and experiences which were not captured in this 
research.  
 
5.7. Future Work and Recommendations  
Section 5.4 has covered aspects of future work in relation to medication 
nonadherence in diabetes, particularly the interventions and strategies that can be applied 
in the primary healthcare setting to improve medication adherence among patients with 
diabetes. However, policymakers and managers shall take into consideration their 
population’s characteristics. Over three-quarters of the patients in the current study were 
taking two or more medications for diabetes management; therefore, the researchers 
caution against the initiation of several adherence-improving-interventions at once as this 
will likely cause a significant increase in the incidences of hypoglycemia and other adverse 
events. If a patient is non-adherent while being prescribed three medications and suddenly 
starts taking all three together, they are more likely to experience adverse events. 
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Therefore, the researchers highly recommend that the interventions suggested in section 
5.4. need to be prioritized based on the resources available and initiated in a stepwise 
approach with monitoring of potential adverse events at the same time.  
In addition to the interventions listed in section 5.4., the researchers also 
recommend a larger scale study taking into consideration different healthcare settings (e.g. 
private sector, public sector, secondary care, and tertiary care) and including patients who 
cannot speak English or Arabic. Moreover, including the perspective of family members 
will add value to the current knowledge particularly that it is very common in the MENA 
region for family members to take care of their relatives and help them administer 
medications.  
 Finally, this study looked at only one aspect of patient-self management which is 
medication adherence. Therefore, future research should investigate other aspects such as 
diet management and physical activity, and the barriers associated with them. This would 
allow a better understanding of patients with uncontrolled diabetes in general.  
 
5.8. Conclusion 
This study contributed to the existing body of knowledge through an in-depth 
understanding of the barriers to medication adherence in patients with uncontrolled 
diabetes in Qatar. The study revealed that over 70% of the patients with uncontrolled 
diabetes were non-adherent to their medications. Barriers to medication adherence are very 
complex, multifactorial in nature, and require a lot of attention in order to be adequately 
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addressed. Results from this study indicate that there are six main players in the patient’s 
behavior towards medications: the patients themselves, healthcare providers, healthcare 
system, the society, the disease, and medications. Many of the barriers identified in this 
study were directly related to patient’s information and knowledge about the disease and 
its management. However, there were also barriers related to the society such as social 
stigma and lack of support. On the other hand, healthcare providers indicated some barriers 
relating to the patient-provider interaction as well as the provider-provider interaction all 
of which ultimately influence patient’s medication adherence.  
In relation to interventions, one main intervention that would address multiple 
barriers is the expansion of pharmacist role and the increase use of medication 
reconciliation services. Reconciliation and therapy management should focus on the gaps 
in patient’s knowledge identified within this study. Generally, interventions addressing 
medication nonadherence are costly in terms of human and other resource requirements. 
Therefore, having specific interventions targeting pre-determined barriers and factors 
associated with medication nonadherence would result in the best use of resources and 
more efficient interventions. In addition to use of medication reconciliation, several 
interventions should be implemented to tackle medication nonadherence. However, 
interventions must be initiated in a stepwise approach to avoid risks of adverse drug events.  
Finally, the findings of this study can potentially help reduce the economic burden 
of diabetes through providing a patient-specific counseling and interventions, thereby 
decreasing the morbidity and complications associated with diabetes. Moreover, future 
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research should target other aspects relating to uncontrolled diabetes such as diet 
management and identify the barriers associated with it.  
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APPENDIX A  
Questionnaire 
For Participant’s Use 
Part A: Personal Characteristics  
Instructions: Please answer all questions and put a check mark () on the most 
appropriate answer. 
 
Age: ____________________________ Gender:    Male  Female  
Nationality:  
  Qatari 
  Indian 
  Nepali 
  Filipino  
  Egyptian 
  Bangladeshi  
  Sri Lankan 
  Pakistani 
  Sudanese  
  Jordanian 
  Palestinian 
  Indonesian 
  Iranian 
  Other, specify: 
_________________ 
 
Insurance:   Governmental  
   Private 
   None 
   Other, 
specify:_____________ 
Religion: 
  Islam 
  Christianity 
  Buddhism 
  Hindu 
  Others, specify: 
__________________ 
 
Level of education:  
   Primary education  
   Secondary education  
   High school education  
   University level  
   None, but can read and 
write 
   None, cannot read and 
write 
Weight:_______________________ 
Height:_______________________ 
Employment status:  
   Student 
   Unemployed 
   Retired 
   Employed, specify job 
type:  
 
 __________________________ 
 
Living situation: 
   Alone 
   With a family member(s) 
   With other(s), please 
specify: 
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Average medical cost per month (QR): 
  QR 0 – 100 
  QR 101 – 300 
  QR 301 – 500 
  QR 501 – 1,000 
  QR 1,001 – 2,000 
  QR 2,001 – 3,000  
  More than QR 3,000 
Average income per month:  
   Not receiving any income 
   Less than QR 1,000  
   QR 1,000 – 2,999  
   QR 3,000 – 4,999  
   QR 5,000 – 6,999  
   QR 7,000 – 9,999  
   QR 10,000 – 14,999  
   QR 15,000 – 19,999  
   QR 20,000 or more  
 
Part B: Clinical Data  
Instructions: Please answer the following questions based on your health condition and put a 
check mark () on the most appropriate answer for each question. 
 
Type of diabetes:  
   Type 1 
   Type 2 
   Other: 
_________________ 
 
Duration of diabetes (in years):  
Number of diabetes medications:  
  1 
  2 
  3  
  4 
  5 
  Other, specify: _____________ 
 
Number of all medications (including diabetes 
and other chronic diseases): 
  1 
  2 
  3 
  4 
  5 
  Other, specify: _____________ 
 
Diabetes-related complications (check all 
that apply): 
  High sugar readings (> 250mg/dl  
            or 13.9mmol/L) in past 12 
months 
  Very high sugar readings (> 
600mg/dl             or 33.0mmol/L) in 
past 12 months  
  Eye damage  
  Nerve damage 
  Kidney damage 
  Foot complications  
  Amputation(s) 
  Emergency visit(s) within 12 
months  
  Hospitalization(s) within 12 
months  
  Other, specify: _______________ 
 
Treatment type:   
   Pills  
   Injection (e.g. Insulin)  
   Pills + injection 
Comorbidities (check all that apply):  
   Cardiac disease  
   Hypertension 
   Hypercholesterolemia 
   Lung disease 
   Cancer  
   Alzheimer  
   Other, specify: 
____________ 
   
Current Diabetes Medications 
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Name 
Indication (why 
do you take this 
medication) 
Strength 
(what is 
written on the 
medication 
box) 
Dose  
(how much 
you take) 
Frequency  
(how many times 
you have to take 
it) 
Start Date 
eg: Panadol Knee pain  500mg Half tablet Three times 1/1/2016  
      
      
      
      
 
Part C: Adherence to Refills and Medication Scale – Diabetes (ARMS – D)  
It is common for patients with diabetes to report missing doses of their medicines or 
take less than the amount prescribed from time to time. Some people find it hard to 
take their medicines, either because of cost, or they decide to skip doses or reduce 
the amount to avoid side effects or for other reasons. We are most interested in what 
you are actually doing. Don’t worry about telling us that you don’t take your medicine, 
or don’t take it all the time. We need to know what is really happening for you, not 
what you think we want to hear. Remember all your answers are confidential and 
won’t be shared with your doctor. 
 
Instructions: Now we ask you how often you actually miss taking your diabetes 
medicines. If you are taking more than one diabetes medicine, please answer the 
questions by thinking about your daily experiences, on average, with all of the 
diabetes medicines you take, not just a certain medicine. There are no right or wrong 
answers. On a scale of 1 to 4 (1 being none of the time  to 4 being all the time), 
please answer in relation to time approximation 
How often do you:  
None of 
the time 
Some of 
the time 
Most of 
the time 
All the 
time 
forget to take your diabetes medicine(s)? 1 2 3 4 
decide not to take your diabetes medicine(s)? 1 2 3 4 
forget to get your diabetes prescription(s) filled? 1 2 3 4 
run out of your diabetes medicine(s)? 1 2 3 4 
skip a dose of diabetes medicine(s) before you go to 
the doctor? 
1 2 3 4 
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miss taking your diabetes medicine when you feel 
better? 
1 2 3 4 
miss taking your diabetes medicine when you feel 
sick? 
1 2 3 4 
miss taking your diabetes medicine(s) when you are 
careless? 
1 2 3 4 
forget to take your diabetes medicine(s) when you are 
supposed to take it more than once a day? 
1 2 3 4 
put off refilling your diabetes medicine(s) because they 
cost too much money? 
1 2 3 4 
plan ahead and refill your medicines before they run 
out? 
1 2 3 4 
 
Part D: Barriers to Diabetes Medication Adherence  
Instructions: This section assesses factors associated with or barriers to medication 
adherence. Here we list some possible barriers to medication adherence. Please choose 
all the factors that can keep you from taking your diabetes medications as you should.  
 (Choose all that apply) 
 
 Time or schedule problems (e.g. taking your medicine(s) during work) 
 Inconveniences (e.g. carrying medicine(s) with you, finding a place to take the medicine) 
 Side effects of the medicine(s) 
 Forget to take the medicine(s) 
 Health problems (e.g. trouble seeing, shaky hands) 
 Too painful to administer the medicine 
 Too costly to buy the medicine 
 Special occasions (e.g. on your birthday) 
 Feeling depressed or other negative emotions (e.g. anger, frustration, denial) 
 Do not believe the medication prescribed is helpful 
 Interferes with your daily activities 
 Having multiple diseases 
 Taking many medications 
 The regimen is too complicated to follow 
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 Taking the medicating multiple times a day 
 Use of traditional medicine(s) (eg: herbs) 
 Long diabetes duration 
 Diabetes is too complicated to manage 
 Healthcare provider is not very supportive 
 I don’t know why I am on diabetes medications 
 Healthcare provider does not give me enough information 
 Not understanding what the healthcare provider is telling me about the medicines 
 Family is not very supportive 
 Taking these medicine(s) is against my culture 
 Having health insurance 
 Other, please specify:  
 
For Researcher’s Use Only (from Medical Records) 
Code: Date:  
Patient’s Characteristics  
Date of 
birth  d d - m m - y y y y 
Gender:   Male   
Female  
Nationality:  
Insurance:  Governmental  
  Private 
  None 
  Other, specify: 
Religion: 
Weight: 
Height: 
Living situation: 
   Alone 
   With a family member(s) 
   With other(s), please specify: 
     
Level of education:  
  Primary education  
  Secondary education  
  High school education  
  University level  
  None, but can read and write 
  None, cannot read and write 
Employment status:  
   Student 
   Unemployed 
   Employed, (specify job type):  
   
Clinical Data 
Type of diabetes:  
   Type 1 
   Type 2 
   Other (exclude) 
 
Duration of diabetes (in years):  
Number of current diabetes medications:  
Number of all medications (including DM 
and other chronic diseases):  
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Treatment type:  
   Diet only  
   Oral drugs  
   Injectable   
   Oral + injectable drugs 
Diabetes-related complications (check all 
that apply) 
 
  History of DKA (in past 12 
months) 
  History of HHS (in past 12 
months) 
  Retinopathy 
  Neuropathy 
  Nephropathy 
  Foot complications  
  Amputation 
  Emergency visit(s) within 12 
months  
  Hospitalization(s) within 12 
months  
  Other, specify:  
 Comorbidities (check all that apply):  
   Cardiac disease  
   Hypertension 
   Hypercholesterolemia 
   Lung disease 
   Cancer (exclude)  
   Alzheimer (exclude)  
   Other, specify:  
   
Most Current Glucose Readings 
Date: HbA1c: FBG:  RBG: 
Date: HbA1c: FBG:  RBG: 
Current Diabetes Medications 
Name Strength Dose Frequency Start Date 
     
     
     
     
Other Medications 
Name Indication Strength Dose Frequency Start Date 
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APPENDIX B 
Interviewer’s guide (Patients with Diabetes in Qatar) 
The following will be the focus of the discussion during the patient interviews. The thematic 
questions will be used as prompts and would allow free expression of opinion from the 
participant.  
Start  
Welcome: Interviewer will welcome the participant 
General introduction: The interviewer will introduce him/herself.   
Example 
“Thank you for being here today. My name is ___, a research investigator at Qatar University. 
The main purpose of this interview is to identify barriers to medication adherence in patients 
with diabetes like yourself and to explore the strategies that you think should be used to 
improve medication taking-behavior and adherence. We are very interested to hear your 
opinions and learn from your experiences regarding medication-taking and adherence… The 
interview is a method of learning from experience both positive and negative. We are not 
trying to achieve consensus; we are just gathering information to help us have an in-depth 
understanding of the context…”  
Ground Rules 
1- We want you to do the talking. Talk freely; there is no right or wrong answers. 
2- Try to reflect on your experiences with the diabetes medications 
3- Whatever is mentioned within the room, will stay within the room and will not be 
linked back to you  
4- We will tape record the discussion to capture everything you have to say, but we 
will not identify anyone by name in our report, you will remain anonymous. This 
is to help us not to miss anything important that you say and so that we revisit the 
information during transcribing if necessary. Tape records will be deleted once 
transcribed.  
5- You may refuse to answer any question or withdraw from the study at anytime 
6- We would appreciate if you could please turn off your mobile phone to avoid 
distractions during the session.  
7- The duration of this interview is about 45 – 60 minutes. 
Participant’s introduction 
Ask participants to introduce themselves, their work and how long they have been in Doha for. 
Example:  
1. Can you tell me the story of your diabetes? When did it start? How are your levels?
                  , 
Introductory questions 
1. What medications are you taking for diabetes?  
2. When did you start these medications? 
3. Have you had any difficulties in taking your medications as prescribed by your doctor?
               . 
Barriers to medication adherence 
1. What do you understand about the role of medicines in the management of DM? 
a. Prompt: Did your doctor explain how medicines should be taken 
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b. Prompt: Do you think that you completely understand how meds should be 
taken 
2. What barriers do you encounter in taking your medications for diabetes?  
3. What about these factors:  
i. Patient – related factors: 
a. Demographics (gender, age, education, marital status, ethnicities, financial 
status)   
b. Psychological status (Stress, fear, motivation) 
c. Knowledge 
d. Perceptions/Beliefs 
e. Comorbidities 
f. Other (fasting, traveling, weekend, forgetfulness) 
ii. Medication – related factors: frequency, duration of therapy, polypharmacy, 
timing, side effects, complexity of treatment etc 
1. Why do you think it is important to take medicines as 
prescribed by physicians 
2. What do you do when you experience any side effects. 
3. Does the fear of side effects influence your decision for 
taking or not taking medications? 
iii. Disease – related factors: disease duration, complexity, low HbA1c, 
complications 
iv. Provider – related factors: support, inclusion in decision making, 
relationship, language, assumptions 
v. Healthcare system – related factors: cost, lack of guidelines, continuity of 
care, convenience  
vi. Societal – related factors: Social support, cultural beliefs, stigma  
Some patients start by being adherent to therapy and then they become non-adherent or 
vice versa, what do you think are the reasons behind such changes in medication-taking 
behavior? 
Strategies to improve adherence  
 Based on the problems you told me about, how do you think we can improve? 
 What solutions do you think would work for you?     
  
Concluding  
Mrs/Mr. X, Do you have any additional comments related to medication adherence in 
diabetes or in general that you would like to share with us? 
Mrs./Mr. X, we have come to the end of the interview. 
Thank you very much for your time today and for your honest opinion and fruitful discussions. 
We greatly appreciate your support. 
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APPENDIX C 
Interviewer’s guide (Healthcare Providers) 
The following will be the focus of the discussion during the interview. The thematic questions 
will be used as prompts and allowing free expression from interviewees Questions asked will be 
open ended. 
Start  
Welcome: Interviewer will welcome participants 
General introduction : The interviewer will introduce him/herself.  
Objective: State the objective of the study, ensure privacy and freedom of discussion  
Example 
“Thank you for your interest in sharing your experience. My name is ___, a research 
investigator at Qatar University. The main aim of this interview is to identify barriers to 
medication adherence in patients with diabetes from your perspective as a healthcare 
provider and to explore potential solutions for enhancing medication adherence in this 
patients population. We are very interested to hear your opinions as healthcare providers 
and learn from your experiences…  
Ground Rules 
8- We would like you to do the talking. Please talk freely; there is no right or 
wrong answers 
9- Try to reflect on your experiences with patients with diabetes in Qatar. 
10- Whatever is mentioned within the room, will stay within the room and will 
not be linked back to you.  
11- We will tape record the discussion to capture everything you have to say, 
but we will not identify anyone by name in our report, you will remain 
anonymous. Tape records will be deleted once transcribed.  
12- You have the freedom to refuse to answer any question or stop the 
interview at anytime. 
13- We would appreciate if you could please turn off your mobiles  to avoid 
distractions during the session.  
14- The duration of this interview is about 45 – 60 minutes.  
Participant introduction 
Ask interviewee to introduce themselves, their work and how long they have been in 
Doha for 
Example: Can you please introduce yourself? How long have you been practicing ____ in 
Qatar? 
General Introductory Questions 
1. Can you tell me what the term “medication adherence” means to you? 
2. How would you label your patients as non-adherent? 
3. In your opinion is medication non-adherence a big problem among diabetic patients in 
Qatar? 
4. Generally speaking, what percentage the patients you encounter in your practice would 
you say are adherent to their medications? 
5. What are the questions generally asked by the patients about their mediations? And 
how do you respond? 
Barriers to medication adherence 
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1. What do you think are the barriers to medication adherence in patients with 
diabetes that you see in your current practice in Qatar?  
2. Why do you think these are barriers to medication adherence? 
a. Probing: How do you think _(factor)_ affects medication adherence?  
b. Probing: Can you give example from your practice where you noticed 
barriers to medication adherence? 
 Patient – related factors: 
 Demographics (gender, age, education, marital status, ethnicities, 
financial status)   
 Psychological status (Stress, fear, motivation) 
 Knowledge 
 Perceptions/Beliefs 
 Comorbidities 
 Other (fasting, traveling, weekend, forgetfulness) 
 Medication – related factors: frequency, duration of therapy, 
polypharmacy, timing, side effects, complexity of treatment etc 
 Disease – related factors: disease duration, complexity, low HbA1c, 
complications 
 Provider – related factors: support, inclusion in decision making, 
relationship, language, assumptions 
 Healthcare system – related factors: cost, lack of guidelines, continuity 
of care, convenience  
 Societal – related factors: Social support, cultural beliefs, stigma  
3. Some patients start by being adherent to therapy and then they become non-adherent or 
vice versa, what do you think are the reasons behind such changes in medication-
taking behavior? 
Strategies to improve adherence  
4. How do you deal with nonadherence in your clinical practice? 
5. From your experience what has worked/not worked? 
6. Are there any strategies used to address medication adherence in patients with 
diabetes in your practice in Qatar? What are these strategies? 
7. How effective do you think these strategies are? 
8. What changes do you propose from your perspective that should be applied to 
improve these already existing strategies (if any)? 
9. What other solutions do you propose for improving medication adherence in patients 
with diabetes in Qatar? 
Concluding 
1. Do you have any additional comments related to medication adherence in 
diabetes or in general that you would like to share? 
2. Thank you very much for your time today and for your honest opinion and fruitful 
discussions. We greatly appreciate your support. 
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